0001193125-12-469871.txt : 20121114 0001193125-12-469871.hdr.sgml : 20121114 20121114130417 ACCESSION NUMBER: 0001193125-12-469871 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121114 DATE AS OF CHANGE: 20121114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SafeStitch Medical, Inc. CENTRAL INDEX KEY: 0000876378 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 112962080 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19437 FILM NUMBER: 121202742 BUSINESS ADDRESS: STREET 1: 4400 BISCAYNE BLVD. STREET 2: SUITE A-100 CITY: MIAMI STATE: FL ZIP: 33137 BUSINESS PHONE: 305-575-4600 MAIL ADDRESS: STREET 1: 4400 BISCAYNE BLVD. STREET 2: SUITE A-100 CITY: MIAMI STATE: FL ZIP: 33137 FORMER COMPANY: FORMER CONFORMED NAME: CELLULAR TECHNICAL SERVICES CO INC DATE OF NAME CHANGE: 19930328 10-Q 1 d409674d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC. 20549

 

 

FORM 10-Q

 

 

(Mark One)

 

x Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

for the Quarterly Period ended September 30, 2012

or

 

¨ Transition Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

for the Transition Period from             to             

Commission File Number 0-19437

 

 

SAFESTITCH MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   11-2962080

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. employer

identification no.)

 

4400 Biscayne Blvd., Suite A-100, Miami, Florida   33137
(Address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code: (305) 575-4600

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   ¨    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

48,797,755 shares of the Company’s common stock, par value $0.001 per share, were outstanding as of November 10, 2012.

 

 

 


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

TABLE OF CONTENTS FOR FORM 10-Q

 

PART I. FINANCIAL INFORMATION   

ITEM 1.

  FINANCIAL STATEMENTS      3   
 

Condensed Consolidated Balance Sheets as of September 30, 2012 (unaudited) and December 31, 2011

     3   
 

Unaudited Condensed Consolidated Statements of Operations for the Three and Nine months ended September 30, 2012 and 2011, and for the period from September 15, 2005 (inception) to September 30, 2012

     4   
 

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the period from September 15, 2005 (inception) through September 30, 2012 (unaudited)

     5   
 

Unaudited Condensed Consolidated Statements of Cash Flows for the Nine months ended September 30, 2012 and 2011, and for the period from September 15, 2005 (inception) to September 30, 2012

     6   
  Notes to unaudited condensed consolidated financial statements      7   

ITEM 2.

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

     15   

ITEM 3.

  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK      18   

ITEM 4.

  CONTROLS AND PROCEDURES      18   
PART II. OTHER INFORMATION   

ITEM 1.

  LEGAL PROCEEDINGS      19   

ITEM 1A.

  RISK FACTORS      19   

ITEM 2.

  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS      19   

ITEM 3.

  DEFAULTS UPON SENIOR SECURITIES      19   

ITEM 4.

  MINE SAFETY DISCLOSURE      19   

ITEM 5.

  OTHER INFORMATION      19   

ITEM 6.

  EXHIBITS      19   
  SIGNATURES      20   

 

2


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS

($ in 000s, except per share data)

 

     September 30,     December 31,  
     2012     2011  
     (Unaudited)        
ASSETS     

CURRENT ASSETS

    

Cash and cash equivalents

   $ 118      $ 298   

Accounts Receivable – trade

     9        —     

Other receivable – related-party

     45        66   

Prepaid expenses

     83        143   

Inventories

     1,687        —     
  

 

 

   

 

 

 

Total Current Assets

     1,942        507   

FIXED ASSETS

    

Property and equipment, net

     349        470   

OTHER ASSETS

    

Security deposits

     2        2   

Deferred financing costs, net

     7        14   
  

 

 

   

 

 

 

Total Other Assets

     9        16   
  

 

 

   

 

 

 

TOTAL ASSETS

   $ 2,300      $ 993   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

    

CURRENT LIABILITIES

    

Accounts payable and accrued liabilities

   $ 860      $ 469   
  

 

 

   

 

 

 

Total Current Liabilities

     860        469   

Stockholder loans, including accrued interest (Note 5)

     300        2,523   

Commitments and contingencies (Note 8)

     —          —     

STOCKHOLDERS’ EQUITY (DEFICIT)

    

Common stock, $0.001 par value per share, 225,000,000 shares authorized, 48,797,755 and 28,003,755 shares issued and outstanding

     49        28   

Additional paid-in capital

     29,396        20,762   

Deficit accumulated during the development stage

     (28,305     (22,789
  

 

 

   

 

 

 

Total Stockholders’ Equity (Deficit)

     1,140        (1,999
  

 

 

   

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

   $ 2,300      $ 993   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

($ in 000s, except per share data)

 

     Three Months Ended
September 30,
    Nine months Ended
September 30,
   

September 15,
2005
(Inception)

to
September 30,

 
     2012     2011     2012     2011     2012  

Revenues

   $ 11      $ —        $ 20      $ —        $ 20   

Cost of sales

     8        —          179        —          179   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross margin

     3        —          (159     —          (159

Operating costs and expenses

          

Research and development

     557        975        2,504        2,480        15,441   

Selling, general and administrative

     822        506        2,803        1,627        11,799   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating costs and expenses

     1,379        1,481        5,307        4,107        27,240   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating loss

     (1,376     (1,481     (5,466     (4,107     (27,399

Other income and expense

          

Other income

     —          —          —          —          1,147   

Interest income, net

     —          —          —          —          79   

Amortization of deferred financing cost

     (2     (5     (7     (36     (1,977

Interest expense

     —          (7     (43     (7     (155
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total other income and expense

     (2     (12     (50     (43     (906
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Loss before income tax

     (1,378     (1,493     (5,516     (4,150     (28,305

Provision for income tax

     —          —          —          —          —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (1,378   $ (1,493   $ (5,516   $ (4,150   $ (28,305
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Loss attributable to common stockholders and loss per common share:

          

Net loss

     (1,378     (1,493     (5,516     (4,150     (28,297

Deemed dividend - Series A Preferred Stock

     —          —          —          —          (700

Deemed dividend – Series A Preferred

          

Conversion

     —          —          —          —          (4,301

Dividends - Series A Preferred Stock

     —          —          —          —          (366
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to common stockholders

   $ (1,378   $ (1,493   $ (5,516   $ (4,150   $ (33,672
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding, basic and diluted

     48,798        28,004        45,155        28,004     
  

 

 

   

 

 

   

 

 

   

 

 

   

Net loss per basic and diluted share

   $ (0.03   $ (0.05   $ (0.12   $ (0.15  
  

 

 

   

 

 

   

 

 

   

 

 

   

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4


Table of Contents

(A Developmental Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE PERIOD SEPTEMBER 15, 2005 (INCEPTION) THROUGH SEPTEMBER 30, 2012

($ in 000s, except per share data)

 

                               Additional
Paid-in
Capital
    Deficit
Accumulated
During the
Development
Stage
       
     Preferred Stock     Common Stock             
     Shares     Amount     Shares      Amount          Total  

Inception – September 15, 2005

     —        $  —          —         $  —         $ —        $ —        $ —     

Capital contributed

     —          —          —           —           1        —          1   

Net loss

     —          —          —           —           —          (76     (76
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at December 31, 2005

     —        $ —          —         $ —         $ 1      $ (76   $ (75

Capital contributed

     —          —          11,256         11         1,493        —          1,504   

Net loss

     —          —          —           —           —          (1,060     (1,060
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at December 31, 2006

     —        $ —          11,256       $ 11       $ 1,494      $ (1,136   $ 369   

Capital contributed

     —          —          4,837         5         5,088        —          5,093   

Net loss

     —          —          —           —           —          (3,041     (3,041
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at December 31, 2007

     —        $ —          16,093       $ 16       $ 6,582      $ (4,177   $ 2,421   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Issuance of common shares in private offering – May 2008 at $2.15 per share, net of offering costs

     —          —          1,862         2         3,986        —          3,988   

Issuance of common shares as repayment of stockholder note-December 30, 2008 at $1.22 per share

         8         —           10        —          10   

Stock-based compensation

     —          —          —           —           239        —          239   

Net loss

     —          —          —           —           —          (5,185     (5,185
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at December 31, 2008

     —        $ —          17,963       $ 18       $ 10,817      $ (9,362   $ 1,473   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Issuance of Series A Preferred Stock in July 2009 at $1.00 per share

     2,000        20           —           1,962        —          1,982   

Fair value of beneficial conversion feature of Series A Preferred Stock

     —          —          —           —           200        —          200   

Deemed dividend to Series A Preferred Stockholders, charged to additional paid-in capital in the absence of retained earnings

     —          —          —           —           (200     —          (200

Stock-based compensation

     —          —          —           —           195        —          195   

Net loss

     —          —          —           —           —          (2,366     (2,366
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at December 31, 2009

     2,000      $ 20        17,963       $ 18       $ 12,974      $ (11,728   $ 1,284   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Issuance of Series A Preferred Stock in January 2010 at $1.00 per share

     2,000        20           —           1,978        —          1,998   

Fair value of beneficial conversion feature of Series A Preferred Stock

     —          —          —           —           500        —          500   

Deemed dividend to Series A Preferred Stockholders, charged to additional paid-in capital in the absence of retained earnings

     —          —          —           —           (500     —          (500

Issuance of common shares in private offering - June 2010 at $1.00 per share, net of offering costs

     —          —          4,978         5         4,969        —          4,974   

Conversion of 4,000 shares of Series A Preferred Stock and accumulated dividends into 4,366 shares of Common Stock in September 2010

     (4,000     (40     4,366         4         36        —          —     

Issuance of 697 shares of Common Stock as Consideration Shares in September 2010

     —          —          697         1         (1     —          —     

Intrinsic value of 5,063 aggregate shares of Common Stock issued on conversion of Series A Preferred Stock

     —          —          —           —           4,301        —          4,301   

Dividend paid to Series A Preferred Stockholders on conversion, charged to additional paid-in capital in the absence of retained earnings

     —          —          —           —           (4,301     —          (4,301

Stock-based compensation

     —          —          —           —           471        —          471   

Net loss

     —          —          —           —           —          (5,303     (5,303
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at December 31, 2010

     —        $ —          28,004       $ 28       $ 20,427      $ (17,031   $ 3,424   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Stock-based compensation

     —          —          —           —           335        —          335   

Net loss

     —          —          —           —           —          (5,758     (5,758
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at December 31, 2011

     —        $ —          28,004       $ 28       $ 20,762      $ (22,789   $ (1,999
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Issuance of 20,794,000 shares of Common Stock at $0.40 per share for cash in February 2012

     —          —          20,794         21         8,297        —          8,318   

Stock-based compensation

     —          —          —           —           337        —          337   

Net loss

     —          —          —           —           —          (5,516     (5,516
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at September 30, 2012 (unaudited)

     —        $ —          48,798       $ 49       $ 29,396      $ (28,305   $ 1,140   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

($ in 000s)

 

     Nine months Ended
September 30,
    September 15,
2005 (Inception)
to September 30,

2012
 
   2012     2011    

OPERATING ACTIVITIES

      

Net loss

   $ (5,516   $ (4,150   $ (28,305

Adjustments to reconcile net loss to net cash used in operating activities:

      

Amortization of deferred finance costs

     7        36        1,977   

Stock-based compensation expense

     337        240        1,642   

Stock-based compensation expense related to Share Exchange

     —          —          77   

Depreciation and amortization

     127        100        469   

Loss from disposal of assets

     —          20        20   

Inventory Adjustments

     —          —          139   

Gain on sale of TruePosition investment

     —          —          (903

Changes in operating assets and liabilities

      

Inventories

     (1,687     5        (1,826

Other current assets

     72        (8     (117

Other assets

     —          —          (2

Accounts payable and accrued liabilities

     391        194        576   

Accrued Interest

     (48     7        —     
  

 

 

   

 

 

   

 

 

 

NET CASH USED IN OPERATING ACTIVITIES

     (6,317     (3,556     (26,253
  

 

 

   

 

 

   

 

 

 

INVESTING ACTIVITIES

      

Purchase of equipment

     (6     (199     (838

Proceeds from sale of True Position investment

     —          —          903   

Payment received under Rule 16b

     —          —          4   
  

 

 

   

 

 

   

 

 

 

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES

     (6     (199     69   
  

 

 

   

 

 

   

 

 

 

FINANCING ACTIVITIES

      

Net cash provided in connection with the acquisition of SafeStitch LLC

     —          —          3,192   

Issuance of Common Stock, net of offering costs

     8,318        —          17,280   

Issuance of Preferred Stock, net of offering costs

     —          —          3,980   

Capital contributions

     —          —          1,431   

Proceeds from notes payable

     —          —          141   

Repayment of notes payable

     —          (49     (141

Proceeds from stockholder loans

     800        1,100        6,135   

Repayment of stockholder loans

     (2,975     —          (5,751

Exercise of options

     —          —          35   
  

 

 

   

 

 

   

 

 

 

NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES

     6,143        1,051        26,302   
  

 

 

   

 

 

   

 

 

 

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

     180        (2,704     118   

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

     298        3,032        —     
  

 

 

   

 

 

   

 

 

 

CASH AND CASH EQUIVALENTS AT END OF PERIOD

   $ 118      $ 328      $ 118   
  

 

 

   

 

 

   

 

 

 

Supplemental disclosures:

      

Cash paid for interest

   $ 91      $ —        $ 155   

Non cash activities:

      

Non-cash dividend upon issuance & conversion of Preferred

   $ —        $ —        $ 5,001   

Stock dividends

   $ —        $ —        $ 366   

Stockholder loans contributed to capital

   $ —        $ —        $ 84   

Warrants issued in connection with credit facility

   $ —        $ —        $ 1,985   

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

6


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BASIS OF PRESENTATION AND LIQUIDITY

The following (a) condensed consolidated balance sheet as of December 31, 2011, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of SafeStitch Medical, Inc. (“SafeStitch” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of results that may be expected for the year ending December 31, 2012. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2011 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2012.

SafeStitch Medical, Inc. (together with its consolidated subsidiaries, “SafeStitch” or the “Company”) is a developmental stage medical device company focused on the development of medical devices that manipulate tissues for endoscopic and minimally invasive surgery for the treatment of obesity, gastroesophageal reflux disease (“GERD”), Barrett’s Esophagus, esophageal obstructions, upper gastrointestinal bleeding, hernia formation and other intraperitoneal abnormalities.

Cellular Technical Services Company, Inc. (“Cellular”), a non-operating public company, was incorporated in 1988 as NCS Ventures Corp. under the laws of the State of Delaware. On July 25, 2007 Cellular entered into a Share Transfer, Exchange and Contribution Agreement (the “Share Exchange”) with SafeStitch LLC, a Virginia limited liability company. On September 4, 2007, Cellular acquired all of the members’ equity interests in SafeStitch LLC in exchange for 11,256,369 shares of Cellular’s common stock, which represented a majority of Cellular’s outstanding shares immediately following the Share Exchange. Effective January 8, 2008, Cellular changed its name to SafeStitch Medical, Inc. and increased the aggregate number of shares of capital stock that may be issued from 35,000,000 to 250,000,000, comprising 225,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”), and 25,000,000 shares of preferred stock, par value $0.01 per share. For accounting purposes, the acquisition has been treated as a recapitalization of SafeStitch LLC, with SafeStitch LLC as the acquirer (reverse acquisition). The historical financial statements prior to September 4, 2007 are those of SafeStitch LLC, which began operations on September 15, 2005. The accompanying financial statements give retroactive effect to the recapitalization as if it had occurred on September 15, 2005 (inception).

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the period from September 15, 2005 (inception) through September 30, 2012, the Company has accumulated a deficit of $28.3 million and has not generated positive cash flows from operations.

The Company has been dependent upon equity financing and loans from stockholders to meet its obligations and sustain operations. The Company’s efforts have been principally devoted to developing its technologies and commercializing its products. Based upon its current cash position, availability under the extended term of its $4.0 million Note and Security Agreement (the “Credit Facility”) with both The Frost Group LLC (“The Frost Group”) and the Company’s President and CEO, Jeffrey G. Spragens, and by monitoring its discretionary expenditures, management believes that the Company may be able to fund its existing operations through June 30, 2013 when the Credit Facility matures. However, given the short time period until the Credit Facility matures and the probable inability to pay back the amounts due at maturity on June 30, 2013, the Company is exploring more permanent or longer term financing alternatives.

The Company does not currently generate sufficient revenue from sales of the AMID™ Hernia Fixation Device (the “AMID HFD”) and external financing will therefore be necessary in order to fund the Company’s planned operations, including the continued development of our Intraluminal Gastroplasty Device for Obesity and GERD (“Gastroplasty Device”), and the anticipated expansion in 2013 of clinical trials for certain of the Company’s product candidates. The Company has taken several steps to preserve cash, including eliminating staff and focusing efforts solely on sales of the AMID HFD and development of our Gastroplasty Device. If adequate funds are not available, the Company may be required to delay, further reduce the scope of or eliminate its research and development programs, reduce its planned commercialization efforts or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain product candidates that it might otherwise seek to develop or commercialize independently.

 

7


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Although the Company is seeking to secure additional funds through the issuance of equity and/or debt, no assurance can be given that additional financing will be available to the Company on acceptable terms, or at all. Unless the Credit Facility Maturity Date is extended or replaced with similar terms, additional funding will be required to repay both the Credit Facility and to continue operations. This uncertainty, along with the Company’s limited remaining cash balances, raises substantial doubt about the Company’s ability to continue as a going concern.

The accompanying financial statements do not include any adjustments that might be necessary as a result of the outcome of such uncertainty. In addition to securing additional funds, the Company’s ability to continue as a going concern is ultimately dependent upon generating revenues from those products that do not require further marketing clearance by the U.S. Food and Drug Administration (“FDA”), obtaining FDA clearance to market its other product candidates, and achieving profitable operations and generating sufficient cash flows from operations to meet future obligations.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Isis Tele-Communications, Inc., which has no current operations, and SafeStitch LLC. All inter-company accounts and transactions have been eliminated in consolidation.

Use of estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions, such as useful lives of property and equipment, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company holds cash and cash equivalent balances in banks and other financial institutions, and includes overnight repurchase agreements collateralizing its depository bank accounts (sweep accounts) in its cash balances. Balances in excess of Federal Deposit Insurance Corporation (“FDIC”) limitations may not be insured.

Allowances for Doubtful Accounts. The Company provides an allowance for receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance for doubtful accounts at the end of each period are determined using a combination of customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure.

Inventories. Inventories are stated at lower of cost or market using the weighted average cost method and are evaluated for impairment when conditions exist that suggests impairment may be necessary. The $1.7 million inventory balance at September 30, 2012 consists of $1.0 million in components, $664,000 in finished units of the AMID HFD and $19,000 in standard mesh. Scrap materials and quality testing costs are included in Cost of Goods Sold (“COGS”), as incurred. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, obsolescence and future sales forecasts.

Property and equipment. Property and equipment are carried at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs that do not extend the lives of assets are expensed. Gain or loss, if any, on the disposition of fixed assets is recognized currently in operations. Depreciation is calculated primarily on a straight-line basis over estimated useful lives of the assets.

Revenue Recognition. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured.

 

8


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Advertising Costs. The Company expenses all costs of advertising as incurred. Advertising and promotional costs are included in selling, general and administrative costs and expenses for all periods presented, and totaled $22,000 and $106,000, respectively, for the three and nine months ended September 30, 2012. Advertising and promotional costs and expenses totaled $2,000 and $11,000, respectively, for the three and nine months ended September 30, 2011.

Research and development. Research and development costs principally represent salaries of the Company’s medical and biomechanical engineering professionals, material and shop costs associated with manufacturing product prototypes and payments to third parties for clinical trials and additional product development and testing. All research and development costs are charged to expense as incurred.

Patent costs. Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred.

Stock-based compensation. The Company accounts for all share-based payments to employees and directors, based on their grant date fair values. Compensation for share-based payments to non-employees is based on the fair value at the measurement date, which is generally the performance completion date. The fair value is initially measured at the grant date and subsequently measured at each reporting period until the final measurement date. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Stock-based compensation is included in general and administrative costs and expenses for all periods presented.

Therapeutic discovery project tax credit. The Company records the therapeutic discovery project tax credit on an accrual basis when the credit is considered realized, which is generally when approved by the government agency. Such credit is reported as other income in the accompanying financial statements.

Fair value of financial instruments. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. Related party receivables and stockholder loans are carried at cost.

Long-lived assets. The Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less costs to sell.

Income taxes. The Company follows the liability method of accounting for income taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of the assets and liabilities. The Company’s policy is to record a valuation allowance against deferred tax assets, when the deferred tax asset is not recoverable. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance.

Comprehensive income (loss). Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive net loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive income (loss) has been included in the condensed consolidated financial statements.

 

9


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 3 – PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

 

     Estimated Useful Lives    September 30, 2012     December 31, 2011  

Machinery and equipment

   5 years    $ 660,000      $ 660,000   

Furniture, fixtures and leasehold improvements

   3-5 years      87,000        81,000   

Software

   3-5 years      57,000        57,000   
     

 

 

   

 

 

 
        804,000        798,000   

Accumulated depreciation and amortization

        (455,000     (328,000
     

 

 

   

 

 

 

Property and equipment, net

      $ 349,000      $ 470,000   
     

 

 

   

 

 

 

Depreciation of fixed assets utilized in research and development activities is included in research and development costs and expenses. All other depreciation is included in selling, general and administrative costs and expenses. Depreciation and amortization expense was $43,000 and $127,000, respectively for the three and nine months ended September 30, 2012, and was $43,000 and $100,000, respectively for the three and nine months ended September 30, 2011.

NOTE 4 – STOCK-BASED COMPENSATION

On November 13, 2007, the Board of Directors and a majority of the Company’s stockholders approved the SafeStitch Medical, Inc. 2007 Incentive Compensation Plan (the “2007 Plan”), which was amended on June 19, 2012 to increase the number of shares of Common Stock available for issuance to 5,000,000. Under the 2007 Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock and/or deferred stock to employees, officers, directors, consultants and vendors up to an aggregate of 5,000,000 shares of Common Stock, which are fully reserved for future issuance. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company’s shares at the date of grant and, within any 12 month period, no person may receive stock options or stock appreciation rights for more than one million shares. Additionally, no stock options or stock appreciation rights granted under the 2007 Plan may have a term exceeding ten years.

The Company granted 813,500 and 562,500 stock options under the 2007 Plan during the nine months ended September 30, 2012 and 2011, respectively, including 218,000 and 68,000 stock options that were issued to consultants. The options granted during 2012 were issued at an exercise price ranging from $0.65 to $0.85 per share and had an estimated aggregate grant date fair value of $441,000. The options granted during 2011 were issued at an exercise price of $1.12 per share and had an estimated aggregate grant date fair value of $502,000. The weighted average grant date fair value of the options granted during the nine months ended September 30, 2012 and 2011 was $0.54 per share and $0.89 per share, respectively.

Total stock-based compensation recorded for the three and nine months ended September 30, 2012 was $113,000 and $336,000, respectively. Total stock-based compensation recorded for the three and nine months ended September 30, 2011 was $98,000 and $240,000, respectively. The stock-based compensation recorded for the nine months ended September 30, 2011 included a credit of $113,000 for a change in forfeiture experience. All stock-based compensation is included in selling, general and administrative costs and expenses. The fair values of options granted are estimated on the date of their grant using the Black-Scholes option pricing model based on the assumptions included in the table below. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Expected volatility is based on the historical volatility of the Common Stock. The risk-free interest rate for periods within the contractual life of the stock option award is based on the yield of U.S. Treasury bonds on the grant date with a maturity equal to the expected term of the stock option. The expected life of stock option awards granted to employees and non-employee directors is based upon the “simplified” method for “plain vanilla” options described in SEC Staff Accounting Bulletin No. 107, as amended by SEC Staff Accounting Bulletin No. 110. The expected life of all other stock option awards is the contractual term of the option. Forfeiture rates are based on management’s estimates. The fair value of each option granted during the nine months ended September 30, 2012 and 2011 was estimated using the following assumptions.

 

10


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

     Nine months ended
September 30, 2012
   Nine months ended
September 30, 2011

Expected volatility

   85.41% - 111.36%    76.91% - 102.63%

Expected dividend yield

   0.00%    0.00%

Risk-free interest rate

   1.02% – 1.98%    2.25% – 3.25%

Expected life

   5.5 – 10.0 years    5.5 – 10.0 years

Forfeiture rate

   0% - 2%    0% - 5%

The following summarizes the Company’s stock option activity for the nine months ended September 30, 2012:

 

     Shares     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Term (Years)
     Aggregate
Intrinsic
Value
 

Outstanding at December 31, 2011

     1,628,167      $ 1.35         6.26      

Granted

     813,500      $ 0.66         9.39      

Exercised

     —          —           

Canceled or expired

     (237,667   $ 1.99         
  

 

 

         

Outstanding at September 30, 2012

     2,204,000      $ 1.02         7.09       $ 0   
  

 

 

   

 

 

    

 

 

    

 

 

 

Exercisable at September 30, 2012

     990,875      $ 1.24         5.41       $ 0   
  

 

 

   

 

 

    

 

 

    

 

 

 

Vested and expected to vest at September 30, 2012

     2,155,239      $ 1.03         7.05       $ 0   
  

 

 

   

 

 

    

 

 

    

 

 

 

None of the 813,500 options granted during the first nine months of the Company’s 2012 fiscal year were vested as of September 30, 2012. At September 30, 2012, there was approximately $333,000 of total unrecognized compensation cost related to non-vested employee and director share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.53 years.

No options were exercised during the three and nine months ended September 30, 2012 and 2011.

No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.

NOTE 5 – DEBT

Credit Facility. In connection with the acquisition of SafeStitch LLC, the Company entered into a Note and Security Agreement (the “Credit Facility”) with both The Frost Group and Jeffrey G. Spragens, the Company’s Chief Executive Officer and President and a director. The Frost Group is a Florida limited liability company whose members include Frost Gamma Investments Trust (“Frost Gamma”), a trust controlled by Dr. Phillip Frost, the largest beneficial holder of the issued and outstanding shares of Common Stock, Dr. Jane H. Hsiao, the Company’s Chairman of the Board, and Steven D. Rubin, a director. The Credit Facility provides $4.0 million in total available borrowings, consisting of $3.9 million from The Frost Group and $100,000 from Mr. Spragens. The Company has granted a security interest in all present and subsequently acquired collateral in order to secure prompt, full and complete payment of the amounts outstanding under the Credit Facility. The collateral includes all assets of the Company, inclusive of intellectual property (patents, patent rights, trademarks, service marks, etc.). Outstanding borrowings under the Credit Facility accrue interest at a 10% annual rate. The Credit Facility had an initial term of 28 months, expiring in December 2009, and was amended on four occasions to extend the Maturity Date, which is now June 30, 2013.

In connection with the Credit Facility, the Company granted warrants to purchase an aggregate of 805,521 shares of Common Stock to The Frost Group and Mr. Spragens. The fair value of the warrants was determined to be $1,985,000 on the grant date based on the Black-Scholes valuation model using the following assumptions: expected volatility of 82%, dividend

 

11


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

yield of 0%, risk-free interest rate of 4.88% and expected life of 10 years. The fair value of the warrants was recorded as deferred financing costs and is being amortized over the life of the Credit Facility. The Company recorded amortization expense related to these deferred financing costs of $2,000 and $7,000, respectively, for the three and nine months ended September 30, 2012 and $5,000 and $36,000, respectively, for the three and nine months ended September 30, 2011. In October 2012, The Frost Group and Mr. Spragens exercised the warrants for the purchase of 805,521 shares of Common Stock.

The Company borrowed $300,000 under the Credit Facility during September 2012. The Company did not recognized interest expense related to the outstanding borrowings under the Credit Facility for the three months ended September 30, 2012. The Company has a $300,000 outstanding balance and $3,700,000 available under the Credit Facility as of September 30, 2012.

NOTE 6 – CAPITAL TRANSACTIONS

2012 Private Placement of Common Stock. On February 17, 2012, the Company entered into a stock purchase agreement (the “2012 Stock Purchase Agreement”) with 35 investors (the “2012 PIPE Investors”) pursuant to which the 2012 PIPE Investors agreed to purchase an aggregate of 20,794,000 shares of Common Stock (the “2012 PIPE Shares”) at a price of $0.40 per share for aggregate consideration of $8.3 million. Among the Investors purchasing Shares were Frost Gamma, Dr. Jane Hsiao, the Company’s Chairman of the Board, Jeffrey Spragens, the Company’s President and Chief Executive Officer and Richard Pfenniger, a member of the Company’s Board of Directors. Frost Gamma and Dr. Hsiao each purchased 4,500,000 shares, Mr. Spragens purchased 250,000 shares, and Mr. Pfenniger purchased 125,000 shares. The Company issued the 2012 PIPE Shares in reliance upon the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated thereunder.

NOTE 7 – BASIC AND DILUTED NET LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period reported. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding for the period reported. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three and nine months ended September 30, 2012 and 2011, no adjustment has been made to the weighted average outstanding common shares as the assumed exercise of outstanding options and warrants and conversion of preferred stock is anti-dilutive.

Potential common shares not included in calculating diluted net loss per share are as follows:

 

     September 30, 2012      September 30, 2011  

Stock options

     2,204,000         1,629,667   

Stock warrants

     805,521         805,521   
  

 

 

    

 

 

 

Total

     3,009,521         2,435,188   
  

 

 

    

 

 

 

NOTE 8 – COMMITMENTS AND CONTINGENCIES

The Company is obligated under various operating lease agreements for office space. Generally, the lease agreements require the payment of base rent plus escalations for increases in building operating costs and real estate taxes. Rental expense under operating leases amounted to $76,000 and $209,000 for the three and nine months ended September 30, 2012, respectively, and $58,000 and $163,000 for the three and nine months ended September 30, 2011, respectively.

The Company is obligated to pay royalties to Creighton University (“Creighton”) on the sales of products licensed from Creighton pursuant to an exclusive license and development agreement (see Note 9). The Company is also obligated under an agreement with Dr. Parviz Amid to pay a 4% royalty to Dr. Amid on the sales of any product developed with Dr. Amid’s assistance, including the AMID HFD, for a period of ten years from the first commercial sale of such product. Royalties to Dr. Parviz Amid in the amount of $400 and $800 have been incurred during the three and nine months ended September 30, 2012, respectively. No royalties have been incurred or paid for the three and nine months ended September 30, 2011.

 

12


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

The Company has placed orders with various suppliers for the purchase of certain tooling, contract engineering and research services. Each of these orders has a duration or expected completion within the next twelve months. The Company currently has no material commitments with terms beyond twelve months.

NOTE 9 – AGREEMENT WITH CREIGHTON UNIVERSITY

On May 26, 2006, SafeStitch LLC entered into an exclusive license and development agreement (the “Creighton Agreement”) with Creighton, granting the Company a worldwide exclusive (even as to the university) license, with rights to sublicense, to all the Company’s product candidates and associated know-how based on Creighton technology, including the exclusive right to manufacture, use and sell the product candidates.

Pursuant to the Creighton Agreement, the Company is obligated to pay Creighton, on a quarterly basis, a royalty of 1.5% of the revenue collected worldwide from the sale of any product licensed under the Creighton Agreement, less certain amounts including, without limitation, chargebacks, credits, taxes, duties and discounts or rebates. The Creighton Agreement does not provide for minimum royalties. Also pursuant to the Creighton Agreement, the Company agreed to invest, in the aggregate, at least $2.5 million over 36 months, beginning May 26, 2006, towards development of any licensed product. This $2.5 million investment obligation excluded the first $150,000 of costs related to the prosecution of patents, which the Company invested outside of the Creighton Agreement. The Company is further obligated to pay to Creighton an amount equal to 20% of certain of the Company’s research and development expenditures as reimbursement for the use of Creighton’s facilities. Failure to comply with the payment obligations above will result in all rights in the licensed patents and know-how reverting back to Creighton. As of December 31, 2007, the Company had satisfied the $2.5 million investment obligation described above. The Company recorded research and development costs and expenses related to the 20% facility reimbursement obligation totaling approximately $10,000 and $34,000, respectively for the three and nine months ended September 30, 2012, and $12,000 and $33,000, respectively, for the three and nine months ended September 30, 2011.

NOTE 10 – INCOME TAXES

The Company accounts for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. All of the Company’s deferred tax assets have been fully reserved by a valuation allowance due to management’s uncertainty regarding the future profitability of the Company.

The Company has recognized no adjustment for uncertain tax provisions. SafeStitch recognizes interest and penalties related to uncertain tax positions in selling, general and administrative costs and expenses; however no such provisions for accrued interest and penalties related to uncertain tax positions have been recorded as of September 30, 2012 or December 31, 2011.

The tax years 2009-2011 remain open to examination by the major tax jurisdictions in which the Company operates.

NOTE 11 – CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

As more fully described in Note 5, the Company entered into a $4.0 million Credit Facility with both Jeffrey G. Spragens, the Company’s President, Chief Executive Officer and director, and The Frost Group.

 

13


Table of Contents

SAFESTITCH MEDICAL, INC.

(A Developmental Stage Company)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

The Company entered into a five-year lease for office space in Miami, Florida with a company controlled by Dr. Frost. The non-cancelable lease, which commenced January 1, 2008, provides for a 4.5% annual rent increase over the life of the lease. The Miami office lease was amended in August 2011 to include additional office space in the same building, and current rental payments under the lease are approximately $19,000 per month. The Company recorded rent expense related to the Miami lease totaling approximately $73,000 and $198,000, respectively, for the three and nine months ended September 30, 2012, and $51,000 and $145,000, respectively, for the three and nine months ended September 30, 2011.

Dr. Hsiao, Dr. Frost and director Steven Rubin are each significant stockholders and/or directors of Non-Invasive Monitoring Systems, Inc. (“NIMS”), a publicly-traded medical device company, Aero Pharmaceuticals, Inc. (“Aero”), a privately-held pharmaceutical distribution company that dissolved in December 2011, Tiger X Medical, Inc. (“Tiger X”) (formerly known as Cardo Medical, Inc.), a publicly-traded former medical device company, and SearchMedia Holdings Limited (“SearchMedia”), a publicly-traded media company operating primarily in China, and Sorrento Therapeutics, Inc. (“Sorrento”), a publicly-traded development stage biopharmaceutical company. Director Richard Pfenniger is also a shareholder of NIMS. The Company’s Chief Financial Officer also serves as the Chief Financial Officer and supervises the accounting staffs of NIMS and, until its dissolution, Aero, under a Board-approved cost sharing arrangement whereby the total salaries of the accounting staffs of the three companies are shared. Aero has not participated in the cost sharing arrangement since June 30, 2011 and was dissolved in December 2011. Since December 2009, the Company’s Chief Legal Officer has served under a similar Board-approved cost sharing arrangement as Corporate Counsel of SearchMedia and as the Chief Legal Officer of each of NIMS and Tiger X, and from June 2011 through September 19, 2012, as Corporate Counsel for Sorrento. The Company has recorded reductions to selling, general and administrative costs and expenses to account for the sharing of costs under these arrangements of $51,000 and $154,000, respectively, for the three and nine months ended September 30, 2012, and $51,000 and $205,000, respectively, for the three and nine months ended September 30, 2011. Aggregate accounts receivable from NIMS, Aero, Tiger X, Sorrento and SearchMedia were approximately $45,000 and $66,000 as of September 30, 2012 and December 31, 2011, respectively.

NOTE 12 – EMPLOYEE BENEFIT PLANS

Effective May 1, 2008, the SafeStitch 401(k) Plan (the “401k Plan”) permits employees to contribute up to 100% of qualified annual compensation up to annual statutory limitations. Employee contributions may be made on a pre-tax basis to a regular 401(k) account or on an after-tax basis to a “Roth” 401(k) account. The Company contributes to the 401k Plan a “safe harbor” match of 100% of each participant’s contributions to the 401k Plan up to a maximum of 4% of the participant’s qualified annual earnings. The Company recorded 401(k) Plan matching expense of approximately $23,000 and $37,000, respectively, for the three and nine months ended September 30, 2012 and $9,000 and $28,000, respectively, for the three and nine months ended September 30, 2011.

 

14


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains certain forward-looking statements about our expectations, beliefs or intentions regarding our product development and commercialization efforts, business, financial condition, results of operations, strategies or prospects. You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual operations or results to differ materially from the operations and results anticipated in forward-looking statements. These factors include, but are not limited to: our ability to obtain additional funding to continue our operations; whether the Credit Facility is extended or replaced with similar terms; our ability to successfully commercialize our existing products; our ability to successfully develop, clinically test and commercialize our products and product candidates; the timing and outcome of the regulatory review process for our product candidates; changes in the health care and regulatory environments of the United States and other countries in which we intend to operate; our ability to attract and retain key management, marketing and scientific personnel; competition; our ability to successfully prepare file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; our ability to successfully transition from a research and development company to a marketing, sales and distribution concern, and our ability to identify and pursue development of additional product candidates, as well as the factors contained in “Item 1A—Risk Factors” of our Annual Report on Form 10-K. We do not undertake any obligation to update forward-looking statements, except as required by applicable law. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.

Overview

We are a developmental stage FDA-registered medical device company focused on the design and development of medical devices that manipulate tissues for the treatment of obesity, gastroesophageal reflux disease (“GERD”), hernia formation, esophageal obstructions, Barrett’s Esophagus, upper gastrointestinal bleeding, and other intraperitoneal abnormalities through endoscopic and minimally invasive surgery.

We have utilized our expertise in intraperitoneal surgery to test certain of our devices in in vivo and ex vivo animal trials and ex vivo human trials, and with certain products, in limited in vivo human trials. We have also commercially developed the AMID HFD that has received FDA clearance to market in the United States. Certain of our products did not require clinical trials, including our AMID HFD, SMART DilatorTM, and standard and airway bite blocks. Where required, we intend to rapidly, efficiently and safely move into clinical trials for certain other devices, including those utilized in surgery for the treatment of obesity, GERD and for the treatment and diagnosis of Barrett’s Esophagus.

Products and Product Candidates

We received the necessary FDA 510(k) clearances to market the SMART DilatorTM as Class II devices in February 2009. Our standard and airway bite blocks are Class I 510(k)-exempt devices that require no preclearance from the FDA prior to marketing. In November 2009, we received FDA clearance to market the AMID Stapler® in the U.S. as a Class II device, and, in February 2010, we received the Conformité Européenne (the “CE Mark”) which enables the eventual commercialization in the European Economic Area and other countries that recognize the European CE Mark. After we commenced production of the AMID Stapler® in 2010, we voluntarily suspended sales in order to implement several design for manufacturability improvements and a more robust and reliable commercial manufacturing process. As a result of these design improvements, we submitted a “Special 510(k)” to FDA that was cleared in February 2012, and allows us to market the AMID Stapler® in the United States. In May 2012, we changed the name of the AMID Stapler® to the AMID™ Hernia Fixation Device (the “AMID HFD”). Additionally, we will supplement our Technical File prior to marketing the AMID HFD in the European Union.

We have successfully tested our first investigational Gastroplasty Device in five patients in Hungary. At the 24 month follow-up in September 2012, we observed, through endoscopic visualization, that the operative site showed significant scar tissue as intended, with the scar forming a restrictive ring for weight loss or, in the case of GERD, a barrier to prevent acid from refluxing into the esophagus. We expect to continue in vivo human testing of this device in 2013. We are preparing separate GERD and obesity clinical trial protocols for this device and anticipate submitting the final investigational device exemption (“IDE”) trial plans to the FDA for review in 2013. We intend to apply to the FDA for clearance of the Gastroplasty Device for the GERD indication and approval for the obesity indication.

 

15


Table of Contents

We continue to evaluate commercialization options for our SMART DilatorTM and our standard and airway bite blocks.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations set forth below under “Results of Operations” and “Liquidity and Capital Resources” should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this Form 10-Q. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including the carrying value of our long term investments, property and equipment, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. A more detailed discussion on the application of these and other accounting policies can be found in Note 2 in the Notes to the Consolidated Financial Statements set forth in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2011. Actual results may differ from these estimates.

Results of Operations

We incurred losses of $5.5 million and $4.2 million for the nine months ended September 30, 2012 and 2011, respectively, and we had an accumulated deficit of $28.3 million at September 30, 2012. Since we do not currently generate significant revenue from any of our products, including those already cleared for commercial marketing by the FDA, we expect to continue to generate losses in connection with the commercial launch of such FDA-cleared products and the continual development of our other products and technologies. Our research and development activities are budgeted to expand over time and will require further resources if we are to be successful. As a result, we believe our operating losses are likely to be substantial over the next several years.

Three and Nine months ended September 30, 2012 Compared to Three and Nine months Ended September 30, 2011

Sales were $11,000 and $20,000 for the three and nine months ended September 30, 2012, respectively, as compared to no sales for the three and nine months ended September 30, 2011.

Costs of goods sold (“COGS”) were $8,000 and $179,000 for the three and nine months ended September 30, 2012, respectively, as compared to no COGS for the three and nine months ended September 30, 2011. The COGS for the nine months ended September 30, 2012 included $166,000 for scrap materials and quality testing costs. The costs associated with scrap materials and quality testing is expected to decrease in the future as the manufacturing line matures. Excluding scrap materials and quality testing costs, the COGS were $8,000 and $13,000 with gross margins of $3,000 and $8,000 for the three and nine months ended September 30, 2012, respectively.

Research and development (“R&D”) expenses primarily consist of engineering, product development and clinical and regulatory expenses, incurred in the development of our products and product candidates. R&D expenses were $557,000 and $2.5 million, respectively, for the three and nine months ended September 30, 2012 as compared to $975,000 and $2.48 million, respectively, for the three and nine months ended September 30, 2011. The year over year three month decrease of $418,000 is primarily related to reductions in employees, consulting and contract engineering services, hardware, contract research and trial costs associated with the Gastroplasty device and reductions in the AMID HFD contract engineering services and hardware as a result of the product’s commercialization. The year over year nine month increase of $24,000 resulted primarily from an increase of R&D consulting and contract engineering services, increase in manufacturing staff, and increased expenditures for AMID HFD hardware during the first quarter of 2012.

 

16


Table of Contents

Selling, general and administrative (“SG&A”) expenses consist primarily of salaries, market development and other related costs, including stock based compensation. Other SG&A costs and expenses include facility-related costs not otherwise included in R&D costs and expenses, costs associated with attending medical conferences, professional fees for legal, including legal services associated with our efforts to obtain and maintain broad protection for the intellectual property related to our products, accounting services, consulting fees and travel expenses. SG&A expenses were $822,000 and $2.8 million, respectively, for the three and nine months ended September 30, 2012, as compared to $506,000 and $1.6 million, respectively for the three and nine months ended September 30, 2011. These $316,000 and $1.2 million respective increases resulted primarily from the addition of personnel in sales and marketing, manufacturing and quality and regulatory departments, increase in sales and marketing travel expenses, AMID HFD marketing cost, rental cost and manufacturing cost associated with the production of the AMID HFD. These increases were offset in part by reductions in accounting staff and a stock-based compensation forfeiture true-up credit recorded in 2011.

Liquidity and Capital Resources

As a result of our significant R&D costs and the lack of any significant product sales revenue, we have generated operating losses since inception and we expect to continue to incur losses from operations for the foreseeable future. Sales of the AMID HFD have been slower than anticipated since our commercial launch during the second quarter of 2012.

The Company has been dependent upon equity financing and loans from stockholders to meet its obligations and sustain operations. As of September 30, 2012, we had remaining cash of only $118,000 and outstanding indebtedness of $300,000 under our Credit Facility. We have taken several steps to preserve cash, including eliminating staff and focusing efforts solely on sales of the AMID HFD and development of our Gastroplasty Device. Additionally, as a result of sufficient inventory of our AMID HFD to meet anticipated demand through the first half of 2013, we were able to suspend production of the AMID HFD in the third quarter of 2012. Based upon its current cash position, availability under the Credit Facility and by monitoring its discretionary expenditures, management believes that the Company may be able to fund its existing operations through June 30, 2013 when the Credit Facility matures. However, given the short time period until the Credit Facility matures and the inability to pay back the amounts due at maturity on June 30, 2013 without external financing, the Company is exploring more permanent or longer term financing alternatives.

Although the Company is seeking to secure additional funds through the issuance of equity and/or debt, no assurance can be given that additional financing will be available to the Company on acceptable terms, or at all. Unless the Credit Facility Maturity Date is extended or replaced with similar terms, additional funding will be required to both repay the Credit Facility and to continue operations. This uncertainty, along with the Company’s limited remaining cash balances, raises substantial doubt about the Company’s ability to continue as a going concern.

 

17


Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not required for smaller reporting companies as defined in Rule 12b-2 of the Exchange Act.

Item 4. Controls and Procedures.

We maintain a system of disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) that is designed to provide reasonable assurance that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to management in a timely manner. Our Chief Executive Officer and Chief Financial Officer evaluated this system of disclosure controls and procedures as of the end of the period covered by this quarterly report and have concluded that the system is operating effectively to ensure appropriate disclosure.

There were no significant changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 of the Exchange Act that occurred during period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

18


Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

There have been no material changes in our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2011.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

Item 6. Exhibits.

 

    Exhibits:
  31.1   Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)
  31.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)
  32.1*   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  32.2 *   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**   XBRL Instance Document
101.SCH**   XBRL Taxonomy Extension Schema Document
101.CAL**   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**   XBRL Taxonomy Extension Label Linkbase Document
101.PRE**   XBRL Taxonomy Extension Presentation Linkbase Document

 

* Pursuant to Item 601(b)(32) of Regulation S-K, this exhibit is furnished, rather than filed, with this Quarterly Report on Form 10-Q.
** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Act of 1934 and otherwise not subject to liability under those sections.

 

19


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    SAFESTITCH MEDICAL, INC.
Date: November 14, 2012     By:  

/s/ Jeffrey G. Spragens

      Jeffrey G. Spragens
      President and Chief Executive Officer
Date: November 14, 2012     By:  

/s/ James J. Martin

      James J. Martin
      Chief Financial Officer

 

20

EX-31.1 2 d409674dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Jeffrey G. Spragens, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of SafeStitch Medical, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By:  

/s/ Jeffrey G. Spragens

  Jeffrey G. Spragens
  Chief Executive Officer (Principal Executive Officer)
  November 14, 2012
EX-31.2 3 d409674dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, James J. Martin, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of SafeStitch Medical, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By:  

/s/ James J. Martin

  James J. Martin
  Chief Financial Officer
  November 14, 2012
EX-32.1 4 d409674dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT

TO 18 U.S.C. Section 1350, as Adopted Pursuant to

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report on Form 10-Q of SafeStitch Medical, Inc. (the “Company”) for the quarter ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey G. Spragens, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By:  

/s/ Jeffrey G. Spragens

  Jeffrey G. Spragens
  Chief Executive Officer and President
  November 14, 2012
EX-32.2 5 d409674dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT

TO 18 U.S.C. Section 1350, as Adopted Pursuant to

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report on Form 10-Q of SafeStitch Medical, Inc. (the “Company”) for the quarter ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James J. Martin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By:  

/s/ James J. Martin

  James J. Martin
  Chief Financial Officer
  November 14, 2012
EX-101.INS 6 sfes-20120930.xml XBRL INSTANCE DOCUMENT 0000876378 us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0000876378 us-gaap:CommonStockMember 2007-01-01 2007-12-31 0000876378 us-gaap:CommonStockMember 2006-01-01 2006-12-31 0000876378 us-gaap:BoardOfDirectorsChairmanMember sfes:TwoThousandTwelvePipeInvestorsMember 2012-02-01 2012-02-29 0000876378 sfes:TwoThousandTwelvePipeInvestorsMember sfes:PresidentAndChiefExecutiveOfficerMember 2012-02-01 2012-02-29 0000876378 sfes:BoardOfDirectorsMember sfes:TwoThousandTwelvePipeInvestorsMember 2012-02-01 2012-02-29 0000876378 sfes:TwoThousandTwelvePipeInvestorsMember sfes:BoardOfDirectorsChairmanOneMember 2012-02-01 2012-02-29 0000876378 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2012-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2011-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2010-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2009-12-31 0000876378 2009-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2008-12-31 0000876378 2008-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2007-12-31 0000876378 2007-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2006-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2006-12-31 0000876378 2006-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2005-12-31 0000876378 2005-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2005-09-15 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2005-09-15 0000876378 us-gaap:PreferredStockMember 2012-09-30 0000876378 us-gaap:PreferredStockMember 2011-12-31 0000876378 us-gaap:CommonStockMember 2011-12-31 0000876378 us-gaap:PreferredStockMember 2010-12-31 0000876378 us-gaap:CommonStockMember 2010-12-31 0000876378 us-gaap:PreferredStockMember 2009-12-31 0000876378 us-gaap:CommonStockMember 2009-12-31 0000876378 us-gaap:PreferredStockMember 2008-12-31 0000876378 us-gaap:CommonStockMember 2008-12-31 0000876378 us-gaap:PreferredStockMember 2007-12-31 0000876378 us-gaap:CommonStockMember 2007-12-31 0000876378 us-gaap:PreferredStockMember 2006-12-31 0000876378 us-gaap:CommonStockMember 2006-12-31 0000876378 us-gaap:PreferredStockMember 2005-12-31 0000876378 us-gaap:CommonStockMember 2005-12-31 0000876378 us-gaap:PreferredStockMember 2005-09-15 0000876378 us-gaap:CommonStockMember 2005-09-15 0000876378 us-gaap:MinimumMember 2012-01-01 2012-12-31 0000876378 us-gaap:MaximumMember 2012-01-01 2012-12-31 0000876378 sfes:ConsultantsMember 2012-01-01 2012-09-30 0000876378 sfes:ConsultantsMember 2011-01-01 2011-09-30 0000876378 2005-09-15 0000876378 us-gaap:SoftwareMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000876378 us-gaap:SoftwareMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000876378 sfes:FurnitureFixturesAndLeaseholdImprovementsMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000876378 sfes:FurnitureFixturesAndLeaseholdImprovementsMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000876378 us-gaap:MachineryAndEquipmentMember 2012-01-01 2012-09-30 0000876378 us-gaap:SoftwareMember 2012-09-30 0000876378 us-gaap:MachineryAndEquipmentMember 2012-09-30 0000876378 sfes:FurnitureFixturesAndLeaseholdImprovementsMember 2012-09-30 0000876378 us-gaap:SoftwareMember 2011-12-31 0000876378 us-gaap:MachineryAndEquipmentMember 2011-12-31 0000876378 sfes:FurnitureFixturesAndLeaseholdImprovementsMember 2011-12-31 0000876378 us-gaap:PreferredStockMember 2008-01-08 0000876378 sfes:MiamiMember 2012-07-01 2012-09-30 0000876378 sfes:CreightonRoyaltyAgreementMember 2012-07-01 2012-09-30 0000876378 sfes:MiamiMember 2012-01-01 2012-09-30 0000876378 sfes:MiamiMember 2011-07-01 2011-09-30 0000876378 sfes:CreightonRoyaltyAgreementMember 2011-07-01 2011-09-30 0000876378 sfes:MiamiMember 2011-01-01 2011-09-30 0000876378 sfes:CreightonRoyaltyAgreementMember 2011-01-01 2011-09-30 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2012-01-01 2012-09-30 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2011-01-01 2011-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2010-01-01 2010-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2009-01-01 2009-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2008-01-01 2008-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2007-01-01 2007-12-31 0000876378 2007-01-01 2007-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2006-01-01 2006-12-31 0000876378 2006-01-01 2006-12-31 0000876378 sfes:DeficitAccumulatedDuringDevelopmentStageMember 2005-09-16 2005-12-31 0000876378 sfes:MrSpragensMember 2012-09-30 0000876378 sfes:MrSpragensAndFrostGroupMember 2012-09-30 0000876378 sfes:FrostGroupMember 2012-09-30 0000876378 sfes:CreditFacilityMember 2012-07-01 2012-09-30 0000876378 sfes:CreditFacilityMember 2012-01-01 2012-09-30 0000876378 us-gaap:CommonStockMember 2008-01-08 0000876378 us-gaap:CommonStockMember 2012-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000876378 us-gaap:CommonStockMember 2008-01-08 0000876378 2012-06-19 0000876378 2011-09-30 0000876378 2010-12-31 0000876378 us-gaap:CommonStockMember sfes:CellularMember 2007-09-01 2007-09-30 0000876378 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000876378 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000876378 us-gaap:WarrantMember 2011-01-01 2011-09-30 0000876378 us-gaap:StockOptionsMember 2011-01-01 2011-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0000876378 2011-01-01 2011-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2005-09-16 2005-12-31 0000876378 2005-09-16 2005-12-31 0000876378 sfes:TwoThousandTwelvePipeInvestorsMember 2012-02-01 2012-02-29 0000876378 2011-12-31 0000876378 2011-01-31 2011-12-30 0000876378 2012-07-01 2012-09-30 0000876378 2011-07-01 2011-09-30 0000876378 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2010-01-01 2010-01-31 0000876378 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-01-31 0000876378 us-gaap:SeriesAPreferredStockMember 2010-01-01 2010-01-31 0000876378 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2009-07-01 2009-07-31 0000876378 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2009-07-01 2009-07-31 0000876378 us-gaap:SeriesAPreferredStockMember 2009-07-01 2009-07-31 0000876378 us-gaap:CommonStockMember 2008-12-01 2008-12-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2008-12-01 2008-12-30 0000876378 2008-12-01 2008-12-30 0000876378 sfes:CreightonRoyaltyAgreementMember 2012-01-01 2012-09-30 0000876378 sfes:SeriesPreferredConversionMember us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0000876378 sfes:SeriesPreferredConversionMember 2010-01-01 2010-12-31 0000876378 sfes:TwoThousandTwelvePipeInvestorsMember 2012-02-17 0000876378 2012-09-30 0000876378 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2010-01-01 2010-12-31 0000876378 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2009-01-01 2009-12-31 0000876378 us-gaap:CommonStockMember 2010-06-01 2010-06-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2010-06-01 2010-06-30 0000876378 2010-06-01 2010-06-30 0000876378 us-gaap:CommonStockMember 2008-05-01 2008-05-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2008-05-01 2008-05-31 0000876378 2008-05-01 2008-05-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0000876378 2008-01-01 2008-12-31 0000876378 us-gaap:CommonStockMember 2008-01-01 2008-12-31 0000876378 2005-09-16 2012-09-30 0000876378 us-gaap:SeriesAPreferredStockMember 2005-09-16 2012-09-30 0000876378 sfes:SeriesPreferredConversionMember 2005-09-16 2012-09-30 0000876378 us-gaap:PreferredStockMember sfes:SeriesPreferredConversionMember 2010-01-01 2010-12-31 0000876378 us-gaap:CommonStockMember 2010-01-01 2010-12-31 0000876378 us-gaap:PreferredStockMember 2010-09-01 2010-09-30 0000876378 us-gaap:CommonStockMember 2010-09-01 2010-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2010-09-01 2010-09-30 0000876378 us-gaap:MinimumMember 2008-01-08 0000876378 us-gaap:MaximumMember 2008-01-08 0000876378 2011-01-01 2011-09-30 0000876378 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0000876378 2010-01-01 2010-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0000876378 2009-01-01 2009-12-31 0000876378 2012-11-10 0000876378 2012-01-01 2012-09-30 xbrli:pure sfes:Investor iso4217:USD xbrli:shares xbrli:shares iso4217:USD <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock--> <!-- xbrl,ns --> <!-- xbrl,nx --> <font style="font-family:times new roman" size="2"><b><u></u></b></font> <font style="font-family:times new roman" size="2"><b></b></font> <font style="font-family:times new roman" size="2"> <b></b></font> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 1 &#8211; BASIS OF PRESENTATION AND LIQUIDITY </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The following (a)&#160;condensed consolidated balance sheet as of December&#160;31, 2011, which has been derived from audited financial statements, and (b)&#160;the unaudited condensed consolidated interim financial statements of SafeStitch Medical, Inc. (&#8220;SafeStitch&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Rule&#160;8-03 of Regulation&#160;S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September&#160;30, 2012 are not necessarily indicative of results that may be expected for the year ending December&#160;31, 2012. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2011 included in the Company&#8217;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;30, 2012. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">SafeStitch Medical, Inc. (together with its consolidated subsidiaries, &#8220;SafeStitch&#8221; or the &#8220;Company&#8221;) is a developmental stage medical device company focused on the development of medical devices that manipulate tissues for endoscopic and minimally invasive surgery for the treatment of obesity, gastroesophageal reflux disease (&#8220;GERD&#8221;), Barrett&#8217;s Esophagus, esophageal obstructions, upper gastrointestinal bleeding, hernia formation and other intraperitoneal abnormalities. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"> Cellular Technical Services Company, Inc. (&#8220;Cellular&#8221;), a non-operating public company, was incorporated in 1988 as NCS Ventures Corp. under the laws of the State of Delaware. On July&#160;25, 2007 Cellular entered into a Share Transfer, Exchange and Contribution Agreement (the &#8220;Share Exchange&#8221;) with SafeStitch LLC, a Virginia limited liability company. On September&#160;4, 2007, Cellular acquired all of the members&#8217; equity interests in SafeStitch LLC in exchange for 11,256,369 shares of Cellular&#8217;s common stock, which represented a majority of Cellular&#8217;s outstanding shares immediately following the Share Exchange. Effective January&#160;8, 2008, Cellular changed its name to SafeStitch Medical, Inc. and increased the aggregate number of shares of capital stock that may be issued from 35,000,000 to 250,000,000, comprising 225,000,000 shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), and 25,000,000 shares of preferred stock, par value $0.01 per share. For accounting purposes, the acquisition has been treated as a recapitalization of SafeStitch LLC, with SafeStitch LLC as the acquirer (reverse acquisition). The historical financial statements prior to September&#160;4, 2007 are those of SafeStitch LLC, which began operations on September&#160;15, 2005. The accompanying financial statements give retroactive effect to the recapitalization as if it had occurred on September&#160;15, 2005 (inception). </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the period from September&#160;15,&#160;2005 (inception)&#160;through September&#160;30, 2012, the Company has accumulated a deficit of $28.3 million and has not generated positive cash flows from operations. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company has been dependent upon equity financing and loans from stockholders to meet its obligations and sustain operations. The Company&#8217;s efforts have been principally devoted to developing its technologies and commercializing its products. Based upon its current cash position, availability under the extended term of its $4.0 million Note and Security Agreement (the &#8220;Credit Facility&#8221;) with both The Frost Group LLC (&#8220;The Frost Group&#8221;) and the Company&#8217;s President and CEO, Jeffrey G. Spragens, and by monitoring its discretionary expenditures, management believes that the Company may be able to fund its existing operations through June&#160;30, 2013 when the Credit Facility matures. However, given the short time period until the Credit Facility matures and the probable inability to pay back the amounts due at maturity on June&#160;30, 2013, the Company is exploring more permanent or longer term financing alternatives. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company does not currently generate sufficient revenue from sales of the AMID&#8482; Hernia Fixation Device (the &#8220;AMID HFD&#8221;) and external financing will therefore be necessary in order to fund the Company&#8217;s planned operations, including the continued development of our Intraluminal Gastroplasty Device for Obesity and GERD (&#8220;Gastroplasty Device&#8221;), and the anticipated expansion in 2013 of clinical trials for certain of the Company&#8217;s product candidates. The Company has taken several steps to preserve cash, including eliminating staff and focusing efforts solely on sales of the AMID HFD and development of our Gastroplasty Device. If adequate funds are not available, the Company may be required to delay, further reduce the scope of or eliminate its research and development programs, reduce its planned commercialization efforts or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain product candidates that it might otherwise seek to develop or commercialize independently. </font></p> <p style="margin-top:0px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Although the Company is seeking to secure additional funds through the issuance of equity and/or debt, no assurance can be given that additional financing will be available to the Company on acceptable terms, or at all. Unless the Credit Facility Maturity Date is extended or replaced with similar terms, additional funding will be required to repay both the Credit Facility and to continue operations. This uncertainty, along with the Company&#8217;s limited remaining cash balances, raises substantial doubt about the Company&#8217;s ability to continue as a going concern. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The accompanying financial statements do not include any adjustments that might be necessary as a result of the outcome of such uncertainty. In addition to securing additional funds, the Company&#8217;s ability to continue as a going concern is ultimately dependent upon generating revenues from those products that do not require further marketing clearance by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), obtaining FDA clearance to market its other product candidates, and achieving profitable operations and generating sufficient cash flows from operations to meet future obligations. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </b></font></p> <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Consolidation.</i></b><i> </i>The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Isis Tele-Communications, Inc., which has no current operations, and SafeStitch LLC. All inter-company accounts and transactions have been eliminated in consolidation. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i></i></b><i></i><b><i>Use of estimates.</i></b><i></i><b><i> </i></b>The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions, such as useful lives of property and equipment, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Cash and cash equivalents</i></b><i>. </i>We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company holds cash and cash equivalent balances in banks and other financial institutions, and includes overnight repurchase agreements collateralizing its depository bank accounts (sweep accounts) in its cash balances. Balances in excess of Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) limitations may not be insured. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Allowances for Doubtful Accounts. </i></b>The Company provides an allowance for receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance for doubtful accounts at the end of each period are determined using a combination of customer-by-customer analysis of the Company&#8217;s accounts receivable each period and subjective assessments of the Company&#8217;s future bad debt exposure. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Inventories. </i></b>Inventories are stated at lower of cost or market using the weighted average cost method and are evaluated for impairment when conditions exist that suggests impairment may be necessary. The $1.7 million inventory balance at September&#160;30, 2012 consists of $1.0 million in components, $664,000 in finished units of the AMID HFD and $19,000 in standard mesh. Scrap materials and quality testing costs are included in Cost of Goods Sold (&#8220;COGS&#8221;), as incurred. Provisions for potentially obsolete or slow-moving inventory are made based on management&#8217;s analysis of inventory levels, obsolescence and future sales forecasts. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Property and equipment.</i></b><i> </i>Property and equipment are carried at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs that do not extend the lives of assets are expensed. Gain or loss, if any, on the disposition of fixed assets is recognized currently in operations. Depreciation is calculated primarily on a straight-line basis over estimated useful lives of the assets. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Revenue Recognition. </i></b>Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. </font></p> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Advertising Costs. </i></b>The Company expenses all costs of advertising as incurred. Advertising and promotional costs are included in selling, general and administrative costs and expenses for all periods presented, and totaled $22,000 and $106,000, respectively, for the three and nine months ended September&#160;30, 2012. Advertising and promotional costs and expenses totaled $2,000 and $11,000, respectively, for the three and nine months ended September&#160;30, 2011. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Research and development.</i></b> Research and development costs principally represent salaries of the Company&#8217;s medical and biomechanical engineering professionals, material and shop costs associated with manufacturing product prototypes and payments to third parties for clinical trials and additional product development and testing. All research and development costs are charged to expense as incurred. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Patent costs.</i></b><i> </i>Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Stock-based compensation.</i></b><i> </i>The Company accounts for all share-based payments to employees and directors, based on their grant date fair values. Compensation for share-based payments to non-employees is based on the fair value at the measurement date, which is generally the performance completion date. The fair value is initially measured at the grant date and subsequently measured at each reporting period until the final measurement date. The fair value of the Company&#8217;s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Stock-based compensation is included in general and administrative costs and expenses for all periods presented. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Therapeutic discovery project tax credit.</i></b><i> </i>The Company records the therapeutic discovery project tax credit on an accrual basis when the credit is considered realized, which is generally when approved by the government agency. Such credit is reported as other income in the accompanying financial statements. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Fair value of financial instruments.</i></b><i> </i>The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. Related party receivables and stockholder loans are carried at cost. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Long-lived assets.</i></b><i> </i>The Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less costs to sell. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Income taxes.</i></b><i> </i>The Company follows the liability method of accounting for income taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of the assets and liabilities. The Company&#8217;s policy is to record a valuation allowance against deferred tax assets, when the deferred tax asset is not recoverable. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance. </font></p> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Comprehensive income (loss).</i></b><i> </i>Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive net loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive income (loss) has been included in the condensed consolidated financial statements. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 3 - us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock--> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 3 &#8211; PROPERTY AND EQUIPMENT </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Property and equipment consist of the following: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="51%">&#160;</td> <td valign="bottom" width="10%">&#160;</td> <td>&#160;</td> <td valign="bottom" width="10%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="10%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Estimated&#160;Useful&#160;Lives</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,&#160;2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,&#160;2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Machinery and equipment</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">5&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">660,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">660,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Furniture, fixtures and leasehold improvements</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">3-5&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">87,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">81,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Software</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">3-5 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">57,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">57,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">804,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">798,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accumulated depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(455,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(328,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Property and equipment, net</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2"><b>$</b></font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2"><b>349,000</b></font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2"><b>$</b></font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2"><b>470,000</b></font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2">Depreciation of fixed assets utilized in research and development activities is included in research and development costs and expenses. All other depreciation is included in selling, general and administrative costs and expenses. Depreciation and amortization expense was $43,000 and $127,000, respectively for the three and nine months ended September&#160;30, 2012, and was $43,000 and $100,000, respectively for the three and nine months ended September&#160;30, 2011. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 4 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 4 &#8211; STOCK-BASED COMPENSATION </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On November&#160;13, 2007, the Board of Directors and a majority of the Company&#8217;s stockholders approved the SafeStitch Medical, Inc. 2007 Incentive Compensation Plan (the &#8220;2007 Plan&#8221;), which was amended on June&#160;19, 2012 to increase the number of shares of Common Stock available for issuance to 5,000,000. Under the 2007 Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock and/or deferred stock to employees, officers, directors, consultants and vendors up to an aggregate of 5,000,000 shares of Common Stock, which are fully reserved for future issuance. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company&#8217;s shares at the date of grant and, within any 12 month period, no person may receive stock options or stock appreciation rights for more than one million shares. Additionally, no stock options or stock appreciation rights granted under the 2007 Plan may have a term exceeding ten years. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company granted 813,500 and 562,500 stock options under the 2007 Plan during the nine months ended September&#160;30, 2012 and 2011, respectively, including 218,000 and 68,000 stock options that were issued to consultants. The options granted during 2012 were issued at an exercise price ranging from $0.65 to $0.85 per share and had an estimated aggregate grant date fair value of $441,000. The options granted during 2011 were issued at an exercise price of $1.12 per share and had an estimated aggregate grant date fair value of $502,000. The weighted average grant date fair value of the options granted during the nine months ended September&#160;30, 2012 and 2011 was $0.54 per share and $0.89 per share, respectively. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Total stock-based compensation recorded for the three and nine months ended September&#160;30, 2012 was $113,000 and $336,000, respectively. Total stock-based compensation recorded for the three and nine months ended September&#160;30, 2011 was $98,000 and $240,000, respectively. The stock-based compensation recorded for the nine months ended September&#160;30, 2011 included a credit of $113,000 for a change in forfeiture experience. All stock-based compensation is included in selling, general and administrative costs and expenses. The fair values of options granted are estimated on the date of their grant using the Black-Scholes option pricing model based on the assumptions included in the table below. The fair value of the Company&#8217;s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Expected volatility is based on the historical volatility of the Common Stock. The risk-free interest rate for periods within the contractual life of the stock option award is based on the yield of U.S. Treasury bonds on the grant date with a maturity equal to the expected term of the stock option. The expected life of stock option awards granted to employees and non-employee directors is based upon the &#8220;simplified&#8221; method for &#8220;plain vanilla&#8221; options described in SEC Staff Accounting Bulletin No.&#160;107, as amended by SEC Staff Accounting Bulletin No.&#160;110. The expected life of all other stock option awards is the contractual term of the option. Forfeiture rates are based on management&#8217;s estimates. The fair value of each option granted during the nine months ended September&#160;30, 2012 and 2011 was estimated using the following assumptions. </font></p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="60%">&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine&#160;months&#160;ended<br />September&#160;30,&#160;2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine&#160;months&#160;ended<br />September&#160;30,&#160;2011</b></font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected volatility</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">85.41%&#160;-&#160;111.36%</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">76.91%&#160;-&#160;102.63%</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected dividend yield</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">0.00%</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">0.00%</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">1.02%&#160;&#8211;&#160;1.98%</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">2.25% &#8211; 3.25%</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected life</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">5.5&#160;&#8211;&#160;10.0&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">5.5 &#8211; 10.0 years</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeiture rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">0% - 2%</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">0% - 5%</font></td> </tr> <!-- End Table Body --> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The following summarizes the Company&#8217;s stock option activity for the nine months ended September&#160;30, 2012: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="62%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Exercise<br />Price</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Remaining<br />Contractual<br />Term&#160;(Years)</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate<br />Intrinsic<br />Value</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December&#160;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,628,167</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.35</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6.26</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">813,500</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.66</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">9.39</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Canceled or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(237,667</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.99</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at September&#160;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,204,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.02</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7.09</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at September&#160;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">990,875</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.24</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.41</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Vested and expected to vest at September&#160;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,155,239</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.03</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7.05</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2">None of the 813,500 options granted during the first nine months of the Company&#8217;s 2012 fiscal year were vested as of September&#160;30, 2012. At September&#160;30, 2012, there was approximately $333,000 of total unrecognized compensation cost related to non-vested employee and director share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.53 years. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">No options were exercised during the three and nine months ended September&#160;30, 2012 and 2011. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 5 - us-gaap:DebtDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 5 &#8211; DEBT </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"><i>Credit Facility</i>. In connection with the acquisition of SafeStitch LLC, the Company entered into a Note and Security Agreement (the &#8220;Credit Facility&#8221;) with both The Frost Group and Jeffrey G. Spragens, the Company&#8217;s Chief Executive Officer and President and a director. The Frost Group is a Florida limited liability company whose members include Frost Gamma Investments Trust (&#8220;Frost Gamma&#8221;), a trust controlled by Dr.&#160;Phillip Frost, the largest beneficial holder of the issued and outstanding shares of Common Stock, Dr.&#160;Jane&#160;H. Hsiao, the Company&#8217;s Chairman of the Board, and Steven D. Rubin, a director. The Credit Facility provides $4.0 million in total available borrowings, consisting of $3.9 million from The Frost Group and $100,000 from Mr.&#160;Spragens. The Company has granted a security interest in all present and subsequently acquired collateral in order to secure prompt, full and complete payment of the amounts outstanding under the Credit Facility. The collateral includes all assets of the Company, inclusive of intellectual property (patents, patent rights, trademarks, service marks, etc.). Outstanding borrowings under the Credit Facility accrue interest at a 10% annual rate. The Credit Facility had an initial term of 28 months, expiring in December 2009, and was amended on four occasions to extend the Maturity Date, which is now June&#160;30, 2013. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In connection with the Credit Facility, the Company granted warrants to purchase an aggregate of 805,521 shares of Common Stock to The Frost Group and Mr.&#160;Spragens. The fair value of the warrants was determined to be $1,985,000 on the grant date based on the Black-Scholes valuation model using the following assumptions: expected volatility of 82%, dividend yield of 0%, risk-free interest rate of 4.88% and expected life of 10 years. The fair value of the warrants was recorded as deferred financing costs and is being amortized over the life of the Credit Facility. The Company recorded amortization expense related to these deferred financing costs of $2,000 and $7,000, respectively, for the three and nine months ended September&#160;30, 2012 and $5,000 and $36,000, respectively, for the three and nine months ended September&#160;30, 2011. In October 2012, The Frost Group and Mr.&#160;Spragens exercised the warrants for the purchase of 805,521 shares of Common Stock. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company borrowed $300,000 under the Credit Facility during September 2012. The Company did not recognized interest expense related to the outstanding borrowings under the Credit Facility for the three months ended September&#160;30, 2012. The Company has a $300,000 outstanding balance and $3,700,000 available under the Credit Facility as of September&#160;30, 2012. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 6 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 6 &#8211; CAPITAL TRANSACTIONS </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"><i>2012 Private Placement of Common Stock. </i>On February&#160;17, 2012, the Company entered into a stock purchase agreement (the &#8220;2012 Stock Purchase Agreement&#8221;) with 35 investors (the &#8220;2012 PIPE Investors&#8221;) pursuant to which the 2012 PIPE Investors agreed to purchase an aggregate of 20,794,000 shares of Common Stock (the &#8220;2012 PIPE Shares&#8221;) at a price of $0.40 per share for aggregate consideration of $8.3 million. Among the Investors purchasing Shares were Frost Gamma, Dr.&#160;Jane Hsiao, the Company&#8217;s Chairman of the Board, Jeffrey Spragens, the Company&#8217;s President and Chief Executive Officer and Richard Pfenniger, a member of the Company&#8217;s Board of Directors. Frost Gamma and Dr.&#160;Hsiao each purchased 4,500,000 shares, Mr.&#160;Spragens purchased 250,000 shares, and Mr.&#160;Pfenniger purchased 125,000 shares. The Company issued the 2012 PIPE Shares in reliance upon the exemption from registration under Section&#160;4(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Rule 506 of Regulation D promulgated thereunder. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 7 - us-gaap:EarningsPerShareTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 7 &#8211; BASIC AND DILUTED NET LOSS PER SHARE </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period reported. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding for the period reported. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three and nine months ended September&#160;30, 2012 and 2011, no adjustment has been made to the weighted average outstanding common shares as the assumed exercise of outstanding options and warrants and conversion of preferred stock is anti-dilutive. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Potential common shares not included in calculating diluted net loss per share are as follows: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="64%">&#160;</td> <td valign="bottom" width="9%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="9%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,&#160;2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,&#160;2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,204,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,629,667</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock warrants</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">805,521</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">805,521</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Total</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2"><b>3,009,521</b></font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2"><b>2,435,188</b></font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 8 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 8 &#8211; COMMITMENTS AND CONTINGENCIES </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company is obligated under various operating lease agreements for office space. Generally, the lease agreements require the payment of base rent plus escalations for increases in building operating costs and real estate taxes. Rental expense under operating leases amounted to $76,000 and $209,000 for the three and nine months ended September&#160;30, 2012, respectively, and $58,000 and $163,000 for the three and nine months ended September&#160;30, 2011, respectively. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company is obligated to pay royalties to Creighton University (&#8220;Creighton&#8221;) on the sales of products licensed from Creighton pursuant to an exclusive license and development agreement (see Note 9). The Company is also obligated under an agreement with Dr.&#160;Parviz Amid to pay a 4% royalty to Dr.&#160;Amid on the sales of any product developed with Dr.&#160;Amid&#8217;s assistance, including the AMID HFD, for a period of ten years from the first commercial sale of such product. Royalties to Dr.&#160;Parviz Amid in the amount of $400 and $800 have been incurred during the three and nine months ended September&#160;30, 2012, respectively. No royalties have been incurred or paid for the three and nine months ended September&#160;30, 2011. </font></p> <p style="margin-top:0px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company has placed orders with various suppliers for the purchase of certain tooling, contract engineering and research services. Each of these orders has a duration or expected completion within the next twelve months. The Company currently has no material commitments with terms beyond twelve months. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 9 - sfes:AgreementWithUniversityTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 9 &#8211; AGREEMENT WITH CREIGHTON UNIVERSITY </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On May&#160;26, 2006, SafeStitch LLC entered into an exclusive license and development agreement (the &#8220;Creighton Agreement&#8221;) with Creighton, granting the Company a worldwide exclusive (even as to the university) license, with rights to sublicense, to all the Company&#8217;s product candidates and associated know-how based on Creighton technology, including the exclusive right to manufacture, use and sell the product candidates. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Pursuant to the Creighton Agreement, the Company is obligated to pay Creighton, on a quarterly basis, a royalty of 1.5% of the revenue collected worldwide from the sale of any product licensed under the Creighton Agreement, less certain amounts including, without limitation, chargebacks, credits, taxes, duties and discounts or rebates. The Creighton Agreement does not provide for minimum royalties. Also pursuant to the Creighton Agreement, the Company agreed to invest, in the aggregate, at least $2.5 million over 36 months, beginning May&#160;26, 2006, towards development of any licensed product. This $2.5 million investment obligation excluded the first $150,000 of costs related to the prosecution of patents, which the Company invested outside of the Creighton Agreement. The Company is further obligated to pay to Creighton an amount equal to 20% of certain of the Company&#8217;s research and development expenditures as reimbursement for the use of Creighton&#8217;s facilities. Failure to comply with the payment obligations above will result in all rights in the licensed patents and know-how reverting back to Creighton. As of December&#160;31, 2007, the Company had satisfied the $2.5 million investment obligation described above. The Company recorded research and development costs and expenses related to the 20% facility reimbursement obligation totaling approximately $10,000 and $34,000, respectively for the three and nine months ended September&#160;30, 2012, and $12,000 and $33,000, respectively, for the three and nine months ended September&#160;30, 2011. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 10 - us-gaap:IncomeTaxDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 10 &#8211; INCOME TAXES </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company accounts for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company&#8217;s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. All of the Company&#8217;s deferred tax assets have been fully reserved by a valuation allowance due to management&#8217;s uncertainty regarding the future profitability of the Company. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company has recognized no adjustment for uncertain tax provisions. SafeStitch recognizes interest and penalties related to uncertain tax positions in selling, general and administrative costs and expenses; however no such provisions for accrued interest and penalties related to uncertain tax positions have been recorded as of September&#160;30, 2012 or December&#160;31, 2011. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The tax years 2009-2011 remain open to examination by the major tax jurisdictions in which the Company operates. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 11 - us-gaap:RelatedPartyTransactionsDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 11 &#8211; CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">As more fully described in Note 5, the Company entered into a $4.0 million Credit Facility with both Jeffrey G. Spragens, the Company&#8217;s President, Chief Executive Officer and director, and The Frost Group. </font></p> <p style="margin-top:0px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company entered into a five-year lease for office space in Miami, Florida with a company controlled by Dr.&#160;Frost. The non-cancelable lease, which commenced January&#160;1, 2008, provides for a 4.5% annual rent increase over the life of the lease. The Miami office lease was amended in August 2011 to include additional office space in the same building, and current rental payments under the lease are approximately $19,000 per month. The Company recorded rent expense related to the Miami lease totaling approximately $73,000 and $198,000, respectively, for the three and nine months ended September&#160;30, 2012, and $51,000 and $145,000, respectively, for the three and nine months ended September&#160;30, 2011. </font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2"> Dr.&#160;Hsiao, Dr.&#160;Frost and director Steven Rubin are each significant stockholders and/or directors of Non-Invasive Monitoring Systems, Inc. (&#8220;NIMS&#8221;), a publicly-traded medical device company, Aero Pharmaceuticals, Inc. (&#8220;Aero&#8221;), a privately-held pharmaceutical distribution company that dissolved in December 2011, Tiger X Medical, Inc. (&#8220;Tiger X&#8221;) (formerly known as Cardo Medical, Inc.), a publicly-traded former medical device company, and SearchMedia Holdings Limited (&#8220;SearchMedia&#8221;), a publicly-traded media company operating primarily in China, and Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), a publicly-traded development stage biopharmaceutical company. Director Richard Pfenniger is also a shareholder of NIMS. The Company&#8217;s Chief Financial Officer also serves as the Chief Financial Officer and supervises the accounting staffs of NIMS and, until its dissolution, Aero, under a Board-approved cost sharing arrangement whereby the total salaries of the accounting staffs of the three companies are shared. Aero has not participated in the cost sharing arrangement since June&#160;30, 2011 and was dissolved in December 2011. Since December 2009, the Company&#8217;s Chief Legal Officer has served under a similar Board-approved cost sharing arrangement as Corporate Counsel of SearchMedia and as the Chief Legal Officer of each of NIMS and Tiger X, and from June 2011 through September&#160;19, 2012, as Corporate Counsel for Sorrento. The Company has recorded reductions to selling, general and administrative costs and expenses to account for the sharing of costs under these arrangements of $51,000 and $154,000, respectively, for the three and nine months ended September&#160;30, 2012, and $51,000 and $205,000, respectively, for the three and nine months ended September&#160;30, 2011. Aggregate accounts receivable from NIMS, Aero, Tiger X, Sorrento and SearchMedia were approximately $45,000 and $66,000 as of September&#160;30, 2012 and December&#160;31, 2011, respectively. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note 12 - us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock--> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>NOTE 12 &#8211; EMPLOYEE BENEFIT PLANS </b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Effective May&#160;1, 2008, the SafeStitch 401(k) Plan (the &#8220;401k Plan&#8221;) permits employees to contribute up to 100% of qualified annual compensation up to annual statutory limitations. Employee contributions may be made on a pre-tax basis to a regular 401(k) account or on an after-tax basis to a &#8220;Roth&#8221; 401(k) account. The Company contributes to the 401k Plan a &#8220;safe harbor&#8221; match of 100% of each participant&#8217;s contributions to the 401k Plan up to a maximum of 4% of the participant&#8217;s qualified annual earnings. The Company recorded 401(k) Plan matching expense of approximately $23,000 and $37,000, respectively, for the three and nine months ended September&#160;30, 2012 and $9,000 and $28,000, respectively, for the three and nine months ended September&#160;30, 2011. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table1 - us-gaap:ConsolidationPolicyTextBlock--> <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Consolidation.</i></b><i> </i>The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Isis Tele-Communications, Inc., which has no current operations, and SafeStitch LLC. All inter-company accounts and transactions have been eliminated in consolidation. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table2 - us-gaap:UseOfEstimates--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i></i></b><i></i><b><i>Use of estimates.</i></b><i></i><b><i> </i></b>The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions, such as useful lives of property and equipment, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table3 - us-gaap:CashAndCashEquivalentsPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Cash and cash equivalents</i></b><i>. </i>We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company holds cash and cash equivalent balances in banks and other financial institutions, and includes overnight repurchase agreements collateralizing its depository bank accounts (sweep accounts) in its cash balances. Balances in excess of Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) limitations may not be insured. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table4 - us-gaap:TradeAndOtherAccountsReceivablePolicy--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Allowances for Doubtful Accounts. </i></b>The Company provides an allowance for receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance for doubtful accounts at the end of each period are determined using a combination of customer-by-customer analysis of the Company&#8217;s accounts receivable each period and subjective assessments of the Company&#8217;s future bad debt exposure. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table5 - us-gaap:InventoryPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Inventories. </i></b>Inventories are stated at lower of cost or market using the weighted average cost method and are evaluated for impairment when conditions exist that suggests impairment may be necessary. The $1.7 million inventory balance at September&#160;30, 2012 consists of $1.0 million in components, $664,000 in finished units of the AMID HFD and $19,000 in standard mesh. Scrap materials and quality testing costs are included in Cost of Goods Sold (&#8220;COGS&#8221;), as incurred. Provisions for potentially obsolete or slow-moving inventory are made based on management&#8217;s analysis of inventory levels, obsolescence and future sales forecasts. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table6 - us-gaap:PropertyPlantAndEquipmentPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Property and equipment.</i></b><i> </i>Property and equipment are carried at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs that do not extend the lives of assets are expensed. Gain or loss, if any, on the disposition of fixed assets is recognized currently in operations. Depreciation is calculated primarily on a straight-line basis over estimated useful lives of the assets. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table7 - us-gaap:RevenueRecognitionPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Revenue Recognition. </i></b>Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table8 - us-gaap:AdvertisingCostsPolicyTextBlock--> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Advertising Costs. </i></b>The Company expenses all costs of advertising as incurred. Advertising and promotional costs are included in selling, general and administrative costs and expenses for all periods presented, and totaled $22,000 and $106,000, respectively, for the three and nine months ended September&#160;30, 2012. Advertising and promotional costs and expenses totaled $2,000 and $11,000, respectively, for the three and nine months ended September&#160;30, 2011. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table9 - us-gaap:ResearchAndDevelopmentExpensePolicy--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Research and development.</i></b> Research and development costs principally represent salaries of the Company&#8217;s medical and biomechanical engineering professionals, material and shop costs associated with manufacturing product prototypes and payments to third parties for clinical trials and additional product development and testing. All research and development costs are charged to expense as incurred. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table10 - us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Patent costs.</i></b><i> </i>Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table11 - us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Stock-based compensation.</i></b><i> </i>The Company accounts for all share-based payments to employees and directors, based on their grant date fair values. Compensation for share-based payments to non-employees is based on the fair value at the measurement date, which is generally the performance completion date. The fair value is initially measured at the grant date and subsequently measured at each reporting period until the final measurement date. The fair value of the Company&#8217;s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Stock-based compensation is included in general and administrative costs and expenses for all periods presented. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table12 - sfes:TaxCreditForResearchAndDevelopmentPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Therapeutic discovery project tax credit.</i></b><i> </i>The Company records the therapeutic discovery project tax credit on an accrual basis when the credit is considered realized, which is generally when approved by the government agency. Such credit is reported as other income in the accompanying financial statements. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table13 - us-gaap:FairValueOfFinancialInstrumentsPolicy--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Fair value of financial instruments.</i></b><i> </i>The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. Related party receivables and stockholder loans are carried at cost. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table14 - us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Long-lived assets.</i></b><i> </i>The Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less costs to sell. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table15 - us-gaap:IncomeTaxPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Income taxes.</i></b><i> </i>The Company follows the liability method of accounting for income taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of the assets and liabilities. The Company&#8217;s policy is to record a valuation allowance against deferred tax assets, when the deferred tax asset is not recoverable. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Accounting Policy: sfes-20120930_note2_accounting_policy_table16 - us-gaap:ComprehensiveIncomePolicyPolicyTextBlock--> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i></i><b><i>Comprehensive income (loss).</i></b><i> </i>Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive net loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive income (loss) has been included in the condensed consolidated financial statements. </font></p> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: sfes-20120930_note3_table1 - us-gaap:PropertyPlantAndEquipmentTextBlock--> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Property and equipment consist of the following: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="51%">&#160;</td> <td valign="bottom" width="10%">&#160;</td> <td>&#160;</td> <td valign="bottom" width="10%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="10%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Estimated&#160;Useful&#160;Lives</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,&#160;2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,&#160;2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Machinery and equipment</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">5&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">660,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">660,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Furniture, fixtures and leasehold improvements</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">3-5&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">87,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">81,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Software</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center"><font style="font-family:times new roman" size="2">3-5 years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">57,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">57,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">804,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">798,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accumulated depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(455,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(328,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Property and equipment, net</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2"><b>$</b></font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2"><b>349,000</b></font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2"><b>$</b></font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2"><b>470,000</b></font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: sfes-20120930_note4_table1 - us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock--> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"> <font style="font-family:times new roman" size="2"> The fair value of each option granted during the nine months ended September&#160;30, 2012 and 2011 was estimated using the following assumptions. </font></p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="60%">&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> <td valign="bottom" width="3%">&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine&#160;months&#160;ended<br />September&#160;30,&#160;2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Nine&#160;months&#160;ended<br />September&#160;30,&#160;2011</b></font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected volatility</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">85.41%&#160;-&#160;111.36%</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">76.91%&#160;-&#160;102.63%</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected dividend yield</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">0.00%</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">0.00%</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">1.02%&#160;&#8211;&#160;1.98%</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">2.25% &#8211; 3.25%</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected life</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">5.5&#160;&#8211;&#160;10.0&#160;years</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">5.5 &#8211; 10.0 years</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Forfeiture rate</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">0% - 2%</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="font-family:times new roman" size="2">0% - 5%</font></td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: sfes-20120930_note4_table2 - us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock--> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The following summarizes the Company&#8217;s stock option activity for the nine months ended September&#160;30, 2012: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="62%">&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="6%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Exercise<br />Price</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Remaining<br />Contractual<br />Term&#160;(Years)</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate<br />Intrinsic<br />Value</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December&#160;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,628,167</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.35</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6.26</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">813,500</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.66</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">9.39</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Canceled or expired</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(237,667</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.99</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at September&#160;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,204,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.02</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7.09</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercisable at September&#160;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">990,875</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.24</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.41</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Vested and expected to vest at September&#160;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,155,239</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.03</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7.05</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --> <!-- Begin Block Tagged Note Table: sfes-20120930_note7_table1 - us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock--> <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Potential common shares not included in calculating diluted net loss per share are as follows: </font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"> <!-- Begin Table Head --> <tr> <td width="64%">&#160;</td> <td valign="bottom" width="9%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td valign="bottom" width="9%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,&#160;2012</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>September&#160;30,&#160;2011</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> </tr> <!-- End Table Head --> <!-- Begin Table Body --> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,204,000</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,629,667</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock warrants</font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">805,521</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">805,521</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#160;</p> </td> <td>&#160;</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Total</b></font></p> </td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2"><b>3,009,521</b></font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> <td valign="bottom"><font size="1">&#160;</font></td> <td valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> <td valign="bottom" align="right"><font style="font-family:times new roman" size="2"><b>2,435,188</b></font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"><b>&#160;</b></font></td> </tr> <tr style="font-size:1px"> <td valign="bottom">&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> <td valign="bottom">&#160;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#160;</p> </td> <td>&#160;</td> </tr> <!-- End Table Body --> </table> false --12-31 Q3 2012 2012-09-30 10-Q 0000876378 48797755 Smaller Reporting Company SafeStitch Medical, Inc. 200000 200000 500000 500000 200000 200000 500000 500000 113000 250000000 35000000 4366000 4366000 4366000 36000 4000 -40000 4366000 -4000000 P28M 4301000 700000 1985000 4301000 4301000 139000 8000 10000 10000 2.15 2.15 2.15 1.00 1.00 1.00 2000000 2000000 1982000 1962000 20000 1998000 1978000 20000 P5Y 1000000 P10Y 2500000 3192000 35 5063000 5063000 150000 4000 0.045 0.04 0.015 0.04 P12M P36M P10Y P12M 1.22 1.22 1.22 1.00 1.00 1.00 1.00 1.00 1.00 6135000 1100000 800000 0 205000 51000 154000 51000 0.20 5751000 2975000 33000 12000 34000 10000 P10Y P10Y 0.05 0.02 P5Y6M P5Y6M 0.00 0.00 P5Y4M28D 502000 441000 P9Y4M21D P6Y3M4D P7Y1M2D P7Y18D 77000 84000 0.40 805521 1985000 469000 860000 9000 328000 455000 20762000 29396000 4301000 4301000 1000 1000 239000 239000 195000 195000 471000 471000 335000 335000 337000 337000 11000 2000 240000 98000 336000 113000 36000 5000 7000 2000 2435188 1629667 805521 3009521 2204000 805521 993000 2300000 507000 1942000 11256369 3032000 328000 298000 118000 118000 -2704000 180000 5000000 0.001 0.001 0.001 0.40 0.40 225000000 225000000 225000000 697000 28003755 48797755 20794000 20794000 28003755 48797755 28000 49000 4000000 4000000 4000000 179000 179000 8000 27240000 4107000 1481000 5307000 1379000 2013-06-30 14000 7000 28000 9000 37000 23000 1.00 1.00 469000 100000 127000 100000 43000 127000 43000 22789000 28305000 366000 5001000 66000 45000 2523000 300000 -0.15 -0.05 -0.12 -0.03 P1Y6M11D 333000 0 0.00 P10Y 0.82 0.0488 -20000 -20000 903000 -159000 -159000 3000 -28305000 -4150000 -1493000 -5516000 -1378000 576000 194000 391000 7000 -48000 1826000 -5000 1687000 117000 8000 -72000 2000 155000 7000 7000 43000 0 155000 91000 664000 1687000 1000000 19000 79000 993000 2300000 469000 860000 300000 2013-06-30 300000 0.10 4000000 3900000 4000000 100000 3700000 26302000 1051000 6143000 69000 -199000 -6000 -26253000 -3556000 -6317000 -76000 -76000 -28305000 -1060000 -1060000 -3041000 -3041000 -5185000 -5185000 -2366000 -2366000 -5303000 -5303000 -4150000 -5758000 -5758000 -1493000 -5516000 -5516000 -1378000 -33672000 -4150000 -1493000 -5516000 -1378000 -906000 -43000 -12000 -50000 -2000 -27399000 -4107000 -1481000 -5466000 -1376000 163000 145000 58000 51000 19000 209000 198000 76000 73000 16000 9000 1147000 838000 199000 6000 366000 0.01 25000000 143000 83000 1431000 17280000 8318000 3980000 141000 903000 35000 798000 81000 660000 57000 804000 87000 660000 57000 470000 349000 P5Y P5Y P3Y P5Y P3Y 141000 49000 15441000 2480000 975000 2504000 557000 28300000 0 0 800 400 20000 20000 11000 2000 2000 11799000 1627000 506000 2803000 822000 1642000 240000 337000 0.0000 0.0000 1.0263 1.1136 0.7691 0.8541 0.0325 0.0198 0.0225 0.0102 0 990875 1.24 237667 1.99 562500 68000 813500 218000 0.89 0.54 0 1628167 2204000 1.35 1.02 0 2155239 1.03 0 1.12 0.66 0.85 0.65 11256000 16093000 17963000 17963000 2000000 28004000 28004000 48798000 -75000 -76000 1000 369000 -1136000 1494000 11000 2421000 -4177000 6582000 16000 1473000 -9362000 10817000 18000 1284000 -11728000 12974000 18000 20000 3424000 -17031000 20427000 28000 -1999000 -22789000 20762000 28000 1140000 -28305000 29396000 49000 697000 20794000 1862000 4978000 20794000 4500000 125000 250000 4500000 11256000 4837000 0 0 0 -1000 1000 8318000 8297000 21000 3988000 3986000 2000 4974000 4969000 5000 8300000 1504000 1493000 11000 5093000 5088000 5000 0 0 0 0 0 0 0 28004000 28004000 45155000 48798000 1977000 36000 5000 7000 2000 EX-101.SCH 7 sfes-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 06031 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0601 - Disclosure - Basis of Presentation and Liquidity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0612 - Disclosure - Employee Benefit Plans (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0611 - Disclosure - Certain Relationships and Related Party Transactions (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0610 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0609 - Disclosure - Agreement With Creighton University (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0608 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0507 - Disclosure - Basic and Diluted Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Capital Transactions (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Debt (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06042 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06041 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 0604 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0504 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0503 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0402 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0131 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0140 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0212 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0211 - Disclosure - Certain Relationships and Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0210 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0209 - Disclosure - Agreement with Creighton University link:presentationLink link:calculationLink link:definitionLink 0208 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0207 - Disclosure - Basic and Diluted Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0206 - Disclosure - Capital Transactions link:presentationLink link:calculationLink link:definitionLink 0205 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0204 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 0202 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0201 - Disclosure - Basis of Presentation and Liquidity link:presentationLink link:calculationLink link:definitionLink 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0130 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0110 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 sfes-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 sfes-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 sfes-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 sfes-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
Basic and Diluted Net Loss Per Share (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Summary of Potential Common Shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share     3,009,521 2,435,188
Basic and Diluted Net Loss Per Share (Textual) [Abstract]        
Weighted average outstanding common shares 0 0 0 0
Stock Options [Member]
       
Summary of Potential Common Shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share     2,204,000 1,629,667
Stock Warrants [Member]
       
Summary of Potential Common Shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share     805,521 805,521
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Significant Accounting Policies (Details Textual) (USD $)
3 Months Ended 9 Months Ended 84 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Summary of Significant Accounting Policies (Textual) [Abstract]          
Inventory Balance $ 1,687,000   $ 1,687,000   $ 1,687,000
Components 1,000,000   1,000,000   1,000,000
Finished units 664,000   664,000   664,000
Standard mesh 19,000   19,000   19,000
Selling, General and Administrative costs and expenses 822,000 506,000 2,803,000 1,627,000 11,799,000
Advertising and Promotional costs and expense   $ 2,000   $ 11,000  
XML 15 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Certain Relationships and Related Party Transactions (Details Textual) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Certain Relationships And Related Party Transactions (Textual) [Abstract]          
Credit facility $ 4,000,000   $ 4,000,000    
Lease period for office space     5 years    
Percentage of annual rent increase of lease     4.50%    
Current rental payments under the lease     19,000    
Reduction in selling general and administrative costs and expenses 51,000 51,000 154,000 205,000  
Aggregate account receivable from NIMS 45,000   45,000   66,000
Mr. Spragens and The Frost Group [Member]
         
Certain Relationships And Related Party Transactions (Textual) [Abstract]          
Credit facility 4,000,000   4,000,000    
Miami [Member]
         
Certain Relationships And Related Party Transactions (Textual) [Abstract]          
Current rental payments under the lease $ 73,000 $ 51,000 $ 198,000 $ 145,000  
ZIP 16 0001193125-12-469871-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-469871-xbrl.zip M4$L#!!0````(`)EH;D%9X?*>NW<``+$H!0`1`!P`%OU2K[[?SA(_M1>$+S0/38LPR&]-TMUY_9A?+'6@Z&`7MW\2WKCMG# M`[M4GB=<5XQ9M1IWMYM&B<=L6\0V@V@'G?G)#GYLN M-8XNT!.JC69UOYD,'?J3?T$S>+4WN2'=^+!N+R9-C9RE$VC9K/]V^['M#,6( M5Z`M863@#,M02":T[TO>Q]O_?X+-PG M<0O?#,V5UQ.]SG[S4C@@U%'GK->3>"-W._=<]CHW7N>"^S*`S[=BU!7:#AIZ M%!Z@/HX^P6?9PV_Z4FA&PHB,XF(-7-S\<^^'!OQW?'2X?W3\H3ZY;=*5$8,1 M?)M\`5]96$[%B^]*1P9V+*PGH9VUT(@>I^T`#!#OOOJ_$,9WH4:^\N"C.7N1 M9N^'N-E$3A3SQHN$M/U^J,]\W&2`]>P(/]0SROC@"RU5+R5/P'5P">/Z`76, MX#>:T$?R;=)0>+U),Z#)?A.[[J4:?:BG.O]0CV#]*Q@?EACGCO'AIQTHY_-NH6HE(\&^"FLMD=PFF[SS+(P6Q=;)M>ABK.Z<*ZY[G;M^ MYU)J",U*F\[%D$L]XEX$:N?Q674>ARHTW.MU+",Z]](7X)^?(,7"6[8#_@?A M8A)\#VH>/VKN&4ZYB#D?IZ]DN4#ZN>LGVHF5LQPQEAD=YDT39EZXW)B[?JQ: M.QAJ`C#$*%@0$(,$@OR)BMEAZ\^):INU3E9-U*59V+G7PA!U.F?0]&(H1;]S M]2*<,)!PSUV_+QUH56S*KI,4>9D0#3`!`[`@*!(D(B!VGK@S/.S7[%B)%=-> MM?2FA?6FBQ($Z+W@#-T9/SHO#T&`=X6LGZ27K34:;>$37AEMX`+CT)5_DH%6#,!T7W M*DMB3(8;B9V2V@J=DIE$S@=].P,<9$"-O_L"4.TD0+-93MGE#%HSKOI7"5II MB9NUQ!Q`;926F#-HC3Q`*RUQLY:X>E`;)Z4EY@L:9#$Y@%9:XD8M,1=0YP%:Z6DVZVGR`+5(GB8'^H1?(T M.8!6>IK->IH\0"V2I\E!OH/2T^1,RH,\0"L]S68]31Z@%LG3 MK%"^Y@$M?9>>9@VDQ/FU@]6"5GJ:37N:E8$ZV81RKT5?:`U0[N!>HD2X'+<3 MY;VAI`2HT/L,FN56O*)"TRAMI]`[`P"@TG:*"4WCI+2=@J_EE[935&B.2]LI M^.IT:3M%A>:HM)V"K[>6ME-4:`Y+VRGX"F)I.T6%YJ"TG8*OB96V4S1H)BM# MI>T4] M(5C\9S[&R^9\_"@#5^"9+G&CU%Z&E#J*!/X7':XQ#_QF"?XF MP6\N!WYS=2>K).E.L;;/?5'.,-^SM54_>`8"Q,=2;5<&<:\5*"`8WP-\>!(> M)GFTE0HH//:GPE4LZG*LW;U$)A?W.(-!6Y76%)A!Q.\B_7%F`&&L`WN2JO\Z#&W`T@Z`V@\38%/%"<%.9178"`FCL!KN=-5@/3 M2WNQK)&HB:0[`_2"J9?2-M\`V1JF4N;:9K/$[*]CUES.S+YP/7T!9J4_78\_ M70_0\W?-E+;Y%LC6L-=EP4:GTC3799H;Q+E\8]1&3F#:1.8TV7R9?,<``>_U&OJ3_+B0/GBC,USX'@Y M#ASGQ8'RE0:;Y\#1Y<:!8)K$F=;R: MNBW/B"^,1=B?@1W^&04.OHP"<[9(ZD[;UR"GMRV[0_YL6E?'\FS5!KF9@.!. MGFNM3-#Y4:O0WS6`0#R2CH3;3K1V#IWM`63Q[@Z0KA.+MQO(9"]\!7LW2A17 MA.*:?QDSV;^XA2<+V8SQ!B33P@0WQH2B=Z?Q7]YUQ:S-Q.L]5/6+-C'.CF%; MB%+QSG_*)[TH7X6T-:`M]'J=UHX`M:7.KGGR<^@AWAN?^\F2[[#:/%FEQV@6 M2;[FZG\_UBB2?%_X9HV[F7GO[#.T.Q?"=4.7ZRUQ^VO(HO[*<,Y#`UFY,6<. MC,M0I$FGY)%NU[,<=++4^D=.)=6O'+?-;D-S+W0]O2S\>P.LL2+5+(SE=B"(YW(H=SY MJ*UMF>Q="P5(,9%>=IX'S=();-();'HW>.D$BN$$-KU;O)Q9V`TWOV`W>`EQ M88QX55M9IB#>>#6\"6W,W\E2$GXW=JK,A[A0A%^3-N)Y(JN*ULFUZ%($?WQ6 MG<>A"@WW>AWK(SKWTA=`^R=A`J6+GM[1Y$M"^0N7&X.'D]O!I^9G0-!83BLF M2ID(N9Y(WEHNDK>JK9.5[,\JC(=?W1$W\W^TM'DI7\>Q_27C6`Z'DQ1+&QL^ MJJ5XW%C#[^]?+0W0TF*ST6G#[7C"UYR3H;;]P*@H!M#8IZIS$OSL+6=&Y9"` MK>/HJK?]I##R7&NFW>XDWMO"P,W5O,6FXM=-M*T$-G3I-\ME:"N$8UDW[7`] M?(F,RC;;`.W*T/;5A+:"4_'K)MHV`AL?Q5!NL%X-C'12PK('*JRN^(YAW)U0 M4%0'O%F`"S73M"9=+/SU57ELX"YN$WAU8EB4=TRR#M#7D]"HS*\A"[;+4*2# M1`43#7Q]:?"FSR];BI%?.=^V`-_,SV^.RD7K-2Q:9W];U*HVCU;Z:\2-YT]HE]3*Z:F5.9## MY1;0#E>Z-R2"<7=JM`(71AL$>./I5Q%T<& ML?19NPUPH7S6FG2QZ%#VDN]KX/M&#UTO'N4WJXXR4F\5L:]P'6Q\K4*=_KUA M868`W_#SJR]=.5NLD9V9G"G>K$B1X"U7HK88XK=/]N\"[(6===TT^S8]X5_. MO&X9DK,/[)OK1'8$R4VLPRUQ1IYMML*9Q1C,TB9W`L9RIF4W`)Y]Q/*M].0H M'&T)E`^XY30+6R1`WON`5GF&X\%/;]YX M#"D4ZC&:6_8A'E8+(>&:?I+TMVKU%T\&K"T<-.IJU7X=XG>HGOM0BT07(\$- M?/X!;5R>^O#GAWK\G>T;[YOJ(=YB_ZH7FFZ,KR[1T2_MRZO[=M)-3SZ!4B=Z MP':?PI'0'+I+.\"X8VG4=ZWFT2GTDWV:U='L^ZG;2^&ID?3F=6S58?!D8S.O MY]==?*BG))@I,)V5;.9H?];CYJGM51=S59'N`:C!KER*"#$]6,P/O'8N!M)C MYZYR/K-'/AB('OND`I&TB0/&G1YP3_Y!9T%?*,\H5_;HPYG7NP<9H/_HG.AK M4)#G2.XFH`]27-Y=//[G_HH-@Y'+[G\Y_WASP?:J]?JO^Q?U^N7C)?OMI\?; MCZQ9:[!'S3T3A;YZ_>K3'DM;_O-^3>E!_?&A_H)]-?'FZ,]JD+JSU@MZ>Z"C M;P;!>T(E&LA<=399E6U*E3.&B>RK>&:6!/;2R_2E/L#!3#!VP57BW]4^'TEW M?!I`"F*8)YZ95B/N[3$C_X`FK3V\&V_LQG^$\1_UR5_)Q3KVN>('KKSWY.ZE M'N''_8^X!E)4`^6?-EO^R_OH?+MG'FW_]'EZ_+]?)N#C4+"^,].`EXA`$K M0_5$6.[EYOUEA6$!7V/-0.D,VA(9=(3S6@T#[ M!-WT83`D/`\A6\8O8GL$&6*#K##N]=B[;FI4`0PX].*;YHQ1XEM\Y&AFGSC> M-N^+-N06,+!;T0,;=ROLQG-J[%T,<*OQ?M(H^1)05YKA$%+ML`S@WCC5Z%L0 M]TE8>7TM?(A#.";&P8_H'FGO609#^FS]"C23,%#?%8:4,A`>A%G7'6,;X5N9 MZ,&8B\`G8IR#6 M>O3V`P9R80?VP=G!])4*H"E(I@746*`W4D=WS%`ZDL@!=;L"W/XL<&L`(W6L M?.EAI_`L!V8[@>TW@XZW.I$>WH^XY$E/ ML!&54TQ@/44RMQ'V*:-JD%&U&!"*-!J/!,PC!8\$U/A$'-=>$6S4&3L*(>;8VT\;,4(5N#Q^J!2?NPCV_AY[- MD8C\.("4&2<=DO`S.T6"6'+`O5H`3Z<%@:[FNZ($B]B4I@RW>?3>L#//`[R! MW+[2`8.QQJ;PSPH,RH6;D\%/WLI!([MZ<88X;8O=CJ3!F8.L.[FZR%@G7+[E M.G8N:7AK["W!8G;X6VVTF.\W`S40B(I5CP2T,B0Q81>L1W+<.5%A*W*R$A1/ M*NF))^$J'UEB&0,HC.SX\)IT!'D-N!\8XX1(864ID+J37$7FIL1Z/.FCJQ,L MD/A:.&NY0#=E'/`S#L$_PM41\MC2>^(&S1`2R8&(O`0^+`!;".)'J:Z`A!<\ MY("#[U7"*'\(XR;OTW?#%]:3!LH.D77Q5P^7:1542/QSKL$:@@R/KVQ_(6@[ MU;7J3OQ\A84^N*3H^1@GT`U"HZXK!+J$"@,\/(1SV:D`_%=&?V#]_>45U6);_?#+E0( M,=T@^X&\!_R.TN!/HM2$-4^.CS%Q^G319O\&J:#>P`=KOP:9#808(HO+GTT< M)2G8VSP+O@;G#]'$8S^'[GCB/%H'E@SX*KZ)A()>9T@)D8*Q4KULR[2^T)6) MST)@Z<@9V0T)Z>0X&3#MK"7:/N([,P9)MI_R$1\_7J"&_BT14R"2*T?D[EW) MN_0N\5A/),^,@/==A>2I3`3BCDT+TDG$B.XR*?XS01.TI!`9O=$1<9@:''XC M8A6@E4*^VCHXK.P?GC`[>X"/F`:>[,NAC0G`/Z@!XQP7,CV;!.#PP&W\KC3* M.*\+%08X'4?1-WJ:'*$'`K#=<2HK)PIDM%YC5_T^3CB`EX'Z/81<))6@D=*. M)THC-=@;>^2:/3X2F.;-=>=(!V"M1@=D,T0HM[48(`V]D*;'0:J)BAP[PVW5 MD6,,4(9/*AV#L!N,< M*6[R_LY)$421`%D"$0RS3:N^:-IBJD`A(YIA67AS\@`-HWFG!6Y$S#SR6TK> M2/JAQ%E$\G8SLRO0/\8IM<`.*>\,AB#!4<6Y0>L!S(N=`86OX MSH%Z*/ MBVC(Q[^WCFO[D(>Y;IRJ8',LDVPUC3>`84JBC\/-D/7!P9K)3,2$M,5&/JV- M:$[%%]0]I'0@N@U^,2>PB@5=N`J"O@6,/-I0N9!J4+4_PHDN/8G+MTXSYCD58"% M+10A*Q@A;;"+OW]7:R3,H3GE6/RHR!LO2(@NP+"`@=?
]SHB`"T/2V;56 M)F`_`NE]\N#I]'+J>J:7>)IFELYQ4IN6SFP.=W5783\##EJ,V8\UUO8U9/Y> M-)'6'>,T@\0P$"D5B@R(\C3O#H4*3A!`/D():24U;P)8NA(@LW-3L>M(>!B% M>GQ--H+;#SV;9HB7>&9E$@UBD_\Y],0K:]^'&"*BVCRK5'@&C:K&?E+/&.8J M%!%L6S/$6AW-)O9+&(G=1?TD*@56=6G@8"P15T`$'R7BE,J`7".,[*"KT'I+ M2FX"RPKES9$DZ[LY]L$7HM M7VQDO[0%_;05XFWLI^O+5X:#!J^]2=8#FJ4X1W-(?<0"N#N9TD-7I\E91$R> M9WB^RST/\XF$W)5HABG*V6W:'473WO14@PHUY-I01+L8D&%X/U(=#KT"`K&0 M6)/X1&(8!CIB=,!`14X[6U!8,CM,L%UI2V&H`;EK MIS@@YEO?WY^O!>N5P?F"X\"YGFQXP!AEG0;_#-9JT'0I21$^A1XJF'04C]/Z M$U@K>K:FA@#4[T?3PTY(14(<:8QRL5;"RF":0T@&NFF&XF>HK<9NX!D]B)W( M5$3>)-.L42AQ1666WXMGJFU@H$'J"YA9R6)W2Z?G"5K;'!RH,SD M745K^O8^''EJXC@2+R,Y2*I!``_K#*A[\?>(!&=$&)+[-3-LG^"-1WB#?="S MA&+""/$YE18P.\N?B(;..4EQW/';?&$C?U=XYD)MA%J>%#:R*0H],:D>J31%$Z!VJL@V)ZHAM4@)64RFMJ!QI&'L8!$72<[C_K M]3!.QVR.BZ=XJ,J+5IOL18A&0#NL;0.<;:FQ7SPP,3,SK-[&`?&2&&TF:1;< M#\6'RYUXZMP`[W$F)^I_2A6I@4;6,S$N+&+&-IN:-09R=6I2OV0S5AA3Z$7\ MQ&E7CD%W,ID_R[?%TU5:C.`FJH,PQ8P60-$D.;#7T.0V[JO"\JNGPBZHJZO" M8&Z_J41C4;&5T+FH8?_/*]#IA3\@67KUS?H8<@:9&!Q-B^`*5NS109_PL,0F M3`B^,H4GK?O%5$H,C;*H*5.K?"$L2&X8EQS96;JITBM*=>PJ'V4X4H# MA#0;!-()PO7E638AL&$!>___]KZUJ7$D6?2O*/IT1\Q$@-ORVW-W-L+-HX=S MNH$#S,R93X2PRZ`=(WDE&9K]]3*DH_?43"AJ'T1LSMD&0A#=+I` M#5VU157=Q^56[O@+47YS=EI$2E']? MI@^"&=JJ_[?0E6J$O_DY_%4M^"M*B4W2!J2@\(1T0;N;N^9"%@B/3Z`&^P3: MZ]NQ_6HMQ9@O7=VS&CC$"L+`H-X*,-(QPJ&E)H$M)%Y)JR^$:81=W0QO- M9CR>="SCR1)*KGW@/3!$&DW@!/-5?9D(H6"R0`%?$'4GD,/G57\,_^UW'A_` M>/(S6829WZ3%/7E';AMT:/OADCAB$L$_Q#<&L%&R)R==%9-P)22YJ[K.2*[^ MS0)L<`F*?OBYH#129H`0%RZ;+F:@=K[(&!32H]!L\=5SGL3$57P1_Z#@!R:K MH#M<>*K@65B`>8$75T9<(UL^![=!;DN3\!X]&-;?KI(]HF8C MPD%Z"X7G"AD`H+V@YP^-`Z`2`9EF2#>\RST7'M[:($@`ZC@&`&R'.R-QW8!% M_^2^,C;W?_\9(:,`@FK587@A`)S]0)L$L7;.)N2Z.N4K@!21YO>)2.Y85KTO MPAE?9$\*;1<]*ZC\/U#R)=S#2;4(.4Q_(TQ%X$A!O^`I&KG(JH22YC82&;4D M%N!E6,J!1(!4R]^&+Q-6_I@!W3P@)S:#<`/YB@2B\+21X9%+"[T1-\HSZ*A[ M!?KV&(J#J1]&>*._3)!B)$V#T+2U[<6"(J%>:X87?1K_X(^/??&8@X[C< M)OJ$ES),/3%D[JX)Z#4=4B^(TE'%-CE?H9@;UQ#K%N>]K^1WTHGZ!4*<.9`';:6C7R,=<0C6>Q!PL6'+\ M81#B`:,1J"`YF@MG?_QLDX\D0"B"\@R\`#`K!@$PUH@U;Q]TXZN8S7>U.9F_..$]K'AP`VE:XEDP95B M%.UJ.LD$$_A`+>&6V7=,X//]AYS$X"H!`4AEE]XKTH[8A&S*&9XPFHB6(4\& M3173"?O\N'N<)WI*=5^JW@Z3JC+0VU>*OV&(V,7X(H;!WH[\[&73E?D.W`KZ MP5-\\#4F\6_[T4+0E&"LB,ZHSO%39=OXW-B8C05&P$)ZYN4%*!DU=#$BQSJ> M8CQJVE?Y1?NC#& MN4+-''?!D\$9JC]*5`?UH"`8Q_FV<$X_$FSQM%OIY"$?6M4*[V";EE*"\*\7MU!2F5`%W/MH@IQ,L8EX$$ MQ`QZX5;@O'0Z=7F)/&1_%@A MIB5]6Z!739_SL\MY``QT,U(Y5ZCU44;(,"Z@8C'%`;7R)<0)X5^@@K>Y<#/-C3<1Z<-( ML^G@)S3@EJ>71%).^"7QPW7RG2I:)"4*%8][9!.3)X++"3MW'KD-*,@U?,VK M1$_KM23#\W>76C8$$00AH9Q*!XZYVHXV#6QG\TB(FB;G&]F2YU,M@5A!O3;L>3ZSWYCOMP45 M`S-UC@(;`L[%=+1'4`H\[J"E>E2J50!Y>*)`2XLE+81U3,%BH`FH"RCOE(X) MT12#+AHN*T,JINI,%[GB5$$FW1VB@!?AP>>X":J\WT0J,851)5:9R%65;0H_ MA`N*/E=MU>^2PR+J75;R0J>4>(9;\"Y7\0_`;E$4RC=PQX"H!J$=HBHX?B(XY9?D M6V@#@"$>*&&8-Y5$Q1SE@?I2D-:R9W<>.:;X"!X@.2[_18$6XX>.PM=H?FD6XSL+DO6H0N3R\^2%M\Q7;4\'33XP!Z-7DAZU)B3%3N1 M:26/Y&KG`A:^.D92P9A4\/H@GN/Z!:"4CR."9/&I0%Q348KS]XH>SD-L(!RR MW;RWVSK\7A&;4J$ MZR+#E<<$,).]\NLNSY[VRT6SK#V911<3CD50R:DN(>SK9>1M>>'>=D=4=5*H M:FPZX\4SNDEY[(JZ0;"@6B.&_!3GC!J00CZ%_FA8'A1LV,DRB$]LQEW1W`6% MLL)1H[Y\2=\!3M0EB#T*A:/2([GDN(RA)#X,].P5Z5QPM@@,?%W>0P+5\+)? M5[@&94XBE_SDJ0C2%WA_EV`]7@`N:Y%%*H*HCI1>+7S%1):VHIB)9@8H-,C+ MI63/$.Y?)LD$LH:4KK&P/T%MM!TT`GBP)?ASPH2HV1 M_(/DDK,Y)H=1EK5G*T)6,S0>,2'ES(\W&H\&XLKT$#6,>+6P?MQ>..-5U#T. M;# M#+]4J;R[2\"5`:3K&:YM3R+<@OZ?D[@8!+A=C[ MFJ/QO>XQ;^89_V-0S]RY@<5%OWYH?J#?Y^C`%;^_FA/OZ=-?OGUPYCX\8<$FKXCH'[#?F,1 MHO0<$A3![Q,)6U?_%+=;;[+TP(N`@:/)WYS>3/F""JWRON`-\HN6R&"9+"+[ M"=]GNJMZW,9"EW`]FDIZ;>2:1"Z:N-_Z_(=&,EK[KR;]+RO3TL.,^$SJO<$> M?J=4@.#W;Y@3L(H-[PYSP'R`DUG(BG>*Q?B@I]I+16]5$H.'?C"Q;25#YZ+O M[%RB'"XD&U$Y3I:,4>GYQ9Z\+4M/[>$1SL$&\?U?XS%CT^F'Q-V`4A&6SU%E M"@7Z+Z#G-MES6'TZYA_FTZ&^8VFBA:[TD!*U3E.J#,_.M?EN``HV1'4K=(]S M[>MC'L12`#O?^KT>=8=+!85EOSK&_-*ADARZ/MFMG&PF+7;'S/A\ MX5C43`I;)_\(^B[-L*8"0T:A=-KWP:/;QX?*I8O!<0&7>M#?DSM=GW#6$];W MY(17<>W]4:IO[:F'7:??#8?6:L96I8YPN%&V0+QWK95H:/J+%OCL60\YK)9LYU,28RY2K#LO9`8-#M[(B7J M(\X(2'\XV),C/@P+;910Q,XS.I^Q"(9W1JRN"5?SV:(OX4^=;K<2M_#GFM.6 M=\CM5C58;8I#KHVN"FGM53,6:CQ6P.A:K;ZTRU)?\,$'_"$^!?8($]QI2P\^ M1ZEUF%+%FSR0CZO0OE5!YX/4[@Q]@9<>L%*M#`E:Y,0RHZTFBX[$<_YQMI][&N?Y+HN22["_"F2[S2<1)I'9B_"5JD'6'4@>7W$L+!VA\[ M;:736*N_W&HL;Q\TWGCM50PQ"Z\G9Q<7N-ZJSF9!?>0FY7EE5$D&RUQ-U?9" MHE$$=9JB>=4TJ/-:]!@ZU,+)CE(XF1,SE1ALT@D/-KF[.OF?XR^CV[-3[>3J M^_79Y>WH[N+J4DMOC^VHG/(*)[F^1`<3M^5$>;RD7VQL*`S<]%2VU>+\)C2[ M?67_)SE%U^^H(^<^)HY6ISG:\!.V#7YAX?9<>*&7!EO2`_@7_S/J2LS;/"`7 M-)[%I+7H+%)]*#HT8YFXF.;.>PG$C'#G<])YBRBE)0%U')`#Z>`]_JQT'`);.L<]U%'M"'O%FV.&W=24QFI8<+N8X4`W3@XO@%XDC<4\HX-H%"'1S-L!L!\X_M"5S5WQ MK$)-PK"36Q(VU&8N8F2?H;1Q$VW(UW@,I)Q MM'?>?H"Z"V`'7.IS+3L'L4WV@=BA<;FT`1L%J>@MSF'#-J6R7R3V%:5V!JG? M3CNA'N1+A$P`TP``@X_EQ4$0C$]V91;/#]R+F;S^)@?`^KI"=^GV6O1SI.U< M#!J442T;Z4VT#"HTO"=-N/MK,.6UI0]\A:K'?PS#1-V+7IFX'4P.>)3WDU\5 M^66Y50$TP:$^BU-SK.C%PA;,U$P'6W-\;#9Z75P#?AATD7@YH8EI\A-ZWF_P M$O"!V.:+DA-\['1TSC%7`ZNO!Y9WV(=MY89,^]AMM@*HE@81)#[G)>\A0B7< M:$A-*5RC;S:ZGB;[GKW88+KQ)FS1GKA/<*1@)F`':^5;`1Y\_8_CRC'=OX^G<)]H MXS1&$.#0'.*QV/)/-&T26I7HK`1@\XEH*CZ6$;H$W)N)+?K@^S@S%FQCZG2+ MTY-QW+3XCL+DHW/"_/Y2H29PI`K%P"!55O$U"6K,N=/>)34OM3=6>Q`'*GFP M-YJQ&[&/7!,>,*>F[#Q!!I)LF(=X5;X[G^$XC1?#`BW24+\N*6'"W+%C/G"* MOST[P;%_TZD6M*'2OH#^CM-YP;AL**86FI2*+0;&SB9/Z\V`%2YAT?"];0DM MAZ.4HIZ2/)_S@+4Y?`JALWX,C3)DSP@O=)]=U&=QW-`R,,?JM:>+\.&V]5IKUZ#6X/['KWV56E,3NG$U>RJ?^BH_U,D3=$' MPGD_XOE3ZD=G(H=+_>P:T[GJ0ZONH=VP9\,$S>A1_?`D"+*K']\QYSG`SD]_ MH7GUE;3A<^V_F+AV`=74^E&O-3C2>_U4<-2-V3;9T:[G'.B-=K<^UL.] MN[U&JU>?[^[[$A1G%.]8*G_EN9RUS"WWWHJBK/KJ'IS$;39Z-4<^X)L[;+2' M]?GNH<3='\M8^@UK*5SR7?;CI2T5ILV@>Y_7O#[Z=WOTN^7P[W/7^VA)GF!+ MDQF6&3I8VF@ZM3PKFZG]U&KWCWH5<.0>8./W7=N5>F-8VQU5Y<_O<]'CH,YTPD;6%%QG2M[9:K$;6.6O5`N8/5=ILQ]Z<^ MUD.YN_U&L[9F#N_:[@,K/FBKI0WFP\1>8'[H5LV6@M:M,5ECLL;DN\/D/H8W M1)">4O%K.W"G&3G#YM&@7ZZ^GP/[MK65F"M)]8: M=Q76K3%98W)O,'D8\<$_F$OS.L1DR[$8=X"3)VH[<A75K3-:8W!M,1EFR_WO9+7WSR9I+ MG&,LQK/)J;PK)JI.30=L1K5)[XI)BS1';6JZ.),0VWSSD;(OPACUAU.O,#\; MVFBE>4J3NN&=-'D<.'XSD<+-A^9FHDC,#6' MS0QA%^/@/P&E/_\/;6G5R=U?UV?:D_<\TZY___+MXD3[[[-[AO3>T.;K,K)KI__GQV^4'[\.1Y\U\^?WY]?6V\MANV\_CY[N;S M#WR7C@^+'X\]Y$%[Y=]/?-#$'T[X!.9S8QS,8*,_-+0+%`F6A8.AX4;2 M,%J:13S^]\+DAXH,^=:8LEO/],9/VK=O)T>J%-2HW2C-;87[;O!3E2.6;]F8 M3[4=/0(CQ#NC_129(AN%3?Y%_W\_] M:5\;VNT<)8CE'B7*YY,GDTVULQ\`$(V"OII.S3'*(7C1M<-<',_E\9G1ONQK M+"T+LLW0SF>V8TX,;68^FWP`C/'`)Q"/!4I>GVQ@9\_$V?G@73'/6;[,>'XV M`/4H>(F1P.U;P.<_*7A1OJGBY`@`\.C+-'C6GLWXT-M31QEK>_UDSF;FG*_& M<3(#4D,7.&?68^":VI,]`X51*C6FZRZ$W]Q62FQ(_)/FH\Y5/@JO!VQ(F;/X M6T/[S34-._$P"",G3X;I`,G*];_8AC,YHO5O/?;"+.VTH=TL'DSK:.E((C2C M@3*$\]5<[6,'.-DS;AX'A%M"&S)>#'/&!VC;CD,#'(!2`'^N*<913T&':@S] M)Z=PF6))[J/>;/(!YOB-[RH.)`D*"`4E/!G*"''-%==!D(08FP5PHOB:PR^2 M!E&XL7\OX%>4;7@7'1*>,Y1&.-PT,E&R2S!S"1O1BX_X=UR\9O`7W"=0 M*35OIHT#H*#JP;']-(=W`B1'&O]!(X\67F(<*0[,\6_XV67."]Q43?S*O''C MYX:F5H$%AYJ\#4#BV%DHL\I`6S4TO?D),&7AZ&8<5A-/7$\&W@IXTD1=PY_Q MW!H(=>Z(=U=`2.!49!M=4-V:0T[.H+QP=4:,J$8"LQ=P\<9CPR4%$L=Q__!P M/B""_EV.`C\%F(Z`F9C`=H'S6/:K]M\+]:8)7;%=714Q0;QP'!-T$L]AH2+O MS"M9&1ZA:+YPQG"?4+IHANPWC4<7M#8_:1KA\.%`3 MG3`D`M)$N8'S43\:#KKF!=H[;@`-0SYH'B?*,]K3L^UX9)^2/4@R2JP,/W,1$<>*)(4$ M*_(7A4T*Q<*%M\$'B4`A[V_1T1&#[^./@#+F(CJ`A\.O';[- MW5-L[M0XJ(05W@M9X2>CZXN[T3?M[F9T>3LZN;NXNKS=(ZN<1,.U8[Z@++X& MQ8!)+3V&F=(35Y9VSAZ&\!;=+[RO^X22KG'QP/@OGPB71)"?`N.YT+9F^ M;\`O&^CM+JR"IJSMN/'ONKZ`^W`AOQ-Z`X#D+E!7`C"YIHLOB'F*PSM9J0BV MFD?](;4D2-(%$\'C[@H^TDF%C^R$.0X-(DVAV>@TT5'-WT_,.("`+$JX2(9T MFWP<--K2J&QH(P"#:W;!IL162+APB,F)JAC_,:;V&O,ZR;26_I*USA+"1=@I MLLI]<@.G!@MHUU-F6>8C<]!@Y\Z/51$3@@J_<"IL>]`T5?<(OCJT==JUQ@R@ M$4D!$ZV#41SEQ(\2E)O@B58W_/TEAH!PN8F^YT13`U?FI];-$J'"LF?#ZT9AX MACYLMX]0!DLS,TKJX4,`Q% M,*82Z*DE3!DB_LQP<):4>\T<.HU#%>E]1:0G[KD2(KP?$N%?1K>`R]'EJ79Z M\>WWN[-3[?+L3OMV=7NK79_=:+>_C6[.JB_2OP`''U/\"4C:)?DPYE*'BPDP M>M$91T&QAS=NI2/+]Y^003/2L$'"R:>5JX,/DETFPJ9= M,'6YUQ2$L^,*"3YWI-_`Y@[.YB4"9GO8:SI MK:K>K1._5;DN^UH65+<`?0>'C/-IAY48:Y"O6*C:'$M:6#7+*I>:1>AZ#VBY M/N*#/^)5[&KO:QOK"0Y5VE#5\+B2](NV-MIER6[?/+S#3.-5]M]A2'&YW0@, MF6W>(B<*2MBP%F[H"X#TH)4J"HI&7$T=&6%K'77:W2-],-AWZCAHW>%0*Z=K M3%:M!CU(5$G,FR@C,06STDQ>_#6R)B=P3V%I9HU-YAY^`NI`R5;9#!&52&$9 MA+-0K[Y_O[C[?G9Y=TN)+"=7EW<7EU_/+D\NSO8@'364U6H_:C%'JI(2*S\?D&(QMS17D1V+Y: M^L$+1`;!6GJO7KC$I+J9&`H1\LP+E1`QX]=X@\?>C!FE+\(')PZEN]B6 M]KME4C(*UA,JV8[^%T+9O"+YTC5F/#=X[MB3Q1@H9@;4:V&2)V5C!F]7TY,- MS".2A8WB`=XK@P%V[3F1L))5[<*)$;L;_AQ-%@7%UK67[AJE,XO'"0V47AVN M[#6<%_,_VNC9]/%B:)U/`CEO^%GH^_3%Z*X1!K%S"3N6VBTMA@^'4G8-%S.N M,)%5U'A.9*W:Z/O%J?;;^2FO8C*47AX>LW@=&4=MT%@%9$&\,.3\<)XPA0`O:!4I70].E:W8PE? MK4M;H="8%0$M<\.Q^81E2=+L,9HCD4-$UZI['("D_+$7YTOA&#@`O>X*C%PGZ3E#T*&JE99&J("@+<*-YKVSV(@\H?)'I:*E&&U]M MV1HVY'%D0IG0:D35*W.>L?3QS<8JW_`K$T\ST$TWTY**5%C=*7-_\:L__H2] M!!SW4/73(>BGJ?9="75T&%)'1U]OSLY0&]7^O+C[33NY.;OX^MO=U:7V^^7% M'V/*_ M>,3KO*4DD6S!T%YM9S9Y-2=,`>@G:FIAN#)A=^&3T\\2V"/^?MX&@5H[@/TL M_R12K9/*::1`'V/V+A:>F!GN.Q\9-ES^S' M-T6R<_;[I&Z"0$-0X,@64V#&P':.M(7`L\L$@,O`5%?WO%94/%'6*I#BDT"X MM,[D!LR2@JJ0!;9'T_Z],!R@3I`.@'`3*XU\-8WW./LDJWD<)(T%;[/!Y5%` M0+[6))4D57OSU=905>XR^*#XN5*H^OT__'/F9&`R6JH8U029YO>CQ!G2"O2CSRU4-9J'>$57UH[7E@U#6Z?ML7:D30[OE] M/1Y0/%CR(B0P),]^-9R)&^(QXI3\T_%5VKLGT/U#:YI^$R!)4+R-@<@\#]3E MC[JH6Z,B#[1RPST.)<$JH=YV70SP` MG<#7@-4!#(N9W\!'L&U!;<'A\X.@G?@L&&^\X_&">]ZBQ(<5Z)ZL--E)1K$! M="*Z?IC>L3\--JMSIZ8@F!0$-F'NV#$?L%P$MQ/?6D,Z*N)/(G"U"(?*$D7B M<4]E=X#P02F@4(\F4N7#32WUIM(PH[/<,".W'T9X6I3F'[R-9IR#)J_5MDK' M3Z5IEN&#OK"`YMF=\>/P/R M,19J@?#=`MJY]J"T.:(>8G2E@D9ZSPSTD0GG<_;#O_@]1*;H-\/"EEDNQG%, M]XEV'-/Y,_125%7\6\R>Y[9C.%B*.87'P)!F:)R#7QYRFYBE<(L`0(#/1>&+PW+KS&(3T]TBX7"%A45[X^`3CD%),Z&]:7H6>; M-TYR0./VO!F;<*_02&DF%?1.59AR'(Y,I7D3K6=2"]]GVT$9]C(A$DZX#P5%GT!$W/M)4.+##P'DJ-K-5F$O[D6!3PT[W+V18')>>$6M M0?N/V_UDP82Y8CR&S#E:9V$)780$U",H`N$%Q:C7/P_#?0FU)H0?.DH%F!RIS-U^)N$8*.= M;P1?0&5J2[/5?8WP%B1I:U7NWRQ5>\0`=]%CTT(4[3KL_IE4]#DR1&Q/".^S M^.42A>C/QK^0G<*S_UHXICLQQ_X)+YL=FP@^WQG$RPQAU&-YWCQ:4WAR*G5H86P,>%&D'1CZ"P5'0%)E'9#OH M;Y3-;E'NRU2*V/Z;?#D."&U(;I/O^U7I,P1;'BT>L2,U"0[RN_%FU]AG@#,F M\31AP4<4=VJ",BGS.#B9B*`:`0E/"C>,VA)1Y)-@JX6(RX`G:&`[!K+,$SJ& M.KXC::E3J-@L7R'),]%O*XD:PT&JCJ&T]2S^B:ZN+-;I%M^>M,(*RG+47W0^ M6[XSX:$EHH,XM0\G0J&N8:X)ZBO0H4&@**UUX-G/\)1\G/2]2[A^%]:+06&/ M[[9EPA^H3=N;"X@$W@A:2B.488+`LP4OA>W#'YM:1G>11#6><*^O_/02]`[S]L+ M\0$P_#:0+0=_<>W9"[_%2NMJS!RZPQ9HVO]IWSG(,9"(;X0"9#\!,3Y3T`-] MG13O.@&SR@Z_)@XWA`S^=`1-`8JH.SRY(_%UAO:;38S#U;Z)7OPJ>,H7TQR+ MX:,F2`D#O`*)`YTB?D#268:`P28>18VE'6-.B(X[*_F]=>NK?E77`^%+R'@P M[@QQ!Q!-$O",Z=25@."7CS3\TTS#V3&<$A<\](0DSKVP(C&* M-PL\)C[\0ND:<.-Q>\2=@T%$Z,%PF#!0>/-_UYC!UP)G32Q$`??D&"97#;`- MPB"Z*_!J\AP/#R22`Z=ASDEL"#F6")!KHA3NCW@ZW]BC1!YP5 M&@E#`=]F(B]'DH#D,OQ:4:P3<47[%N%GT!4?G^+D%TA[*2CC8$.I*._?4Y7OC"6./3#=;[^0KI+,#N+\M5"4K[;*2<,$:=2M)KE MJ!0CORNJ[P,&E#,04ZC,TD$C#8B['I"!SUF#$3(!??$!4V%EK*/T5>^);-VU M#AOJ+9KHL4F=-1NX+#:PG@?N MC);BSLB*DVKX-EHAW\;9]^MO5W^=G6E?SB[/SB_NM.MOHWWP7IQ1'(,T:"/. M1J56MH&'N=/4?_K[9^R%;2UE9\'?_J:_A-3-.0[B`-XB9Q>Z/))OB1ETVF(N MZ4U_P>*!!2A9;TI>#.:6RCF)_CHD/9Z- M-XQQ4$]&RO^9.^Q8Q(IXP,K`&,,"A:[8J)09Z$7@"1-3#\NGP@\I2+BQO2=E M_Y'W1))3?2SX"=2(4A^/X3>[<`H@&)T'VU$7`"[+!;9$'V^_+#6@2#@EC!!A M40<+"N3"2W]0J@_.'_%SH)+>N71>3)1I)1CW*@T1]-2M5!C[8@IG1(2T%'N^ M7=X`D*$B==,Y#0I,,LC+%7-*K5&@=5_;8/J\_4()MB1@FL-V\QX4:]:Z#Y3S M^SE][9Y*]?3EZCF+6A/0E>0O/$"9EA-IH2*[9'RED'>QDB*_N#-],C5#$M#_ M6PCL1OB;G\-?U8*_WI$]A@*,3QR5[PB&_PC>+O1OZ:Y4K$.1X1D*]_+Q11C1 M!I,:3'?[%0=`X:0V$W13-#&/M`MDVG=LQHXQ87]A@=%.O)"[!J3W5A0+2$>G M<#?0U\BY$$IQYK%R"FH>CZ-I%922H*B;2OB2H,0:%(81QA#:53C$N9V+S.&E:Q@%4?YG2>& M,KFCU4QEU9NTN"?O*`^7@2[CSP")8SF\QI%N)3H\_6"%_,W"[`A*P;DL+DC MD7R$Z5ILNIB!'OSB%T[R&8[D!H%7SV4B-@Y,$;WA*;.=MW0/ADY.E=0HPD,H M/4KDDG/E@_M.1*F3MR*EBG*/Q`R8#%C`\=F M\.@99OTBNUC,)B*#3*;IX]S7@+C2\-GP#2N-L[9*Y:SM)07-<)^P4`W^P9D? M+\8,SZ#6U.*QIVIJ:1"W0SZ\7F<#R'D<%W]@P1Y6;Q/^0J@L0(/IAQ*Z5M'B18:47UZ<1(2,HJ;A-PA(NW3Q#=A&"6-VIF& M_DOCDNU2N60GRB7O,/HG37'Q;O?&=Y/S)6HN*;"G<,E4B*N,MCJ2V<@\%^?4 M7CQXJ$U)P!N)NJ3D1'XNCZ'F-L/+9&JOV+B+V=L/8/JQ%_ZSO(6BLA!O/&:2 M82^4X!F,=+X"\\16#?9TREDE8/:-_C)!=B09YL(2;S(QC$/JXFPFWTZ9UQXF MU\MT[3'FT4PX5PVZ,SP8&/%^\`*G'?(L9-]K*=Y/>_(G./-"!`K^/\@,5]0[%RY0`XX5>#N6/P-H MQNP-3?Q5B?\QX:[H]MR%7].`2JWK^H'`I+>*='0?L$8HO-6*YSQ"`L50\7CJC+<4P)HL@1&J7R!)VUXY/7"&E_[ M54Y%&&FH[,."%#?B(* M"-@/'$K&*V46<%88^E>^+J)$%D.URW#$4/./>J,?JMBD$PF&,7LKHPMB$AK/ M)-"5C%^3IWO9%J\$_MCK\>&H*`4PH^&)\D',@/7(-CZ^<2Y3*K%L`^>"8:H1 MG-Y30[L=.\;<;WC"=5^*U6`7(C2!@VY<.$%.&:5U8O.I;5]M&]3K6U"RPYV; MKKY&T^A.&OD*V:8J@7(Y(NY8R:G90L6S;LL`6@,M&XO;<%#_!TLC1]W2^7' MO:7T!.$MPJ"6PXCLF9 M/3(;[E!$@Q8PNWA>\-1NL)GA-IHB]O&=ZI9D;CIG7,"@,?U-.`KIO7/3X\6* M%+69(=_`((QER/N.;E[3$:,M)S:IV7`83*BOOJM4NBU1B'`W(W"QKU1#S#>#-//:"J`.G*G"PY@/W*W70<+BT5E\;Q>J5RO/YR M21EU=+GA1U5'J9,Q%RI`6X.TRNBD`E)-`35>-Y5?I/"`[-K#583P3>;N28:] M;JCB@*&];XV#E!4KE(U+6J8HT'HD/8JG*YOS.1,FM.G-&(6:Z6!Y/?61Z!2# M2?78R(4X"]K/PA[&$SGR+7#%K!>' M&;G33)ALAO*BD*FCKN`7LP-LMBBJBS>O,J:P3T4K!^ZFPDO.7*Q^G`A^@,44 M#%/7E'XY>K-70K9A'"74C/68NV"FDZ\>V_8HTW+>G;XL:*I!:#MV\1'(87!4>JM.)\ MX+(H$-_]8-K/;/QD6/2)VA`8.[:``4C'"PJ2WY&7_.Y/]EPRCZ`O)D60@WZ6 MXB6DJ<&_P%C>YB(UQ:]%IM1FTYGPK&7!/4F_&">_,P5.;0Y(CE0:VE@A+8U/#M'7G67R6,)-$%A^FVLFV MH;S]HVP.*4TK9"R!:879=,#]/.Q(YG?BE>&,`NYZAG,K+\6W6>[E7ZH5H%D^ M7]#??Z)4^ES-!0XN+!PG#[HANJ;<6FD)(U.Y_!GP6.7+3U.7CWD<2"T!VZC, M0)U9$NIUB)84%8^+%53-(:A54WM68+]A&90"#F$ZO+TP!JJB MGQ9+6@@[R`2+F6YH`>6=,EGBF1GHP>$]FJE/LM]N,\&]VNIW*8DBFI0K.@C(I-_9TAZ6 M8%FA8%)/$,V>\T06WM;9='VO?=`HYT7$-[%ACEHI0B7>LS?>6R!XE]KM\I$W M?)!OD(TN27#0#O&FCY\(3ODE^1;:`'99I_QR*DU.HF*.\L`I4)`O()6TR<`H MRI,VY5:4Z*W0F(P[XP=OLG5N._'Z=:UE)N!13MS8&(55EC%*=QC>(A\8""7S M_8OJ(XP?HJ]^9IG#$^A+1/IOS)[YBNGX/-)G[?UEB! M0(_Z_4-$[Y5'RFT6`S>8-496A:4DP>N#,@Q7Y$R+_L"R6_]85+LA2?GIU-Q9 MX!=UK.^KO3$]E<>*RBW!T)=J,,Y!Z/V!(N-JZO?JN;"`[R^>@YSJF@-)]"FJ M;BK,59GQG(?TG7`Q@MC$9N6TAN/010QJIKCBEU3L<127!ZM\"&JJ_PEU[0U" M(^B0M[$837Q'K=97%;F(MNP^`3LYQC"F7PN"62&U MJI.`337Y-@,BJ\QW$/)CS!&2^4I9-!LDD@5QW**EOU2&^))^XC+Q-L%JHU`X*C?D M$Y[(E!-MS-)EGF8@P/+X6+EE`GI,G8!H-%[SJ@2,Q4U-V2-^=*&,',G$BJ8V MUAJY(J,S/)Z$6&3G_2$KPC-NH@6PRN,C0P&XOPZ=KA)DNL)'&R27S)?7(344X\?#Z+8J!J1NQL#N/10(4T M;MK'46"1+O\5WX\<-\1N(ZVOR'1UE036`&.D5(J3$BFX2N6N\6*8O..VGX+' M+5PJU))N/(O)2A`O/*W$EU.1S6XV^&!K'+?<0@!]J1(`3\AA3]B$ZH7Q[?+W MUAPX`8.A+D[ID%=ECAS:@[R%/^$=_'F#$&SB.Y`UP'7$RDX>E!%:)&E[5.\. MC)AW"3"T!W3+H]Y$7?[GCNDRV0#$GV#.^WJH+98"5B&T2;)_0SHD/831%^P1 M!::IO7#&J]CF.+0ABWF<*6'L08Y.1#[C_V%UKAX53!FR>^QBYAW1R!SI-./U M<,D8Q)1A.;K[._QJW'O;") MA*VK?XK;K3=9>N!%P,#1Y&].;Z9\0856>5_P!NT*ELA@F2PB^PG?9[JK>MS& M0I=P/9I*>FWDFD0NFKC?^OR'1I)4^Z\F_2\KT]+#Z;NRG]@DV,/O5,`7_([^ M'3>L9U4%<\!\@)-9R(IWBL7X*@!E"#C(NDIB\-`/)K9U?^A<])V=2Y3#A60C M*K#)DC$J/;_8D[=EZ:D]/,(YV""^_VL\9FPZ_9"X&U`JPO(YJDRA0/\%-,PZK3\?\PWPZU'<#NV]C%D)(B5JG*56&9^?:?#<`A69K5N@>Y]K7QSR(I2SH M?.OW>C07/A44EOWJ&/-?/_!_/Q2*ATIRZ/IDMW*RF;38'3/C\X5CF>@"/\*R M;_Q!^/6Q11LF082:8+P/'MT^/E0N70R."[C4@_Z>W.GZA+.>L+XG)[R*:^^/ M4GUK3[U7PV'OAD-K-6,NX]IV:\92(GZB#,"TA\. M]N2(#\-"&R6TGN4)O4K+C>J:<#6?+?H2_M3I=BMQ"W^N.6UYA]QN58/5ICCD MVNBJD-9>-6.AQF,%C*[5ZDN[+/4%'WS`'^)38(\P#9VV].!SE%J'*56\R0/Y MN`KM6Q5T/DCMSM`7>.D!*]7*D*!%3BPSVFJ2V`RD3K]Y""11ZT<5$K!5D^LU M'LO1C_S?P\FR<8FPGZGL1:R48M!,FG*RS>J],I5$=1**QF['3VRRF+&K:=`^ M[YKW1&OY=BV'!N,D_9*WQ*)C;3JN_NVJSSG*U68E8S5QD&UNG MYK\GDX"CIY?[7%(_2='.DKILHD,R&'"_T5`&,@(PL5Y[-=S07"CY.K\6CJ`Q M`KRM*`:5'&*3"K9^K[H5;+VTI59)M5KM;12PY5XDDUF[GR4ONRQSN80+&H#/ M;VKP.UU9^JZC?<:O[VVYTH$A.47M44J]YST4"9W)EC8O]@PD+O;762@"0A]+V2^B_,GG:;GKGG MCP.4Z/G-'$"(^O[S>+E;:0((ZOP=VB@?PN..PYO%":H^^`5$45HY8PB]*K3\*T& MMP;W/<:-JM(JC>19-?O\'3KJ_V2851<.'XVP7_TC4S\Z^\&F&/KMVS#&K M#ZVZAW;#G@T3-*-']<,36,W!&?+&3/WXCCG/`79^^@L-_)_KP]W!X8X>'QWV M*%P.\G@NX-!,,#/&ZH=H!>[N`M;A8=^@N5IXV%5_0DWY/2VV\Z?F!]TKZ47* MM?]B,BL*R._6CWJMP9'>ZZ>"HRX5WV1'N^Z\J#?:W?I8#_?N]AJM7GV^NZ^4 M*,XHWK%4_LJSB6N96^Z]'>CMHVX%RLFK>W7W5>(V&[V:(Q_PS1TVVL/Z?/=0 MXNZ/92S]AK44+ODN^_'2E@K39M"]SVM>'_V[/?IJEZP?YJ[WT9(\P8FI,S;! M2?%N6ZB"_?NB]/708SIE(VL**C.E:VRU7(VH=M>H6]P>K[39C[D]]K(=R M=_N-9FW-'-ZUW0=6?-!62QO,AXF]P/S0K9HM!:U;8[+&9(W)=X?)?0QOB"`] MI>+7=N!.,W*&S:-!OTYS/CQU4F^T.O6Q'N[-Q;Z(]?D>W+6MK8/(PXH-_,!?[0M)D-=DDTK.U%VR16MN)NXT7ZMWN4:LNWSA`E1-N M;KL^UL.]N_U&LW;P'-ZUK2W%6I>LM?(JK%MCLL;DWF`RRI+]WPMM*KU9F^"\ MO:-;N7I']]<.GQQ9GCDQ9PN`G=VR\<(Q/9.Y9S_&L\6$3;,X<]J])\K.E:[>],\NM(C*#LY MFT,_`764#5,+N.[R.GGL[\[(^F#1S,DO"8$K-\#WT5R655RVISK%?#P1Z4-Y1MU7GW]5'7($C M/N@@2]U*HDH;JAH>5Y)^T=9&NRS9[9N'=[;'AZ0DV7^'(<7E=B,P9+9YBVQM M*&%K@T$R]`5`>M!*%05%(ZZFCHRPM8XZ[>Z1/ACL.W4C6M/F/G+Z)E9$QSW?#XS'M.%HZ?&S&7_^+ST=/#2DX7CX(>F.S9F M.,@-`#TU`+14[S\^UEO';9VOD/2J8+%3>[QX]K\"V#+MR3E\YJ9;[7_;?*'$ MUR2MA,!LL`[^?]Q*_FN6U^%`;(0[_/_CYA`^"*\5>M7R2G=O\Y0+Z,WC_PV_ M&I\-WG@&1.Z]G3`<\3>[`)WXQ_^PMW2OQML\Z/?:_0%?(/952RM1C)V<77R& MI]I23%WVBS'#'KHC]VIZKSP/#RDW;"Y[5!J@)A(K<(0>F]T MT1OV:+J8R>%=&L\I#_;6F+);>'C\I'UG$Q,H\TB[L,8-=='P>_FJR&9^&4W^ MM7`]I`;WSAY-)B*!Y-HP)Q?6B3$WP8PY9>R934[-%Q,,IVP*8/+/2%$ M/MDSX/'N">`3&%GB2RZLT8/+X!ROIC?,,TR+322?#&WS[I7-7MAW&\=QG^$T M[ONV?LK&+=#AE3/__?94/?#C-EX@_-\_/E=F6WN*Y?O@U??X[OL+ZUZ\_?X[ M13SKU!X:]P/GE@V-DZ?RL*?S.PCD%) MGL0GHI_]P!_9#S:=LK%W-07.:3VR"^O,]6`7\/RY[4R9B6N&9<(E M,,T0QIJ@5&/25C(^FF!$Z6T%'27`J*!`(#2P5D8+[\EVS/^P2:)]U!R`F0`< M87#_W?AA/B^>EP\YP5QJ\9/V-[=B]>)@-*V-8&QWLX#HT][5=#0&RQ?3M@,) M'*:*JWBBV.P:+4./-ZG3[O44V-=`5?@&N.E[3\C:$Y!]YK`#J,.,:61-XIZ] ML#Q;<2ELBR>W$[:7!>9=;'\U*<9LN+/?^XVGXWLN`96_!@"EPLIQIUE)O/!; M61`U;'K%LP.\.PP401_Q>.(D4B*BX'G3.S?&YLSTWBX`&%#V[ICSG,YS>=T: M?)>@);U)62UL.H>6.,.(\-NYO7`(Q6%)TLI]U3IM."'QWV".0F//%3 MA=`N7'?!)E=6,L$68QV&S[58"'>^];QJQM:0\P(&I>V\!=;E!C=G]1;T]E#= MP=)"*A@`LT$>-;$1VM;(O6%SXPV_"R9KX*'#<.TF7!Z,G2QR;J!`GQ&^7%ND MLTZ[PS5'TUO)>W6VL=D+Z]HQ7^`"7DWA8D6#IDM&U7?C;?F0SJYO M5=`Q#-W0NRL!7UJV)$`W/8(J;V6MP5-%X/][82T+T&5`,6NV$H#F)YCJ;"4# MP10$?%A,;R3BAFL,F13*;;P4;(6,F-6P%KRIM=9953:UB7A;$Y`#I;ZU'K)D M(94#L-QR=]C;&>BYZ20IMK?]W:PSF_3A,%8SW0)@^2FDOS/0JT(AWYCA,IDG MZ8`X,,?L=FZ,4^:;77?_$@LFODA93,2A+A>X%]%7RH5O__EDCI]XU.;5<";N MB6%]85_1:1`)':WW2\0PV)[0P7W<9`%C>1?HD!(/\Z]O`O`_K_7F7V%PDMZG MKLQC9&B\VPAL<+9D,:O!MC2&/_DGH4JVI`'G)O!/# M?;IV;'0[83#8MBPVQGOZI^D]C<;_7IB\-U5AIGU;'RJL/CT`*M2"&/@^;<=- MQ*+>/VB'@R,5Q MP\;,?.&E$A>6:V*.&]S5J5F+QRF@@?0-1O-CKSLJ99,`/':<#QS;,[1M_Z_\*0Y-=F$OR0V M\W%S8%L[(8>Y@28RV*0:L>A]:$!=>!=SN'EX,2LP+, MI+2AUOV)PY!\@6&(]]W[%V*90:3'^AK@PEOBBABP# M@+'RA7%K9U!7DD%I]Y9`V5@UX4_Z>"SN,%5U+K)(S/*WB_E\EH"`O&!$#FQI M,14[-&;E*-K)X5[HZ5P*S5:`+=3]7:%M[<42&I6KQ>T)7Z8#>.[I*N:TM M'I$]9FSBHAF@L+5OMF&YA5D?/;VM),*L6C(+9!ERU;#)S8KN?"IZ*$H(C*A593(=#LD!2_G;LG MP/[F^^GJU=Q.-O]*IYJ;23R;U?LIX6S,YX>%XS+1$2&PCIG+#+B(\-@I&,0S M>X[?R'@PL49Y*]A()AA"NXC3KXL51-U^&/F)*V:`*Q/';PW[W@ZK2 MFV@7HC0<,BH-*6+9;#2[)6(G#/+N\+.YKB"QT]I_['`/>R:^T?W+]]B7#=.N MMK\J+>90-E\2YVB6B)VMWHU2.,=^84<,`3S[`8:0Z6)SPC_)K<(FHQ>P[A[9 M#7LV3`P*G]C8!F[L+7@]WY451EA\LA+>IL[WUN`T+U+RP%D@GBALBBG8%*&C MW["?GW]D*1-5UKA$FHH-4#;$NT).%ONBT]$/`#$1PDTIE89XC_2B[M%*B`K< MN=*7,>5]O7NUD_F*?WW^>=W[J_V]4Q0Z,H%9730I[+?_E_Z]=2AH^H.YN"1W M+9(.9>-'Y0DOP%YAHJM(X%6',X MHKM0G(BT9?-A00^),&EA8`\Z$;#7+!R%DZ=UGBZP^(HST%`,,[XK#H>P-V#(;Y1>%);5*R)/.3@CQH=KLM7<"[T?HQ M\LTT'O#[)G-% MS^T4@G!U+FV/E\UG6+H$F%->SEZS6)AY^C`^B\4%Q0`9C]:XE99@\GNSL+D# M[R0N"3_/&$D3V-TSMIS^#WU^[=ASYGAOUP"@AY+CWPMSOKI,))6!T6X-HALH M!*QM;S:55[_3[6YCL_%=%)/X9X;+W&KV15%D^C6+@S'=O6@-V\->3AA3M-X- MVAJ!*L%@KK&8HJE"M\91`?T=:BRN53[ZFS/PP\-1;FWE76(Q=;2)*O#;[_$R1E"4 MNY?S^T%BIO31=KO_7O"37+*0F\9VB\,7YGCPE/4HO/J%S&&(["BZQD8P9$RY MC7I5UL"0:EI$$94>G8@G--7"N8'-B,3A8!?`9LI2;OH^$L*+K4Z[JP\&RCZ*@&YG&Q8UM2*#(/5\';W7&O9Z_8/!@@BVIMZ_##+O MU?8SA]1!/@SW;[O)6G(VFF^UFITP!]MO+%21YEV7>+,4.[>N2=P#U\@YNQ;.?'T<<:GVZ[V0Z?4ZI5"P4T M7YDMY2P1T/1$'@9VR: MR55**"\&;F"_)G<0X@L`,"`M!H8<<[4?KOF+9`Y"_9A M\WOXN?BEDD@R9BF1.Z0Z.5TLV79>:`KK^0)KI&0?[>1VP$,^J"&%DNU/+,T, M1>(FK@WGRKGUT*=#UUZJ8(E@!X-7X^1K!'V1A&&_2DV/W4H2+,4!GT!0E0,S MGA@K"V;.]F)B(YUX`M_F/C;MA%@PY/P2;S3]>-.!8,)<7<51HE#D!S?NVE4% MM)BKM@W08@R9=2K],EC4-&[87PU2K+V1$9PT!P@*1+O?[98-4?ISZPSZP_X6 M(VW:6)<`:R$K9R*:WM4*@9YQTEA]Z MU[N:?K7MB7MKSS89J[S&7NY'Z3BT3GH@LEGK1:V>)6P;S)9-O7QBC\@\1]#J M1Y-5XIM`I@(DH\.GHS>C:EAF$++D&Q`Q=`9Z43!DHL9N>PM(6#NL.>9*),-P MRAZ\"\OUG`5ZC[X;'H:JWD[3-BRB1L`@4^YEM:T_4`'^V#YN]@!Q`2C)BT6! MXAR2)S[PEJ:7+'=\2`^K:@FKY`0E9>U^)DBP8.L+L^`'#PLB_6IY#-5^>3M[ MGL_LMTB!4\;DMT$4OG1+%P%QU@RXW4&<*0UNB0(J@.$U*4KM`D%6OXO/RB\# M4Q@_R:X;\N^\37`1'<)XY_O\L*3:DV@XR(<[15XBUF#;WML&,$7W&%1K1XJT M"U-DHAT35JR9#;BL(P`BJG?A<&73?5M1'I(!JJ3"^R*RRU=@+6G9G(!FE!V= M*&U7G/>V\;FFZ4-^?/I-GV^Q/?P99I;,'1-#K5-S;'IJ&PGJM1-] M(K=KJ-4?1)E17IBVM\>4=N.@W>R6NT?9>$#U\2VUNL@UP+873G]/7#$!L,B@ M^$)A`]SJ\<#%K!J!;\$P25!T[J*9D87U)8IB;,5210"54O1WLP-U9_.AV8Z+ MT49UY)HU+@9EK6Y4^4VS:J&`IKP.49F[.9S17-0OAFN.L1$_IK-&0BDI%8/E MMFG'S8:NA`#6K)D=P+0*02R$S6U`F$H3B$=@:Y<(3`-ALYT50F&)B`+)^&*K M2YMZ];$)'_I^9_/.1O[?T8UR:7M_,4^45OX'.(F<@*I46^JISN.?U_I?O>\Z M]H#=#91;PA"Q")'^G[/W5[L=9II;@3D#FNZ,'\*+(1/SBRYZW!0):R$*[S*N M9[GL#A^@K9;PI5TY#.]7P[2^V:Y[99V:[MSF50)7TYC*DCP* M]G$KK.VL7#4K@)DSH'/!=F7=&C-V-0U&=!>'MF&SO01:S'H1H!P`_MJQ@2<5 M=WYZ-VQC*XND6SV3XRS_LEF#<^UTRUY88_N9(;5P]H_IW`M0GJ[FS#&X=YU- M;1PVC=\#8<%P1(7M*#4XH%F%W\)+=+XS[PGSUHLGJN-E;\(6MU$-_&5E%1V] MVWS?F,L:\C_6.Y&"QG>'NFPLL-O5>^\;;UEY^+'>[@^JA#IXH;`*A,VPJN1G M,Q;_.?=ZJ5EB_J72\Y#\:Z6\="5N*L5:H=JT"RM-+_?B?-_])?:2`9S"MY0U M`!S)\J[(;K+U@AOJ6]B+9&SB'=&4J8SGT%\#^?*J.>',)EP[2_*A`#A?@/^# MS"CPCNJ#UKI+JBR;%<*L2O&2+5$\:-G2+GJ#]628&C1J^BT"6P5[1W1]'9S+ MB^<$-^-9K[LNA<.9[5KW6^7`&43B"J:`5/!&5X^"S#E5G"<\%W%VH_<[M$YZ M(`J2)!E7SVJW%K1\)CKN1`WFHO>>F!2^$JQ-0<("IM+)$1=)N7RFLUC2Q9*7 MY2+E[=RT3/>)3:C()&>`KM>+JK5QBR0`4D`6?(PH#5Z>L.R-\?K=`"R9\)9< MZW=EAF+<^NHJ"8#\:3M_7^"`(ARHDO,@]&$\&*$UEN'@3@%N54K2*>Q*])=A MBELO#)5B(8#9H*:;<(=&T>W+UJU7%'096YYE!J^D$73KIK:5/U!N/006NYJ& M)_CQ;GA9ZY!C\A*63BG%FNO!!&EE?S:ZZ$6U17^1D^,.?PE)V/I MQA3_;K)XF6#?GSNVZ]U_=>S%?+V6UT7O4U5W\MVYOYWCY%_+O0=FO?'.JGM& MZL[6[22F;J/8??ASE0N])+*B;AWLQ;O78S;+"G!Z(0X#,71W7U78*=R>[JZ1$KN&"@N;9<#J%$=+KT M$!0">59WKC[<*=C9/'Z],D$6X>%2:.2XU6MU4U%X#!2%0)^53MK=;BJLEP5W M1D)I1YSM.:`.$@'6N-O235<][B_A,U@A_^+WHC+L7BD-N^=:\[U2''9/U6&I M'(&%`%QP*ELVI"6.<.RM8Y;-B-E<]/HEG%K9,/?7,8YF9TD/*73]$G!6-LQK M!O<>=_5!J70^*`%G9<.\9@3M<2M:/P959$D9*73],NBL M$)@+2PG.B[&-AI(>=_O=09G+EW%>Q8!<6")RIN4+2N8ME%1;91Q6(1`7E\*; M=OG1BV'.,&7KSE8:#(B8#I6T%J>%MMN]_I)#:!-0BMM'.5QLFSLHZ5YOE MN0,TI:ESW1BFJ_!W"G:1]-L1AV[,6<%Y1NF#[@WH%H*^DY=18`)B$C=MG5_8[\9,^_M?O0(&R`U-4T( MM->.ASD.I.*A_VX:SV8J."-MDTJ!,_DVY$5SQ&#;-O2IT=Q-N-1%PIFI(V`" M!]X&E;;R'GZKN5/HT]^QX2ZI-#>:D[COEJ!/C>9^=HZ+50R\=J&XCF\1HREV MC5Q@I&W5D06*906QP**B3G\9IN4%PU!=&V]4OGQGT]!8AWTWL+,R<]ZP,3U\ M0@ZDPH`48+IEF&PGS$/6DC:2;QQ=I3IIFC-8&8">- MK%H:+9<,QA*X<\.4XRT*2IR/IH?%+I(+CK2<;',P[#%C$[\5!?5W9Q,QYJDX M.=!IZQ'05JV;#*,TZ7M,=F+H$#Z329?=<%DL+!?FAQA0T.79S,VIFXO MV^G:E@&6%9M1.FB>_6#.V'19<=65[6XRY'$++\$)NJ7WAN,K/%6QH/YI>3@] MFAW#I;NW8K%B`;L_7S@`V<)A]^?F#_R75QZ0R8,!C'O0,!S[A92-5*G[@R6B MWMYF?-V/]N`_G@;L7F^)@VP/[EM[ZKV"' MY7VCXL#\V3$5%S">C1P+:>!:\@!E@RJE[(K,:2T`JM]=-EW,OIG3M#/VUA#E M/Z^[?Z4`,%BV+#BS<()[44IV()LQK?!FVM783(0]5!;I2W`6BL\;L)ZYQ^IJ MNA6K(FG!#&!EGBBVX7;^O:4D9TGXV`\PR&\K>L4$"++I(,8UB/)_R]OP5=$!@?-6LLT12P- MDN.G3*786(%`[Q)'6>=P'1R&PA/.A`\J-SE1_HC>:+9Z[9+1%0M_)?"V.8D) MK.EZN_<^L,8]B<506[/1[PWU[>*-PU\)O&6DMF9CT.T<&M;B9B$6RMEPC&ZK M6Q+65D!?`9QEIK.F/AP?$W:]E@=C0=2SO,[E`EVD&Z$@(;%Y.&P.^D57LP\(S8Y,0$]O4$QOIFJ8"+^N&:OUCF[-&F5=QZ$XSIMOW=3-CHI:.IBZM-TM!^L6M^5U:_52[C&:J]^* MS`];6KE@G/2VB)-^-ISTFI$>]F7CI+]%G`RRX:0_[&T7)QOT1LN-D^&N<+(> ML`P-XOR2K#)!TYN9<(;MQ6+\B>71$<"Y-3JBZ.@^X$3?!DZ42.#F..D,HIVF M2L.)#V=FG"@#-+"G@O>VL6H4=0$6OT(10XE*@"J8=G]_;9B3^POK7K1`W!X, MJ^FSK%73]5U=O_!:'73-P(%(9X3E%?)#4/[,TU*@WI@V(^I!7@@+-G**)>0- M3)R""'G-$-AV9,YW"211RAA8O5TZ*?=RDW)GV"D?R!3DN[KNO_0KEL)V+8C8 MUTSO;75:N?>^WB@MGMH[>K]?/MPYJ;W7';3*!W)S:L_-)XKW2A1$[6OF+NN= MR+2+$@ZDC-'+PW:O=$(:Y%=3!GKI=W*=TRD.KL&6R3W=#($BR'W-R&R]-2A= MVI8Q-5L7W>-+!CPOO;>&_2V@=P?T7H`S,45SI\+A6C<-O=UIE7U>I0Q$!Z[: M+EM)`\!S7H=6LQ/M?E0&E!M?A_R":(Z;2\<3F?^;F':4+6[:&\8( MZ310%;&9545^&<*=S7Z<-['@S5RR5_I3RF/)FA8QB),E:V$J;Q\9R:LS[,>( MG_+W<24(B^^A-3QG#T17=Z_V_=V3O7`-:W+/-WM_;<[9/9_.9#L;U)1N1FX5 MVMO]%]MP)O?`PDY-AXWI+R=/AND\&]8]O#TU"CK=:#+(;C$0LR^QXP+/76_% MR.9].'604BYV&?1H?L;)D\FF]V<_V'B!#4!HH MG_!IG&]*$5-8AN9:@$K:0+9TRLX@VI6U2/CICRLG\>5HZY$6Z%@@"MU$JE[1 ME=Q%KBJ@51E7)2!SPR*NYME,2QR6HK',=[*%."5O*G-'>F[VD4QTVRW M"'"R79>3D@:M=.;J=C>UN4NN;%+:V$A=$RD9#M+3TF;:3C9P\](1;"B5ZK.] M#6U.0Q6"?UVDK1,;&=TAN'GIIS.,2PK?GW5A.S=D"/ELJ51M-_K5P/0P_%^"X"F\A(QS%;R:C`ZNBN\G2`+:B6\GH M#-O6;JZF]+SR^!?#-<4\>)4>D]9K@_9HOA*YT+VY)@>NYI.KZ:G(N?EE#UXJ`^A0#^QW>)&S^K#2$W/^K5SP9IQ M3F&DS*YD(+//]MPBD)DG!G\\/\!4$L#!!0````( M`)EH;D$8BQ]@NPT``*FI```5`!P`&UL550) M``-!W:-00=VC4'5X"P`!!"4.```$.0$``.5=WW/;N!%^[TS_!U3WT.1!EF4[ M/YS&O7%L)^,9)_+83N_>;F@2DM"C")6@;*M_?1<@*(DD`(*4*)+NY"&V#"R_ MQ;<`%]C%ZO.O+S,?/>&0$1J<]88'ASV$`Y=Z))B<]1:L[S"7D!YBD1-XCD\# M?-8+:._7?_[U+Y__UN___N7N!GG47#E,?0/:#@9'!T>'@^2AKVXY:<71E*M MGX^3ML/![]]O[MTIGCE]$G"5W74O+D;5;WAZ>CH0?X6FC'QBHO\-=9U(#&DA M+J1MP7_K)\WZ_*/^\*A_/#QX85X/Q@"ASR'U\1T>(P'@4[2<`S^,S.8^!RX^ MFX9X#)^-,0,)PZ/#T^-#WO^72\G:>>!=!1&)EM?!F(8S@;J'N-R?=]#LQR!MO"_.+XG(;[*<81*X.+MQQD>N\6S:T3@MY3 M'!'7\;>#EA&U-<[[""8B9X6-QJ,Y#@4;Y8=/)V:G^.XCZOXYI;X'R\/5?Q9@ M05OA5(G;`>^,@.S;$#-XBA@&L/<;`O*]*H`+Y6T_PHO9S`F7,!YD$I`QV!5, M4=>E"YBCP>26^L0EN()%6(K=&O]M2,'@HB5?5F!4YIS=TFC50G9@O6!BXK5T M06=S'+#2BZ:T6K68K?%=XL?R8Q5WVOK9%\Z<1([_$#J@CUMMV5'*V,D<=L$2 M+HF_`"_E!XYN*&.W.+R?PNI;:0J;Q&T_DG0V(Y%8U>`Q%U3,,/#-JDQ;HZRM MD9Y/0BR6W]](-/T9$.'H55@5M7*V1G@-+NT,/S@O%<8NU7=[5F$]MEK(3OV,"X=- MO_KTN1A$L/SJ-ORX"I?RW@Y`A41[<24),W5V;TS!)J`EAJ!`M$U`MQN`., MP[I!EIOE5I)VXL=7@:?J5X=C7P6;A9B:/?U2$\=25,V0RRQ&=I+JW)U4,@M[ M<;O=KER$F!\_TV"]WZB"OZS,7>YHJN`U=-_W%J>2N6SWB%KV/%7TL)%3]^%E M%=PE1=;I0I;";2-'@H7MDKN(S>L&H*5`0U,<>-A+8'/96X=*Y`-(Q&4='J(^ M2MIO_N@$'HH[(U6@I0;4JD!*&NMPR-&N]J'P,RS@'KA%V.,_,=CU>"(P**4@ M*49`!M`^=5-`?1X\HV':*"1.$2$;.^Q1A,D6K#]QG#F'>S3`?L223X3Y]`^' M,EKVB_SXCW/&-A3PG4?LBS!GZH^#QH!=+,)0G%$;\*W:K&!ND'X>IA$[H9L( M@Q]3C.?CC;+%@/%-+)?6)\!HTG\'1[VT(+!X^F< MB^8S[5F\)L]ZX-S/0T)#,&KQ2Q/CSX]XN.7:9N[2;/#-VR=F' MEG,&WL3<(=[5"]]18S-9FK;M9DD#6M(S/&SY$GD=/`%>&BYA3ZFA)=VDW6RD ML2;K6MM)2#Q8OE6(-MU8/2GF+BT@23U73*"[,F5&T12'L9(_:.`:ES1-VY;R MHT&;$--V=^\2CS%`]KZ2@.](+B@#/;0S2-NZ47*,QI7R#G3PN[+HW6/03IPK MS"DC.I9RK;K!3@ZV9.6D[:S<$.>1^(2[FK!`J_+NE#05=VM8&;/GJ6K8J*'9 MTK!I2P#5(9/P@7VK!DL):$MU!H)=!S*U8D,AW0O0HF,'F+-10W+YONU< M7N(G[%-QP'$?.1-\%40X!%0,P^:-N(0G$2YF"W&\>PG;A6"2[:'=NFXON`.V ML`LUI:U\--E*OPW&DCA\=]C%Y(G[?+";M_-YU5U:<,9DX=^JL5?>MGP>9(+E M>XR@9[*RL^'T895P.GJ3DOJV]IP`W>W`C#9'ELD!:W&(CM%:('KS,W`6L-1C M[VT3*0-@;'&V%,^CTTRO3)MFHC/)\WDD,,Z@6\`ZMQ[(+WA,0[R1^?6=!&)2 M7//%$I@&7S8M)5YOO^-H2CT>+F%QAIXV^+-'!(TN64J32,>6]C@473G%E.M+SS9H]O]=;:WK[F$5M,QU; MX4;>889A1'C6SX8S+!71D%30IU'&=':V25; MD8"PB)OL$S9S:-NY]63:*M*5%^0/&M#TJF,FTM#^__EE:1B6KAR-B^!Q7@]3 MYHBJ=;-.ZN;3)&GABR(5%.W;P[G.EUD*0=MYVTW^#I>#0> MC\9)B@R_.GG-V"+)D]'09].Q.T3::+,^9FNY5[MZJ4B%Y=4JXYF%HG47SA<4 ML&UB5RVA*5XLU!X./#C?HOT32@E[-7.&9DJ:8.%;R.\&AU0_05(MNK`A3P'N MRGZ.K[&C\3=*/79/?4_#1:Y5HWPH;"=[,)("N_+DVKTPW3L^9G?X"0<+K,\( MSK5J,Q4YL*MIT>Z065%9QTR@Z;A2H&E#\-\9BD6C-S)J7'\0K;`29%I)Z,YO M`Q/F^I0M0@R_"`EO"HJPXF87V/@M-]D+*@GIU+ABFNI-9U!]4ZX4KK%.*0"`#<2$(I*!T M^J)GJ$K6M6)08IBEW6A M3Y6SS"`6=1Q2B./6*%W]LC:C*%N[,@L_]VZ4$E%*I#`9*10)J?N=P>I:EUE= M=2XY_\H=XLRQ-[Z1D^4('ZZL6=.D'N>D5U,1VD ML;JR"<'OCP[:O0A?XGF(79*0='V/-1KNN M'2;73D&;0&=+J4[J<.EWH`5]7A6Y*/2D6[DM$$-BRQWD=,,)3L)0Y MH[:=.LB7K6I=J3>C&86X0N@6+V>E@-?X,IC2!YY_J9,0[68ZZI.'6385K6$S:*H5>/3_`[/Y79P-/Y!(YR<`&DHU3?O M,)EZI2R2/%JW`[9@4=^\PRSJE6HJUR.URU[?];FA&UFWJ?VKL7T'J;'0RC:\ MOWMV5K,^=<-+2XZQ>5>Y,2JU\DB,OFKKUC^AR$C@9%T:.S98?076N??O17S$J)IURF9MI,0FCTVI3)(H<_3QH.WIPCS9A^;6-R@H?VI4 MM^QWAJ]L+[FC-[&`/2*68Y5GP!JRE-#( M!<3ZOLQSO]]&L/IFA8T<PSE1W3O$^LB)#6_4=2HM>^4$K!7;Y7]XQXJ M@.<*(Q0B1\,FL&L=JI.\1U6H0;W^$[^,6H1:6'S@`M\!`\'?OD?4$L#!!0````(`)EH;D%] MGA"#$!H``"O^`0`5`!P`&UL550)``-!W:-0 M0=VC4'5X"P`!!"4.```$.0$``.T]77/C.'+OJ$*$X"K^?7'P\/W%0Z$4^#B??3Q)ZZE(/XY.__?>__]M?_^/T M].^7HX'C1UXR0V'L>`2Y,?*=YW=G-'+Z41BB($#OSI,[F2"2S>IE2F!/@^,<^?;Q8_"7`X9_?V'^>X>\. M8!W2;V_/)/#C[R?3.)Y_.SMC__P8D/KY_Y MV(NO7[^>\;\NAU)<-1`FO3C[^]W@T9NBF7N*0QJ[H8=2J!S$.B*?SS*DL_E+ MF`B'4_R-\J\-(L^-^0XU@CG"$>Q?I]FP4_:KTXM/IY\O/KY1_P26V'$6BTRB M`(W0V.&+\BU^GZ/O)Q3/Y@%#B?]N2M`8?C=&%*:Y^'3^]?,YF^0OCS'P`V,- M.AP/YXAPG.F)PV;\?72[Q)ZZ`!KCV)M^]*(98'=Q<0K8?+XX8R//1-.<=8[D M8QQY?TZCP`=6O?YG@N/WK9"MFFX?2#^X!/XT13'VW*"1`@FT"Q-V0P,(-H:O M/1!$87*^J;W0'V#XH@_?[*/8Q0%]0F]Q(DM%RRF[H>.!1,"4\3M\B:W6G*UB M^B4YK&LGZ(I?8$NY)KV*9G,44KXVFRRQW$S=8-U'S_$F.%;!=8/1E3O'L1L\ M$1<(][@>V@1!B6FZDS$/^*J/@P2.YGL4#R)*'Q!YG()(M^)2R:DZ6N=H-L,Q MUT?PR:LHC,$``4,$H\W66WZZCO`'>79Q.$+!XK":XCG[,O\W\D&=QN];\]!V MGUBGTR6>+*D":R(SKY@9\0M?@2E,0;SD&9WZ&!:>67XG3OJA==*6L^`P/H.A M9^F8L\H)=HWU\E.G?C2#U6V'LPY=99CX6?0F#XP"MS#X"<: M!=CG%[W5=$XT=E83.A]^#]T$+"[D_[2X261T!9&7(R9@%YF(5.X07^>Q2Y_Y M8L/=<^*Z\I^<7Z= M*>.ZP7J6$$RA#7W2,,Z*OWT;*Y$OFK@!EB7 M+4+VFW\\(@(F)UQ/QX@0=H,*4Z?877JFY7"2`U&GLCAFO25J?,TJ"9&"V*7: M*AMFM3I+Q.CKZJN*48IZ:T?$Y,V@*DK$[,Y(D.,K0XB1XJV4ED^2!TJUX=8+ M`FND62.-(<)L>&["-V&\-G"74L1O'K4JK81QI2F6+O!*7!9WHF]>$`%??3^) M28)6OXS"&/C\.N"@H%;0A/T@*6.WX10DEH=,G'%$G-6UZ)OCI(A]*Z-O!5!; MEMXGUFZ`Z`B]H#!!]R@6H5P5.3VOWU@D`H[_9QH3UQ,A+1ZNC((1H@BT^)0YUH%3@XA'?U($ M!60TP"B\$`0PY^0'"D'%!8!=SY^!?F9K'.,75$^4++`VO";)8PHQ3H^:<'(; MPC&'6+A&@'3E2&5XWT=AE$4AY! M6Z!R"[8?@=\("!`/5T;!'V!MHN%X/!SWTRLB"Q/?4IHP&Y2)K8`6&4"%^[)8 MV'KE6AJEGVRWE6FE:YXIR1NX;"VBR0G@MS+M+Q%<:=!BW)/[AN@=#B-@H_=L M(^"`R,^RR+.Y0_$T\E?"(]+7>\5`\3H#]NF67X)M(+9(A:/5\3J*&T_>PICN M7,ULOEX<$_RJ2I'*..$O%R^@>2?H/F$.Y^&8,_TPB5E.,,N=+B1/B2R-#2=31OVU2T)` M:)D%)D=F(Y3B@(.DT[3H7=(F8"*'?\G;5`R2:(Y_S@.5XO[9$-P;/#@I-;\8 M0HVLZR8EZXLA9)4].2D!OQI"0*57)Z7A-U-H$'E",FU[;@@A8H](1HDI!X>, M/R2CR93#I.0@R0@PY42I\9-DI/QL""E[=6YDBV/*62OTM4?()HOO)XTY*]>JE:ZN\I@W2I<=:%+G5%6$7Y"\SQM) MWMK$_TF=Q=3.![8$'HXUD$"S4FH7Z\=JRJ.0U^E*Z(QJ&-/JGZJI,*L&ZFB% M;%=LN\\@3AZ=VA-/,%:3P&IM\9%,U=%>TPF7MY%:M"O&*<.YY_MS_:V9+(A M9]9MR7:):%W4:V](A\&J9CH"#Z4O@][=+VS7"#T:+>A.2ZL.&.9UC3C:L\8L M(VYP%%TDX-IW]%TDCE8@MV?QO6(MVJ42UJ*^WBJP9JD1="WO0X1T>9Q"1_+_ M)6D*WE,D\![QS%^A4UD:7BTWL:S8S'_T`)HJ\O_7#1)41YL$G&XTI:S5GJ@< M8'<7C2P7F7>"7[-2^1I673,:`':/V6(AVJ"6072'FXQ0W;B8+#AQO,@\];`; MK"SG&^3&"8$_%FQKCG$5=;O_YG[7)Y\9^A3EL4F/C"O8N@GRA9/ MCUC7[A#Y62K[QTTTF<8^[1*_^+V/R0@M6-MH7L;TA<"7@7VFVM])OV MZ`C-W7?&H#E+^#Z*D81&;CF52FIDM'C;N;JC9Z4RBV<)*]E;BW:M\L'C]:3I M*KJVGU,?^L2[U]7,NND1+C(]#VXP%.=RDENHR3RX;A2FREYDUO,B%HXF;"OU06*]R&H9@7*_5.QU_0^L:X)G[7;QYB_M\&^ZGSV;5> M'[[GS\6GFT9HP=P([.<7[*$%XX^0%TT67K&J,WI_G]6CDXF`_-KN/9I6U50Y MK[0)VTB24'9E:9,T)4=!"P>6-ME3+=BKWGU53)@RDZ*<[\J0CATRSBY#NG1( M.<<,:=BQ)U>8(:T_-')JI2MF2EVWI#O+M-8ILHXL4QJI;.?@,J6URI9^+U,: ML'3D!C.E24NG_C#3FJ_(^\%,Z\;2POUE5*>6KOU?&?&ZVU"=.[9,:W&S>\>4 MT6UQ*IK>Z-\[Y6BSZ&R1N6Z=53JNM[6RIZWLV?(E]=*V967-=@4<@SU6YDJ( MW0/8+&$\13'VW*`L@Q?=RZ#S(?=-#632K#(/V]E(]\Y&5NRL&;JA&6I['=E> M1[;746?FH.UU5$&(YJ76MM>1[75D;U1FFW9FW:AL]R,=NQ]94;,.16F'HNV' M9/LAV7Y(NM!R`/V0[.ES@(;>P'9(.J`.259$]\3T>W7MKI+EUG([%[^&O;@0 MNGH;X793&5Z5GEIE:37#[+K3P&WX0/"+R]_:1*3["N$VT#O"6:9PN@&@.\QRK[=U4?*]Y80Z!(E`(P\)5W.+W.IL'YK# M1F)('>A*A9/O0C,M^=%&Y)A*:'5M;D0MZQRJSP!MXA<;U^)4'!7:Q#`DB&IS MG!A2=RQS_IA4;[SE@61(/7*KP\B0NN3&0ZE84:Q''K.]9]ITKC(-MJK`2J/& MTFC#@NKE[[CJ#-ASZI3;6Q1HY[6/O=`?8!`5'X2ESVI``_H$\R9EJ?QRSJ2R MCRES62<$P3_X?$STUF=TW-!WEG,R`>2S.NFT"@7/FR(_"5@GE83"TM-8EV"S2W7+[?<&C0&J,.C,V@6 M3'X;Q@CV)TY]B82[N0&QR_N6]XELQJ,2V,48>XC\^\ZL"P9J#3SCZ8$PS(84M M6U%80\U8[E6,/_N1H'K'DP1OA`'1MZGF^C`B)7@%C MT&GPE]7C(P7ZVDVA%:77;W-,^%G;A^T0M4V1@M3O3EQK>7=UT&I3BR^[`,VG MM#:5^&WWM/;,UJ8.?PNJ&FN[U9?FMZ5.]O#6IB!_.P(KE8?ZBORV1,D9]N;,./;M7B5"U3D.53GFW@J$NOF6SJ;0YM7:2TF38RUH/)()O MQ.\@E.P@Y@^&I>)3EL;/16G,H+D`+N&7`JA#TD^&XD/@AO$ZE7+)/DW@"@-A M`L0:;6\KE*!2T[9`!RJ4>V59'>AJO.1)02HL-/.FISQ=O(>Q2:EO+_@(M)#]?CE/>N;=Y@FS=HW`7!-F_82YGD@6KOPS>" MA(@-&BJZ9`"5U#[*4U1=`=FT5=J\6]M,J!5W;85!!ZKN4>90JJZ'W&0"_:C\ MG:)Q$@SP6%RW)0&I'UT_2$1;\V,*I(R:7(+VG"`/+[)\T3Q`:7Y#;Q:1&/^+ M_UY(AX#N[J;7;[]!V#:03^66[F;'L91,ZN__W(S&5$BUJ7_:C+SN9%&;DJF. M]YF+9[%B2J/\LV.S\FPH73Z4KB3I;)]Q42N'UC5^%)G/AK6$Y>6KERY%/BM8 M@A5)K8KZ7.B?/Q7%@L]SRB=RUF?2*`-ZY9/BY;HEHGN$L/WD.0&7[ZLQ#XM7 MX'NO+O'EW)-;SV^#N*V#N!WM:7V45[?LS".2WH,_WDR*IIH4I;:1W]V%4/5' MNS)@;6TT7;6\M=&:UZB?=IX1X/T'CJ>WH8]?L`];62(!R'IB/#(K-TMXR[KOQ:;X\V!N6&[+GJP5C>>/V?93@BY6TM3(DU M:L)1IX..=VR@_"#)#;\`$$-O+K"KM_` M,,,4/1#L"<__?6*@V%;>T:FX"X[4)KE1T9IUR74:]W@[HB/^X`.B9N3[Z)CA M=D128'VQQOMBEH,M,!ORFF8,`VDM2>>LU@'789A$LLJV-+YC5M M!$MCNOO^'7FLV13RDPK13)\;S;G+T\-7)CU$\((+H(Q[2@ M5#S%KJSQ6Z8QW.`)D5FS29X;K#"#_CF^#8'9$Z9K[]P8%BI^9V]C"AV_8H#N MUO4/E_`H'(_%(?\I>DB(-W4IZDTF!$W@:VN/!E>M=K\Y7=-O7AMZ13?![3IAR=- M9]-]0IO&=JUWKNY^4>QHIS]5F]Q%4BJ_&$9EY8TFI>57>')*#30=BE=AC):#+)8-KT)9:1^D8S7[3,)_%`#<#:Y3)<,^)LAC!]35U,5DYH:U_06:@+HSED1?&H;5 M'1!D@7:'H3Q:W>/R0!!E@1;V@-#5%*/Q]1ORDAB_H.%XC#U$Q,A)@ZJO^VJO M3D1'AC:&9K,.62>A2?P,(4=65K7)'=F`'%'5E\XT2*N"8FJ(?J5L6AM7^EU8 M6F`T$%3LR`#LM0I-GH*57T*\J,H[@C($O]628X5I;ZR[5;U/>34E"LUDH+K# M\3YABG[E\JI MG:%:FZ893*WG*GV^HS8'HFJ@,JS3,ME:A`MCU,?Q]R"$S6I]G>FTB9O+BE7) MPU/@1Z,)*O!K)]>#G0:;C^P,M5>!/5H<)>=NM^;%0%%P?E>K4_T>:#JXSZ6$5JO3/Z>F>4Q)^T=QZ8$;YB[>)PS%_?8]G>8+3"*J'0 M`^*:XLJ_E>+*J[FXCLG-IE&`>74A&,+ZN@S'`6N3Y/!9/ MA;5^BMC2,YN(Y86NWE^L48!2D)K%?YIW;UV"I2C4-#ISC%*Z5U[6AZY:%[XD M;*>/4K`WRZ-P%+V[0?S>FQ`D1E,.1'W@H05KM=`@VCG=6W':>BO@^OWKQ-#9 M;=77$:K+PS5J*I%J3=+*K8R',1;(E/E MU@):$[U$1X!MVJWU'HF0O/RG`+#]$70;W`H/Z1TV*@[I?J\=D/@]65EK=FI6& M=HA-6HLT?`[PA/O<+M%[%/KW(*Z+-FAW(,73RJH7>5C%!G7[\[M!WI67`;:G MK+UZ4%X,N#F1>4VCO/1O*S_67W`L8E9MWO3 M1=E=1Y:#E[>=!O8PF+!U?M._4LF>+4=IZI7<$#)'B^*8J10=3?I3MSAI+5%6 MZ@]48K:*I[;;.YD8ZY8S:J79Q`_/2V^;>(KN=I'[A!<^[)N(++II/\)G*F.P M-8-W$R?NA2'L,(M190_'#L<48MAR( MCE>&MG:*6`=I$RF6IK-)AVD3%FY'D:3>TR96W)HOY5(6U$>.VVW;-CI2F]AR MZ[VLUY@Z1Y3M5<4ZOSMP?A_1"][I[]E_GD%QPV_^'U!+`P04````"`"9:&Y! M[$9N5`L``00E#@``!#D!``#EO7MS[#AR)_K_1MSO@-N[L=,=4:>[SXR] M=L_:NU&22CT5UE')4IUN3W3<<%`D2N(,BZPA63K2?/J+%]\`"?"!A([#X6D= M"9G(7Q*9>"4R_^7_OAXC](+3+$SB?_WFX_<_?H-P["=!&#_]ZS?G[(.7^6'X M#MC M&GV?I$\__/[''__P0]'P&][RCZ]9V&C]Y0]%VX\__,>GFP?_&1^]#V%,(?L5 M%64CH_OXTT\__<#^2IIFX1\S1G^3^%[.5#HH%U*VH/_Z4#3[0'_UX>/O/_SA MX_>O6?`-T0%"_Y(F$;['!\0$^&/^=B+?)PN/IX@*SG[WG.*#7(HH37^@]#_$ M^(E^-]K#3[2'C_^+]O#?Q:]OO$<'7!&D'W\_8\__>%'AHO^ MYC^OQ*!=Q\$FSL/\;1L?DO3(/MKZ,JE? ML"8_#L`6+7[P$S(:3_F'B&N6DQ_2Y&@DF!`C,2#ZS^@Q:B-JP$EQEIQ3'QM] MQSH*4_URB8A=$DKJIG#\X?/#-_^G($7$52%.C&K4Z+>"_O_[%][_O)`*-\@Z M6Q(:YM#"BOK[-B`=PQ!H&)(,^]\_)2\_!#C\@=H*_8$9S8D?<@JIN9MM&6>.[7?\-O2D"==E"?7R%P\_NW&@$,`*D$JA$@&B/6&I'FML9`X8CVA*T$ M2O//]K^X3+SB0]?_9O7[=CM6^W?:QO:WO,-IF)`I*;@B*[<>^5OMX+ZN5.#V M9VXT`OG>$@G4'YXW)LN6`-'FML;`FG0>4`&N(^])@J7U=_O?7"I@\:T;?[3Z MC24]=[YMV0;11K:M^CK,?"_Z,_;2:_*;K&><=EK"6;9"Z+9MMYJ!6+=4!K5] M\^:(MD>,`&8\<#>C-R(:;:''A$1P^:BH-00<%QTI!D>&F`"LCHW+]QZD_@A3_R_/CQ[Y/OLSCF[ER*VH3:B7B*P,RD-**T# MJAX*B-.J07&41U>,$C'2%>+$J$8]=;`?O.R103EG'YX\[\0'%H[RK/A->X2) M7_\G]:^8+LEVA^LP]F(_).NX)`M[KH3,2.V.MC&PZ)@SH;,V\LR%ZJZLDCC` M,;U+)C]E210&[++ZPHOH/2\9B1CG6<\ED;V!N,XR(LK`D&LW@AE<#=,=MJ"#MTI<)T?=SG^_O-[1Z!CF0]47G;%2HVO"Z,[$LO>U['`?W/YF_G M\,6+B&39.K_TTO2-K$U^\:)S^W#$D!9FY!L!JUN"%J'U58"!5%T3(40LC(+] M4"-?(2]'!0?$6"QB0*?B6JC/Z"_K&^(5WA`ZSW: MD-_OKM'=YGZ[NUH0'UFHI3D(PHO-S]O;V^WMSPOCU'#=LXQ3G_Z`*W(X]WAU MQM?$K=SCB*Z<[\@'#G'A[14:Z">!<88Z,.H^L*^]==.TWSA&(%D_/:4LOA1YOI^6&P>3W1/7._D2O:PEAWK^!ULY8V MM&[//5)T1HMHBT3C9>U78\"/D1WSQH"SV#9^(6(FZ=LM5@WH9A.8<2P3LSY\ MZW^W/FJ[G7<^>-EDA4@CF"G&1,SB(!#*F`QD#2'-I[''USD'<.*T9_"4Q[H) M27H?.B-9QHB2W(NTSY\4@NXID_(HAU-`KET2L@G-W^Z(C.RU!=D\G>BE`3&M M@?-*/5*HE8T^K.9"9Y@.ZG!37[;.F+O>_L?F"NJDD*,6+^6JD@9Y.E M$V>A?0A'*,5%HS$U%H#-P9`P(T87S"PR`0I_]%9AB!?",-%=34=AS[C9N0.? MIF^)#6E=Y0W0P)BW%I"Z??<20,V"&D)UCX[V?]K<0TU_HP1F9UW%DK8B\!$FC!_N\(G&DVBBCYIMP**Z)$+VPC>:3:!&MA2,3HCHVB%`MZLLW58?#P; MRBF:`=[$X`,FQA/P&"A\F63$$)7K,F5KH/N7?N$;5R_RIO9O7?KDZ%ZXB-9( M-$>L_7*++YV[B7$`#CS&+GY"/H?@WJK%9(9R:I6BO3I99+0/+MA[1%$<_]0G M>#=6)(8K$>A#U=X#.-AC5/7Y*=#!:>^)*>1!J8QB% M]&*:[%Y9#/YS$@4XS>A.-G\;V`+JD\.,55-X]=&L2VM]O)L)UAEX-?+R,(@L M81=.AJ2Q))F*:[N^V-YL]]O-`PL%>]CO+O_M3[N;J\W]P^]83-C^S^C;J\WU M]G*[_\X)D],+F>XC`#!I=6NH7>B01,HPZMH8L[Z@,1:Z1N!65/6:QVIE M=]X;C7$BQDY^DYYQT(6HFEE-.``MD\Q!-M92^N3V%URFLG5798(#$BS81"28 M(-FXA9J39H1ZJD'U!-2HXN+2A*3M@=R9@/0F'IB=L_98:49-W*@'!\!D8S#) M@`:D[Y/=X1#Z9-6X2^MKR,$#(DU:L!!U?6"M6/5A0HB@=5VII-'K>8(*:I2D MJ$[?=WYC[7!U`KQ:8Q0E7DP`A;$?G>E3^'+>".,<$]ES].UMDF/TCX#;&?I\ M/\R/[!U+'%PF,I^'C.6?+ M=C+EW'D#6VAKM^C&\!P]"ZMEC>E]2MUI!C=-R,1MSPWU-B`30E<`J?NLTNZP MEBO$,K0%D'.`ON09E_Q__/C]CS]^)+OK%+U0(G0B"Z>,9A%:H=___A]7/_[X M(_U__BLR4YSSYR0-_XZ#%?J'?U[]TT__M/JG?_Q'-H'\_I])PS^P?XK&(5,' M^V/B0D*B=1"PQ#9>=.>%P3:^]$XAV3'6]*8ZQM`@!#HFTX;4.!T;I+)_**8I M4O>`J"1$E)*L[9&@735R8X$=@W5^>46'N;0AE/,YTQ5/357"II!FI-Y0H0TS6/ MR)+HJ;(98NU0Q7J%!'-4XXXX>]0AG-<'2"LTV58-!^_5P`<D?A> MPJC*Q*][ZO>5?J+9"#CA;D-4:6I=U@(NB6ZM>\G<*QJAWU@SR,=9A2B7D9=E MNP,;XNO74'7CU-,>>$2H`$@'1[LQW#B12](]J:/-4'+@$S#ZC3:%S.99D_HJ M.7IANRIG7T.@$V>ER(TSYTXK^Z?."A$&QP1O[((SN0ECO"4_#GJ16D-@]]$1 M6>HWRE9P#J,E0M_D0ILBUA;2552GFV0[24,XZ-$$NY6XPRDK4C!\B:&F!+^^ M&@*EN-%2D4%>6+TM/`6+T,!DZ-L'F@T=_%=<2?FP(7> M."CBCN^D`@+B$'B)DG5YD3@,ODL![@!4(!2&WVX.:?!R608,7=25J:C`C=L, MAK"$SBVV`Z:]#!!`T^91$+K`B]:.F'13^%YSYDWA3;DNAY89.Q2HHH^@.?!# M*0#`0:^NG:9'XLCP5]1-TVD/]1IQ1.DTZ9#J"5&R;]/:&%J&[43AMVWL)T=< M[DD'XG:5K:'R1/<*WTP9+6T*D#VZ1P[=NFTE.3M=VIUPZM'H(S=*9#U@FJ1Y M?9>*1#ILU'_"Q\=._5PM"J@T8X,@FBG'E,WM'T0-R2+)[44IT!J5-,6))2># M"_Z>#?_O`C&^+T-T*HDC\Q3((D(^8G'>-Z)'8'N0D,.LIU MVEL;YOK"J`9'-30J.K"A/AW.6@IH$1Q!XI_IM,-FFP6`G$H@?DGY/>!,YD4X MN\&VLGWR=//N\45ZD4V29\16U`.RL(4UDOVRE+@@ M<&*C<8\S3`8;K3)8"\$6(BJ0#]#`F($6D+HM]!)8=^L:TDA<)Z=AHZH>^R_( MH!S_9"RU,'[(+7A$>#[]C&/B="*:R2@20VW,3:`U]^@Z ME`#;=7VQ)"MG1KQ"@IPGEVHP6-2B!B\!%T=G:3;5.JR8`^I3#:K78.#.*E-S M5>'*JE)G-0EP,R@30&/I!1-GKRDN?X.2&*QU+690+Z3B1_`W2:8:R-*60-G3 MU4(W3:@.I#?I#(NDO7E*@SP.ITY1@3I-\YD()G+"Y>:B#D@&IS`'`1C2X80-32L-05(G]PE;XSEBJ."[)5J1/5(8CJ)K# M5?[N$[]=!5S6%FJ8]\LCJ6@M$EORH;Y<;U*`UR&$,0-]2'6#&*:",@U=R;J)E8Y)FH=_9Q?. M--8I:%;GXN<_UJUF-!Q&2'`<*):RTA@E1@4U*Y@&E?QFJ>]4G`4XN&DR7?0Z MMTDRVARYLRD:LQF".?LRA2`.P9S;_50G'==D9/&\PV>"J8H?O<"'),6\W=Y[ MQ=FG,$YHU<]BDE_'09,+S[+Q">?/25`M#E0':U8E@`Q)MJKD;IBSE>YA#ABM M`^RFOR%4Z)%U4IAW[KT"K-RA%=$X#D74#%`E1CTJ72A+)*/B[%&-_ZIP]$S* M%=J\YJF7I`%9.J1O_'T\+W5`N!.]1'QJ@-YVE(H5L\$%CO%!63Y;V1K232F% M[[J43E.@EQ,*.52#DS0O;L[0MX)BF66$U@&!"8*[-'D)66PRL9X>3V-Q#8WS MP;NS5AN@M;),T,;ZN-X`:E,L$:*[',;Y MA]!NZIWLD]J#09&;CDR\M-D=3L7?Z(M`Q>W=7$P!GIC,IHKR$F@C?;=[+&--%+T8!V`'BMN+QFO)9F_-H3XKIFJ-MB-12*!K2# M/\*\G'%7(:,>X"BR]$'-/]MU*+*^)8G& M:2-4M+)]EFPL:+"(H+J&-T92P#=IS;>PA=A9ZUGY]GA2QP&9L8!9P8^!65_@ MF]!;W\F:"R?9'#9?:I=,RK.4*LT@9P1UI30#V)((?4!S/O!>8%>\?O'"2#5_ M7WA9Z"O49,S%@9VU/ECEWGN8A?T;JS'RZ>P\"U:*Q?H*,7Y@47ZSP8XTEYQP M)KOQ4EK8(2LR,S)$],E7&)US93JT02H8D]0$4S?!`1+K)JFB*"JLI@* M$^*/"CDME#F-@U2:#]V$/998`D[$]V,.I(\6R:_-*KYJT0(GF=8!)LT[W4<( MEXIZ6*IQ&:=J7'^7=8K,./$XO!282T=FL5,2LY++&K43Y#3`8[,/B'1,R@C@ MQJ):&G6&]%4QMBHR\,H*+1R]Q144;8'6"7V"-U8'LH;VUP1J*;HK@=8H<:#4 M@D'Z.Y?RWNDFO',BTYU!7CBKF>T&7\6[*KC&NG:\Z$XD`.XU1$D[\%2_:A/L M-(+,;MT[$.J''<"6YY[(9EF3M85VKG)[K^4-T#A5KUUMD;T$KE1I[QU!K0+M M'ZH"[>!&,"^<6>^T]=7FB4>G"KJ M<)_D%`7U. M8SW0>I3H!5'U+DB035F!S74U0/9'O(P1GP_N)(=&V'&&R&[ME(8O'L^8@%/0*54!D4_[([U& MA]@IMZ&`IN$W6I2N.`ZI6$:>HUCD.>HZ]`#>$7&>O8P9W&4M*LLQYZ$'QLA[ M%!]PQL.?HO_=H?8D(UMG]_CDO75",&Z3'#.G*-NMCF8%+T+)]8$/L&+\1:NN[&ZE'/Z,?DL[*@CTU;" M6$^F6I6XZM$64L@R+JT9KJ*Q]I(2@#JG'@@2#R1I#>5FE*+TCIIVP),+BYYQ M2%1/U5BF5]J@V)?P,@G0]C\.9%6RD1DT>J%T-FQ99Q$BIW#(F@<7%++F;MBS M]C30-F@G9O^16`Q-&A4%Z]VR;6VX;>/F8"!ON:N7+9=>]GP=)5^&:E[VDX"_ M-U+"4#PSZK2'?%VD$&;-/01*C/&@A5Z?$/?4FXHC+]#)4-4<73"8M?!7\XBH^@^N<=TP(<1 M;KQKWR?SV/0R74&%.2^GMF9T]/S]M#V'Y7B["R^C1>Z/-)NG;!4VU!@P\DXI M>B?\KM,2REWW22._QOWP2%O3@ZBRN2H-^_++)B/I:6,A?;WYC/MJIJ"./"(S M[3UF@:[[A`FR>?6?B732D[-1;`!VX!/@EMOR$3SL[M5'"ZB(@KCH#,`RF;+@ M1E.[\(22!4.8K>[3]W]S>-/RS M%\:[^,&+\.XP7']"V1IF(AX0OCX3*YK.ZU[TD[KUBM,96+0UHC=!I#W=Z>_3 M,T9W2<;>9I$]14%O?4X>!^-!P*A1@%8A2#$QV2O,_UM;+HM`ZX&MC`D#L%H% MAA!;Y0LTJ2$J&AB))BMRP`AI[AW^TW/-\&+R$[&>LEF&A;75Q6( M\K(,BP+C4>@]AA';';IDC=1)Q*2W4!DJ0_H@0$Z.=&J:)?GE!9=6#/CU?<7$E)7C$,-:V`JZM"Y,`DIA-*> M?ECE.\$`<0Y0V8RI[OSWFCRXG41DY9I09D#>OLX>)8+-6@I-UY]?:7S8.CYFF.9L!,2X:NQ5+=\8LZH@19P6)+AC*J*T0'2.Z3O+^S/9 MHWW\7X\P,3JS@6&?)RP^SXG1`CY*T5\L3%YMN+^:G;:*=6J/J91/O^FF>9JC&3#3DN%\.T[%RKB%:!M?)G&,?;HZ^#7,G]E:GH<` MRA8+)M0`:V5S<.6B69_4[NK95"Z-D4?S[9=,T!?"!=78P*Q"9X'I4YBG&DR_ M!9-F0?;`[B6YHM+OJQ&&8#CX;=B\@ M54)L*9$+.;%[!--*/64[L4KO@=Q(7,V%J#&79\@`T.($121"'`5XR8@B!F"DQR!O9%?9D/+=@>-D:]N#C/RA\2O MCWQ56Z@8[GYY.L.GD7FP=_0L;KIC)6?94'I-%\;EL]EG=V)%*#:O./7#K"HO MWV/T"CKX2:`7D&HVD!*YL(+J$:Q;,%?\G2V63O!E14QD;TX0_+FN($4E[7LX M>9Q\$N3^2>.T$T;KBRU3T>8X?%NF@L#(*P\#I,651_VBH[K^T#E3M5@`F$!= MQP']#XT7>/$B.LWR.@/M@%B%PLQ8`)4-'@&S45'8@-Y^L6%CX23EM(AETI`6 M]D.-RTI4^$"2H&X8^YP!+;70[>WE_6;]L"%X-ORG[V@(+#/<]>T5_V'S[Y^W MOZQO-K=[0!/=QCDFFLQIG5:%3II-H-Y,=,5LOH2H_@[POJ'=N>35`F_"ZN'" MO4$8E)-9Z(G\'1V2E,R=G`!N>%Z%=)Z,@ZR52;7G$+F?!&;XZL"H#^>^]E![ MGF&9NJXPB3^P>XQ`T*+SB68>*4Y8_Z=W//UO>K%!NL_$'48KPZ_U[=$(F"7) MJIN?&/CHN!2M=@JN93S=]L"6HP(@-9MV8^M3PH`D?4.H>;.RG!&8F+PF"GXH M4!C[G/6^:K4P;A(OSFJ%36GR2EE]70,ZJ+QXFH":B?`&B``RWVE))!\LHA`) MHVU4J\T35<%:*U?X,^&*&"Z_BPKYE@0&&!(N'L;2881*%OD9"X1X" MH+3`@Q`:R7V5K0%3](9/<7@(?2_.N^+M\6M^$:D7(+K$0"E\C:`U4OIJ48*E M^#60KNL7/G_ZM+[_,]I=HX?MS[?;Z^WE^G:/UI>7N\^W+/SZ;G>SO82([IR& MJR)&%34JR-%OE`%B'"!?#*8T+5O^=A=1D+6'60.>3X,.[*90#U#KIK"?""*` M1$D\S.NS_S`ZTZ5GVW:?-[1[B.GLR$L%BA1B3EN55?!SQ^)5`++BQS!X6X%QV"7@UX^;AOE7V]2+3/N,LBL6*+.WEXWU''`)^K'F[@76? MJC&0^?:*WK!*:4NX76Y3GD'OJFKM@MK[O:&\*9B7ZQ.G:]Z;"_LK$D,126OW MUACTP#_D.?9I.$3"MKXXIOM>;4]CR`,H=F<,T$;PC@D#.'>E)>:0%S-EXO`G M[?5Y9AR@7.$8*;L!'[M/G[9[NG-[X)%).W9DM[D%.:^;!U+%A$>=U=G,Z6H5 M=Y7KIQ2S\JKTL>?G.&3!#?F;PEOJD0#<4&K"*"\G!]K;O9?4$J:;5[6@0I0, M7:8X?'K.R5Z@XK!T28_!"[RIR-C;X7-)-V?)>(5HJEE%D\:=H2^=,[0(G!C\ M0WZS-4;J8[['45JYCA^+Z.?[S8;.;>C7[?Y/Z/)^L_WY3_O=+?I\N_UE<_^P MW?_9*2,V_$(R_P1X^<[KR>Z]5_T%93\)6'KV01BM).S*]E!+PV&9)/E?R5)P M@_;K_P!8]XV1EY$@0N/>[OD.QS2]DP3MWDEQ=FP#PRMV-#FB@J7NZ+=VLSBO'C:?[FYV M?]YLT,7F=G.]W:.[F_7MJ/>PM>`XV=3=WQXB?:P&@"IS;$]CRTEC M!R71>8%YL#F*B&^*6%]K2U M:Z"#@O3G`%G8/(<3F)7Q6J.`D;K8*7M3-UYA!&.,2F#/"AT+;IV=,-\`\TVE8SK,#-YVS:'+S'<\9BL6;`12/[EHZZTXL^B*'\S+WUFA M]X#53!EK\=':^406.FP5'M$D&-=1\F7#?S'TAE"/%.C!F@&LPC+'X%G,#C4! M=,*6:V0\[1`E1`7ETK?X`Q8V!ZB@/$+-_@B;X8M*3VM/DQ^KJB9Q(,EIIA\Z M.)DM7":P.=11F.+<>EC,3&<`+DU%1'FRC29+(U/5NJ%SI;2D1OTV!-3&%]`( M8<7+`G@EW2C35QRR_NJEJ4<\$)VVNU4++LG<'>;7GD]K2[_)3JG,Z`&.8<<` M+,]E38CM'M2:2]89604+Q'G("HAP/JA@!',0.B?4L(3:KJSA6U"RY(_.=G,&*1VX`;FKI5IL[D*LSW67S M1*:_>-$9]QF3!AW0=E874+F7-46RW$960W1Y/C4Q)W,JD3%WA1BA8H19V<.. MP*-A]>#&P=[Y9B.LHT'HE'E((`W81P\6VP;2%-[$0CBE>R;2CTAB(P6413"< MN$RYE^8R'.70XD*?\RPG>V^"1;'FO,!/81S3SW#A1?3P5R6\6TM+)B-[W-_, M+<#+Z^$'G+Z$/N;?[Q[[R5/,N#!O-V%%.JU;=Q>RX7*WI'HOLC:7Q,`PKT"Z)-Y=*$DO\9PSD=T&JBNO3#E"ZT#CZCV M0R^Z+--H7V-Z]4[^2."%N)7(6G;6L'R?$(_X+"FR>@2X<(>6'Q%:03/>8R': M.7JAO=-[Y,>R_WH^^0.7@,6C,AFLI)3 M&(XBZ3$ZS#$<9WV-K:&Q*_J<-"C2O.^3IDYXR'!V2>;0)YH>6L%D&Z\?,\R" M1.YQ[H4Q#C9>2O<`TN!\-^1R=$*R]4&,)JVEA7)O8K.#>,+DQP5$A82T=;OA\(<2Z@]JZE=-ET*&%?*K#]&:1C[4IA'R M8_Z,D5=]C+3X&'B1CS'G!.R&V?1,TD'WNYW*SY75S4;]M5#S:_5]J3FG\VH= M(XG%7/ODZYU9OLJR9LLVSI-:W1;9-YW.$V`:G4L1Y10XE:'=Z6L>:25)LWJ* M_P5A"PP7G=^A'FTJ9S9MRMN_+I]9E7LZS+GD+N+0G,=#04OX$ MK<0?WN<,9:#!"?.44!'@`_&^N)*US^]MZ$/"$:%+37*G0C24\'0"F?IP@<0S MM8","&NJ:S684:,,.6OT:%#)'HC5<9;G8S>*;-3`]0* MD'+)\*10QH1+.6IZ6OC&VYYR=3!AV[&E$5RD*U]<2JV?GE)VYBF"J0ZUZ9T# MWL7J98)L43%W#P#;D&645&Y'YF5O=UNRA.R2/)JB$S[U4GLI^RELHVU#PH$D M[)60Y=KM@PMMRUHKKWR]4FN5YVDLK<-2:W[?)#L M)I9>5IF&R&[8']]7?&QM5[IY]7&6#=[US\[=W6A7`^68!+6.T`IH[*J>&B:$ MJ%[5SBT0[\*)V^IE%53>\;/+Q^&;YJ:K7/#>>5+271YURUS?-I;G-\QND[P= M7&],#9*0UQ1<+3VO+JGM9+UF&FRA::(S MO:T!G8+F#J#M!RQM&HT,7W#)+=._$:LCY+*&0=WO2,NC\G9U98]H[PHZ5EA\IXV1?C'5K9A<[M? M[[>[6U:O^V;[[Y^W5Y)"IA9+NI00V6JLEF6!G7E=TL3>51Z&.WXR-+3FF,H4 MJ##,+*HH:\?,JH/%W-)DT/(L&Q>=5"1.+"8V9&6C+.:N:@0S&N6B%J.K7\;% M1DM'*%4"K'WJD>_.JX8X\>7KY^$25:PQ-N:T-EH'3+)]M2*_"B*;= M1+H21-Q?&#BU)IF&\W-SOU]M;=+^Y8:<;#W_:WCVP>8?]ALP[=^O[_9\=6;34 MMZ7K.+@O*]SKES@RX0!4S<@<9%FX:#RZQ6S0#$YG*7$\1PG1[SW7K4'7R\%S`%$,+@/I%QM,_>)VK^-I:T2:X\5KS\DDKEGT M,>11RJPL*SN`QK$OK4"E?&M>\A!%:&M<(,%=X4>)*2LS>#WFD,)VS_\'!'XX M'X]>^L8",H8N3!SP2:K%P(!C&B9S:SFJ=2BD*=6?7M`DWL0319ALWKC7I3NX?4++\=VE"7U*$5R\?GQ#W])^41A_A\JNZ[4+X0H6 MPJLR+55)"P-'=-=-?DM_9A4/SUQQ*"GUMDP-1%JF,2:-WRKQ9$%HTF8@CZ>5 MXM9>0'?:V'[&K!!`LDP2+5'5%.@U[!21@5YRC!':*YL"QBYNXQP3C>2;5[H_ M4]53Z;2"VJ=(A:WV)KU2CA\%>L\0N]))(H-9"X1Y$ZMG]P;B;184;^`@:UA* M42KD[VQ2:NJS_M0KJ=Z"H\)0_;=`!(3MU8<_1M0?@=W4.44XP@7M'=&\P\,PK6VO=3^AJE:#SG]D>\ M:2R?U;#G,-OX+@U?B!O8'0Z89N22KCYU22&V26:PJJV3'IWE[92)4+VO5HO7 M7_S-$[$,P0(5/&#V7K/A:[RNI_A.`E^R)+[A?9H]@(";NOHCO%H"6_YKLJ+X MJ+RB&*2#N@W5!%1?=PX265][:DHTD&*84:[0^D@O'U!)#'5N.0^HZO%GIOGD M=::<]++TSS+/,4P#G$>^#X@T0[R,`"[WNUJ:@9%3(ZRR5($G:A\-1YHL'#YM M^KQX`.=&<6F;W6,?DPF;K_0OS\3/=*X;]$B`[977"%!`U+U>#(&]`'EJ1=TCE9MK@VS?'?X.4F"["&)`N6DWFH%M>Z3 M"EM%NO5*N?1PZ$K7=849S\/E10OE&%.9F[YLK`VBC0`/Q],DR^[2Y!"J?'"C M!=#!=U?(8B#V2+?8%VZ*TSFR3EGP//OS(@,O3W(O4EF&CFQ'+WT*1U5OGVV3 M7#TG9_%;;T.Q^_TD8%OC01B5O]27?T'/U"NP9#59-5_Q0+LW])OX+W#8_10L M<"/_R*E?=/;8;P8QNN:C%>.Z7<;$1W!&J_9U)`SJSEDU<&[:Z M`'#1!-!+>]DS#9_NCK7DWLQF^@15!D) MZ-JP'X$AA)PCR$;CA-/\C;X*RXF]4EL]T9--O;&N3PXS]DWA%;8P%M=BMF$` MI)LBF9.NV-._G#G7DMPU^YD!)P.("SK(IT3$OL]8Q%SJ[Y0UZ*`>$VD"JEX3 M&2)9S'QT1.\&RS(:5"-RS5IF@@59PXE>=(=9&#^Q?&MZ%C)(!55S20M,54O) M",5RMTN#8G??0)44B)&X9A':>BJYX).*:VTH`HEH>SGCMC M=Q(9-+9DM,9Y^()9*HQ>BQK%"2@+XGC093[$Z6@7L\!Q\#K9""B7#X^=%*TK MQ#FQ,5SR$KE2W#+2F13!^V%J2CB6N:CWL99GK)`JWXSU:2% M,4PC8(4ICD*TF/'I0FB/,DI7U6>NDJK7:%V;`R=!+8O6'$JH844+>()]/!'Q M6'F\]$H\7-L=;I+XZ89XBH`_>=,\W1[%"NCD>P+L\E1\!KS+G9B/`]@YB2[9 MH"1%5[67C935!\9+/-9TS5QGT@##&3&<#CSFY!FZ=&^;5,V!\Z$-WC;IR;W@ M;9-24'4:-.>&OS&(G.9R@TU`F>)GLMPDQL9%XJ+K1I'IDL.EGC2!5\\[.0;7 M8M9A`$22:*\B%=FE7+.;V>"%(GD6S?STW9RE1EF1,E8'L"S40W9W98$R*N'9 MBQ1IZ49Q`'B#-0YD^2++C-SN^ZPQLHVJ5/>M8/4=8!ZVKQ3QX"NO>2&?VI"C M@A'@FZ]F(=([+]VEK$I8P#;)17YZ97B('C%4<(@)M/KS:#U*ZV^D3<22A$\T MG@S39)EHE_+Z=X$XQ"D+"D`]F)X3X8I!9$&MAI`=1M+6<%&!)$6;:N-J)11023"V`T"%[U?,4S8B!O61C#.0`F MXFBC`%P%WA,I\?HU5+UXJOT=*+ZD+6`91:*2;+&CD[HHG5@)^C>R;2%_A4QR M3Z7XA(^/..W[GD4+P"_:%++Q3>72+?M52W$4W_4J.7IA#/AE/WFOX?%\[/VV MK38P7UR5<[`NW16I_8_%W]!MO`7)N.55&BR,QC(='8K,-T$B4"5J. MQ#X)EQN)+9$Z7YG_'78D3I319CPM+0N"@Z*F8CT=$SZ$OC)OA@XA5#2M+J0J MF-84RW(SJ8[PW2!33H3*TJC?-I*7<<+O8*)F1^"I"Q_P5G`63V'*MC971$A5UDLM2A@;,0!5&,D(-(M9B9[XG3@60L52Y#(Z M5!"N4$6**"V$G8Q#],G+SRF]]:$-T"%)4=3`...!E2A5MCO4"I5UZYUIW+R. M9`1PR#4)#>^T*<*$Y#+U(=WRG:`N>KD`G>25;1)_%BD[-*Q)XT%:0E*INN$,OC!IJ@ M8D!T&N:4Q(XD7KDFF\GL&0%[!G- MM"FO(,(:NS"'X&117$85D7&[U2X?JR M%``6&C26E08SDA%]3.CJW(N03S,L\#P]Z2>!\>.!^P0G568%=7GZEB`%ME145#CS4![-:8S;G@+^>JB:<2$ M:)$!;&P-X)2;60T:NQM8;8'ZIY^2UIVXC?>+;'!#.A.T M*T_X^`<89J$1H6,ZEUA/OKD0$FM#>&5 MF:Q'XEK,H`R`=$:?(*T/OSX3`WQJI<0FKBS5#\BU*!USY%U0@YY^A@'IX/PBB>H:O+?UBXZE?W.YC,=&Z/3&"/ME?$H'%E69RR+]X M:7_>D'8CH%6C5-1R;=@KXW(KP+90G76>:``Z6J=+Z<#\?T,L:)OCH_%BLT;H MV.S?@30X^2NQV)_[Z\(;'AI04L1H(5U?N7FKBN_<>6]4PC6QA6!S/$7)&\8\ M*251YS-I0>'0K)0\*VR6G8^L1$_&]FA#QUJ+]@B]E5],B=W=_^+:LW!@L(2Z M^LX8ZC6R1(^(=;E"1:=%BEC1+3/=%2I[1K6N'3GWLZS.V@MIEL3OHE-QC!5$ MJLHCU;B[5C=OG:8TNQD_,I!KKRR:5(-!)H!/.'].@B1*GMX&'E%8Z=FENGR+ M*+6_CM^BVES\=Y;0A?6/"@&0D,`AY[NL3AD-)ONKM@;0/:;7 MZ#0KQV42,P]X]B*R8DR/+GEL"R-.YMR]YHC+:NU.8L1Y?-]:3`!/Y9`[\2'W MI5"XQT4`#$L?6H?7E)RIM*P7/3B9OYO;5V,%Z>YB1VL&;#-KHHHQ>]JZL\]Z MSXS@PQQ'NZRAB^DY&+^S4V[EQ?;\NG#O\+7O8GSRV:HKE^=SGDS3=&,^?4A* M-ET!CH-[+U=.3LOW^\Y,S52ABUPGZ6CR75TF*338R?@AFJ&B'7H+<;1,93HK MET2:N!>[(F(U#5HJO9>4-G@'GD[L9';G/*/)/[/;<%V0Y?S_OS),-*6RR MY]+5E'NFVJ.:!4RSO(&J];="O,=%7!O?9&]B9;8)&XIK@.45=XDW8O]&%QYI MZB]ST,3!/^1>FCL'_P(_A7'$G:ME9_V^NUB5GA_:YO.18FC7A19ZJ]1Y(\`*XYCE-<7Z,#E0=+VSYFQQ0 M_HR;9\_C:K:[Z&G[<@TNTM/7X#&E60TM:.N=>#Y5VL%EO=MRZ1=SG-IR74K5 MU0(@5"[H_3EJ%=KR(I4O=`%]+57[-LO..+@ZI[1F&=\-,+'J`2Z;5YSZ(<&L MMR?FX,N"7=6-%/S9,!N+!9M%+W4+AH".*CYH!3_LT! M)S3Z;EAG=5P`O4M#?_2V>DX)'%T@SJ]D[87C1*-2H*E%O1Z^=\A%'M);Z`B MHJTDIL"R_)9/2_,4GWA(]2Y MOXK4;7^UJ]=:'`6`Y];N_7WZ:$/E+A`Q9M7OVHR+,C3J1KC0@#%_A6%4BVIK M,.K*Z4E]O)86"UW\KS#9;.,\#>,L])<,7^OI[]U/*'(%+C"%]&ON74T:'9WU M.KZR-8\#LS(M6/!R@TI8S*^U%/I^_9CPQ_0%Z**/)"3]O$^_I5387/YJ4%/. M6J9,-18B+&A_BSZ26'C7KZ.V!M3W?O!:`P.P4=?N_=W[)YL;]9%:?4>V:;BE M:E@LQ%FE!2\/N,N/P[INKG4_]CG'A3H$](>+JK#A`JWH;EG; M7DI9ULQY8'-E;=ZPI4@3\.]GE?<+SNC4P.ZQ6%Z!?4)_96O#J=_]^USGF:IW MKH7>6+TZNYXQ4.22'I"+45QX\T0<><)^_=7L=">HNJ8>7%//"U//>]\0#^L% M8)\\5:BOU:W:W%7/^PW>L0L&W&GJ.^:O,")I]B_3Z\?=WLL#'\">1]?4_/OW'&J-&SF-DHV5V"?BC MJ%9QZ9W"W(OX3N$>9SA]P<%UDEZ?:;@M?5),`R$4[G8$'Q@W.1IPX=XF(UW, MP,9`Z\1#,QZ\OLH*"39B]X@*1NB0I(BS0@4OB*7;C(!YC96,X_1>O#!B9:TH MT%"!<$J]%=I;QQ726E1G+^JMZZ1'"%'_Q`125<=$A\IR/1)]D12/@2^ZT\JW M@OX[\+),4]')"E):0S=Z^@Z';!L"< M58*6EMMN8-=(Y;UW/BEKAE@[]!MO"6-VFO+NGS&R)O.@,1D(?6!"/]&VWX8A?G;)^\U/)Z/%TF:)E_"^(DLJ& M!Y?O*J'5>PV&29/,G>$B@],W;/IP6!T^+<&U%_5B?/W&*5T;7`.%20=H'!I6 MJG*B1@CL#JB>(J#*">QF6FE/U4T8O7&[(V"?/1H1E3REWE&VCAEJ#''C-21Z M=R%Z=&+I?E&*V-\.PV'0_*'1[!#$".N&7)*B@`;L"&@6DE)I@X:!4XD]P]OSQ MS>ZPC6ED)1%+9LB21@!.72EJZ<@[+>PZ;T7WG0_+V]'/6K:$<=`3!(8YZIQ1 MPQ-LYL++0G\=!U=A=,YQ<(OSFR3+[G#*)B^-H#=#!@"V-@IB:8=&U'9M=(1H MW1F&\F#AT8(+(FP0Y4,3%?/84G<"Y+X^Q(-^;5[(@8`<$\@1A7PBD%E@[9R[ M+AJV&^84%LT#?9G$>1@_X=@/<:;A44RH(>XUC<%5%YW:I)9O/@WEDL9I"P9L MF#58.&1,LP/UZRR`KDSA/YZ]'>P]CFAMD3LOS=_VJ1=G1!SZT.?BK?Z7GJLS M$P8P.UMSB,4N=SRVQ7:\1F#:`U,T0:P-^"5<7>#>:S=90_BA)+]:&Y;5RM!0 M7I^UA@#X9=D=T4`8$%?9>V36:?4#@*B7SR$^;%ZQ?\[#%[P['$(?I[UB]U)` M0'CPGW%PCH@H:S(EL;4K$>R!")B&.9F<-J]^=`YP<$U&/7U230V!-<<4BL10`B^<*T7E^]=!,H:`BUI ME"*7RY)!69=;6LB$D[\X%ZU`+VQG%-?>F/W5H_E>^K=:K38P(U4J:#%(>R5< M;'RV16I_:_%WT$$Y)",?CZ*5"P-RXBKE9B"J=C[V+LWWX]4STP)7J1=75[,W M/1'`L^TR;Z9%##MA4.MC(JT94JF`A"UHAW@/$ MQ.FX:@!7C,UDKCQT2D1.\.QCM2IXZ^`OYXS=>ZK6EF.Y`:U"IX$OUZOSH%Y\ M\3@:;6`WXW>$^>?.B3NH2>1.``!^%F&443^OO=D-UI)UWOCAO1;VS:`<3;F,J M;,K;P<31S*19BP$)7`":UC;.5+>;[49`@0A24^]5*YB[KS6`^0\+7YJ\NJE=,Q^2HS,>.`%B%`Z-\;$X@,T!X%M!.EA3%FD`]D[U;IBD@68_:./`T?S_1; M4C&%[.DG+_>?:8;\^M\Q4;$RBF(*0YC;JNDJ*&ZVYL.^V"W8)+#M$2Z8H7IK M-LI7J&"("HZ-1BLDF$)=WQ77%:HY+-BAT5U5N@WS@Q1;HBQ`WE<-`_L M.R^G%^M^DN5S9EW<>Z\BZ7N2TGK(9+0^TQQO^`5'R8ENHOJM;"P3@$WY:*CE M%MV8@]T-^TCQNI4ZO=W,\X]4Z8S(<^"L+,3TC' M;S19]E^PG]/;?^2S;F#.+.;\NG[U==/ZUPTJ9I#)P<\96<%DV=K_VSG,0JJ0 M#?F)5N'*,9$WSVBA=ASL4E:P_3'"109;'C_._ZI8#LS%'"C9^*RJ*9.2+Z*3 MQ=81LRFADYU4,$8USBO$>:.".>+DB-A.P7Z%JM3(#\N]SQA*A;Z46B[%RQ/Z M"'HE'J"@D+6>-8HHBLZ1)T\,)FT!$N4C$[(6M5/_L^THG&[?DG`)W@CX8MA( M5J!DIK.HT]ZDV33UMJ5?O.V)`#V)K_3)828^4WC%U#86UV*3EP&0SCE6:R*B M3<$S1?7CH2+V9HS2)W=QW'7AZ8T[-2Z@<=<`,C3N9`L@/A;!DTM)UD`]3D_9 MVIG%OE-3W12M:3*H)_;*M:G+GO=%?K;]X:7#MA>DO7G3& M:^(GCR+G61C3.QCZCM+/<5`O0U]??B[?)U0!00N*;-8@7+!#@#*&BZ.1%P_\ M\$B9HGK'J-8S>GQ#]7:B=\2Z7R$J`&(2H)H(*R2$0(44B(H!LMT#TJT]!>C5 ME00:78B/FOI%//*:HRNKM3N)T>71[M&!#JX7-KB\2@)T%*K%A6K)ZG7^BJZS M*8Q?S=N=%F1]OOMI0:W(A::%;H?O>5I0H;$Z+8@XE:]M6M#6K3T%6)X6S$;7 M(M."4.T[F1;X)':=I`<DC;R+IA#L6)0$50[C2L/@L# MU<*"4[%$P6P:4FKYZ_*7?)(`])>%`%^OOVRJV*:_E.OV:_"7I4[U_"5O_M7Y M2Z468/RE7,OOU%_>A]E?KU.,BP!#RZO+WNZ_`E^IH=Y%/*6!7M^':^A7I$7' M0`5!5)(J)K=W'?7NIB(S39NJXVMRD_86E;W=?ZUNTL*"TD"O[]A-0JR?U'YA MP44JN)M4:MI4'0ZYR4REE5VQ:,>I'V8XV\8\N66K9%GQ][LT["1WA1+"49>Y MB*JU'>>B.H9SGW,K=8P3S0:\Z*[:=@IA4!B+!+PKU*G<5[1"3"8G7>G26B_^ M;JZ>*3$#]!5^%W40L(8!<1M_CB8U=6\&;WE>_8QPBF*TE]TC?[; MBA-RI2#&C)`_.`)Y^*)[1LS=6^LY`Y'*C."725Q(]S/QH_GNP!RF#-TP#5C% MU&$@K1*J:@*(FJI#TJA*@=)T3C5"Q"AI3AI&"UEX=0HBOX;HJ4#$PC$@J[,N M@VC.PC1\4]=,\4.D_O4Y])_9OYBTV:477V`F?R=EU@0^$&5L)@"NJMN,8&*Y MZ,UH"9518>WD56R0?J'\1&PVYX@(2_2(D6`*4R1G?O2Q&CT/!/,X>I^C?UH0 M_7!!'5?@SUI"BTM"'P,)2!S$L%-2D\#YGR$8;5>C:@_B5?J%48XA2E:.H,); M..`F#.'P#57"#@<0?O4Q#EBB?#9S@QK\R.^2B^_2,.0%+)BLA+)SE!.^64_V MOFXCB`1^*E&K''[M%I;3^,F[ER1E+-M!)_,SEQ@HI=^,JH5X]2..+9GMEV>6 M[%]77H[+"Z)98^ZU^WQ/+WX,%3G]O8]FA^_DM8\1&L4K#,D9GNZST.*F@J\P M:K<4XL"#"E&[$WY?+WVFZ7:3Y>&15;WUGIY2_$0U47NS0I<"M37..WO^,\>P MF_+X)Q'#[JD<=J(N(C_#"9K*!GS\LXX8MB;1#M,5P2-NYQ&TY4$$/40##D!V4I*=(>*_I"7 M(=XC70+P/NG\52T7:MV"K)Z< M9[D7TT-"?B(_-K)PMNX=C2F<6;V3P[`GZG6QA:%%12X0AET&$'(Q6$&I\@E; MGK!?DU:5,$79'">#!Y=3=77=6NPH7Q@SP!H.HN[G`TY?0A_+=7.;Q%Q.?@.Q M3W):G+3Z^V62Y;=)_F>LM<.]K]"]EJ%H MXE>TW4?;?E8AQ%?F<'M5O;CGU=+QN_43*MVV'4;YR,(3CRQ.54PECUABCB/, M:LE]$QJT5/D9JWDIP!5F;0ZK!;?61'+=/V-^ M-2UYZ%(<.\*YDRM\P&FJ/"KX-.SA9S1XLIJ6.!M!T]>:I:@M?CZ\A.X=[3S1_=-SZ'IWVR MB?,P?^NMSF?,!<8<1H(MQOE$E(L-8'-8.B/S"V&"ZESH3,'Y.%!J]":,">1+ M8K9D#O1\EIZMGHCCZIR&\1-?&2L&K1D+F!$[!F8Q7*?@6VRL&@)J#U1*SF[1 M&0-4<%@UDZH@SD5LC"!6<1-A"G@'08D\WT_/]')7@$PEZ<.GO"!HR-GSB$#: M#N(=08_`U5,"22/+KPF4$JB^>-$6^E'!:,&!WA;,KVB;^YO'?!MG>PHP]VO*"OYRS'/9E@0(<@94<,?G%'8Z]*`]QMHZ#8O.V9C>YJI"$21R= MLDX3)0S8ZACTMBU7$ZZ!'7..[)KEU7)%D^<$'+,K0S:D3)JXF3_)YQ`,ODCDSI:N:,_-G=X'T-$D:%:(4"UB)&1R4T^P4T%`+`I,9;X\I\QNZ?\0&Q;I M_C(RJP"7>L!+ZF'0,3JHB)E+IY4[B3LOS4,_/-'\P/]. M=@7A(:0YHN@&8>.E,9%3ZM2,60#OV0U@2G?O&O1P^WAMX0;VA34^O\M0R:G8 MZ1>\P'>_<^$]-?#^K<0K]L=X2;Q&9QF6`0.FO;S"AS#&@3@;O2-8+I.8O[JG MAY07;^*EORIOI0$]V.-R,X"U]^+CD"UV9F`"I?M"A-$61_>(4J]0@YZF;BPX MP#P9&0]O4T60\%2\]0/X$VDZXVQ^D=`4CX-:8NMJR.?`>?YST198ZH*I'2ZE\:@WS;9:=<5!_ALQ*I9,?>2%" M&19-0JAZY;J0FE7*AZ@`:I/KB:1(K?!D$HR:1HC+0J'!G@W M/9%&5T6LV&N2#D$.]`UX2PZU/=?DOUSA+U,W']25!!2WBQ(A2E^8`O1>;@(T.8'2WO=N4Q@"T M8IL7@P.)9![\9QR<(Q94E8=!&)WI#2W6J7O\FE\00?^J.)IO?2-W7DE.7'9 M(4\;?B3*D>_UI]1OE.*X3M*VQ)=>Y)]YYLCU([T*]MM1CS/P@ZC'.(,"JKJ+ M$YA9KJ\X6=+N*U6%J=,'`!*+KC$F&U[!VKI5+Z4,]>7-I6 MQUW(KQC/N66Z3%DQBR2^3]Z\*'];/Z68[=1Z>G+, M86%DZ1LY%1)DJ*2#SYDY"4\J\'@%'5@J34N?9::P+]'A[O!PPGYX"/V[-*$A M:K0L:WP>?)PU2`X<[J4)3QKJ-4`+%^:E)=A`!%`QT,B/!1!-"4\X%_QF4)Z+P^)$P"(O#Y=(HJ-Z<`*F\*XQOZQ*[[`5D[ZS:O M%D(V&NB5)S5HUKZ:0\`,>93T&9<>>"*?2_HY38Y@?*8O/!^C\(FI_0*_)7%P MBU]S?@3[*8GS9WF8MC8MA%$:`JNL5)/0LMD:2=4=2X(<5?2(,T"40W&AP7D` MF?9,"),*X2-'&%.$.4=X9#R`S-\BPJ57]B-7]*ZNY,>LX)U;N4];L=M8J(]: MODY;M@ZL5@'W'[/BFO,H[E,8A\?SD=^[4ER?Z?/O]N&##* M.F2VWW_KRR1YU\R(446-&'GWE`CJV?@,X,(*'$]=X,A)GB5PLV_)KY-TO%,P M9@&VA3>&V=K::]-#;/D-A5-M1^FMD.L^9';`1\?]"B#@.7V-1R]:[_E;-GWW MHD$%X5&TP51.9)#$LM_0E*<[D!@A$I2.^8:)H(JGEF[9_[*@9LU^$QX?SVG& M^#:V13C#Q+:>UW%P1;8T47*B+?I3WXQD!9+W9A+L6M*;47QL9[R9(*0DNTF- M&VH=7PB&+)E)C>6RF6XT,KPLIX!3\T"@KH"@I@!E9A#=F<$F#2$WI'5RP'6#RC4^LQP1U*`K(8P9=HH'Z%!9Y87?O@ECO,WQ4>7@ MAHA%GH MTZLBFAA#61QX+#.8$YYIT(N3GWDP+W8B-!ID9^4G&"'!"7%6["TL2P"#:NQ6 MB#'D%\"<)41^J_G!>P(\3W6,DCKDQQ)R((<\)1:4]!8&]%(B#BZ?0WS8O&*? MI:C9'0ZACU-U6AAM4HBH4#-856BH'IWE^%`3H20EI@4U&T&,'I4,D.``G$!F M3H0^0XA+A`GG`!0P"OCI[,WULF/$>TROC*@33-(T^4)^((L6\K?\33''FS*! MF=O'02WF]&D8%YO+C4%IG@;3>L*""RK9H((/Q,0]&6D%J'6`/V<"=[H&N*"W M9C0W)B8K?)9=KKJ0O7BKFMSQVL'K+[38RHGM!&HKD-9"I92^=M.[Q^EQ_R61 M>2\@02#2S4.JO,IB#R&%Y>3XCLA$F(R(2%4 M?8>".ON9RF74XRNH:(C(MH@7Y!54-G&@7)BX]!T:^SL#]:W0AJO\PB/\_&5R M#G!5/N1>FG_ERKS`3V$<+ZW/X7H3#BF36_XCLWR_[B&\IH?(:NU.PD-XS$,D MPD/4-O3H2WO3GU:+BMI7R:F'R+\DL]:&F:A< MPKVO275^Y`O.M5Q81*1%A;@T#HW^^K_G1BXEZU'?8&D0`3[>*O]2R_/C"X;Z)PS9G"[ M^6?&X5S,&$<`Z\M+4S!!=2XKNJFK_0(^2XT$Z\U`]H9^$IA1J0.C&($F\B\V MV@8$[O@]R6A2IFP0/Y.__I7\F_R+_$#/$,@__G]02P,$%`````@`F6AN03I< M]-X$-0``18H#`!4`'`!S9F5S+3(P,3(P.3,P7W!R92YX;6Q55`D``T'=HU!! MW:-0=7@+``$$)0X```0Y`0``[7W;@X!^Q9J]/\+_S3[._K=UYN_V`5QO(NNWL[\5H-Z^3;]Q:H=H3@1'/O;A M:);\Q87>GX_H3Q8BP`M_?[.)HMW?W[W[]>O7T?-CX![YP?K=A_?OC]_1@6^2 MD7]_#F%A]*]C.G;V[C^_7]\[&["UWT(/D^P%G<$_M=;.NPM_M7;V8>WQ[.CYW#Y!O'`LOX1^"ZX`RN+(/#W M:+]#\@GA=N=BQ,GO-@%8H=^M0(AFF'UX?W+\'L/_VWDJM;FWO/`B&.VOO)4? M;`G6;RP\[X^[JPS]T$83H%'.YLCQMPB]V>PM0N=X]DX\S[NN:)[:+A;#_0:` M*&R"%Q[YK@3=+S:W=H#HWH`(.K;;#;725)WQO(^0(6*IA(O58@<"(HWF[.-- MTRM^]Y'O_+GQW25:'B[^%2,-ZH0G:[H>Y!Y"-/=M`$+T%<(&I._7$,V_;(-P M[7S=.1QOMW:P1_R`:P^ND%XA$W4%>`[2Y5M![9T+L#;K*9;N`.BX3\&RR1'Q#MN]E.T_D[4W2!!OE[ M`$Z!!U8PND5N37.TV9/TZF>'FTO5_U2-7\2ERH`.[/LU\2@GGIW?/4LH! MD/8O&C@5/3H7QM#!:S3R(M_1@/[JR$A#!#X)&>>(:!$&S$P9HIAD5QU@..LZ&1;&;E4C/UXL>W08\%-X1CWP8WB6D& M]O0;&8[D5`.CW&0QDIMIR--)*[60GZ[?X\I9`'#XV?<.YXTV^#>=L\\331M\ M!>!C'W%:J4NW3PQRYFE#A\P\0P,O,DR*[R]%VC7`K8(W& M`F\)EA1O/'GGNY+T`S#"<[U_;[VUZ/C\C[:WM!)@*P]-D$9HN[Y3P-3%%U%^ M4,=@_)L_1.C-'\,H0.9$)W+M1^`F,TG"O6N$8LI+M&-O04E?/G#,O3R@I\'153MP*$3HA\+ M4J]>WZ4CWNW($?RMLX%NIC"KP-\VXEZ*A2\BP0_0N?_W-^CC[]]8<8AP\W=X M%JS5NP#Z`8+Y_
    *XO*.`V%4:$AE<9'!:1!J7I` MTS*$4/RS5KPOHIZR_*M"+$>.-_01/%\:IZ402C2DTCA10!ISA-X2 MHWCIVFN&%$I_UXK[)=Q3KL_>*\!V2LXE#!W;_2]@!Y?H-Z'`#"HCM1(%EPHJ M%!6VYB*2BJ]D3-PQ"QLP;]\J`I;*B-%+`9\6A(S>;SAZ-/#*L!*X"V MJ^5UP@*< M)'Q5AOZ'0]E/MDLNSZ(S.PCV:`OXI^W&9<>Q(>ST`N?H:U[NDK1D)S##[/H\ M!I>(<;F;+P@HVSC2%X-H(70Q":FLC[\8)NO;`.QLN+QXQBDG0"QDSE@MI,O! M/17K)]-6\BOO"=&'SEHW@"?-XA`MA%A$.1>5-$MX!7[(^%.:B*^$:&5H$%]D:FR[(O);2'U::3=195D= M,/CXM(@V($@LY,;W'*ES<0V,VK9>@SP-?!@GZ'N`:"4Y:3L<#^*%XLJCIA2F ME&[F95O!WEBS/4]Q3X)\X,P/$8^XJS5WM%;2Y5)A[,;,9%&315DS"7-H.!QX MC7*Z$T*%9R75-U.*I3CA3%L)74/[$;H0!]601U@M*JWQD^3!=;PRDJ?.V%TX MQP*Y&R41P)0ZT%31.7K`O77Z9)C@TU+F\-;>XT(RQ#/TFR!&Q%28P5O?F\R@ MB&K(A,N:D&5J(%M:"?26M4"DIL5'SV/PX"]6*^B@)7$1Y!?(6L=<$E81N3=> M_B7)RQ)*#+N+%'848B<=U/<@TD\+A$09>^G5^$2@ZAF@B^@E//]CXR2?2SH5 M)AA5ADU[TFMJTD7=%**4)-/)U!QP`GW#PZP9$:KOZ/;HC#.&*%N4^..(>NU76G.3ZDCE=Y4H29&JVOU(_. MXVB#4/KKL##P]:`*H;G\JP31$Y]I=W@5HJ_",):7.1UMA+PI,?3D95K%4(-* M>3D0(Z3.*I0_.?XR?,GOZ-X:[P&?DJ?V0;+:_C"=Y:^LPX36;S\\.UY"-&82 M?RWI9IIA5^.B<4=/$QI)T2"=>>N$/5T(N%84J^NX\W$T-R]PA22`N MXIXFN1O"E'Z.A&M@)EU3:W0U+^P:,DR5^#UPT9SK;\!#YRD7IPXOM]`CG;TC M^`3$HI<%UD4'9.DQ-K>NS"S)15T?"5.ODR(R?X>$(DSE2_4-&]\SR_2FRIPC?^I"6(H'(_.3XR+8I.RG.K+.`9,V_T ME&*6UMY*63*+$F,+&W'3JI"D\R>D7N$L/O0;;B29-UP[6?-),3:7_2?Z.EBL M5HL5[;"`'T[$5X*TS0)'[#*`VBF`#%$]-"10,T&5R[&FF[J&@A?08FCRZL%= MQ4U$DZ*M&%%_N-`\!2L_`+E'$K]#C^!,ET5T?BG.DF1Y?@?1QE\>UE*>PS\J M!NJ[EZ.RH[_(@8)*C7B36F_ZI*10`1FC=5$6!NI4L,8%"&]`5!M"*(U17XPE MA)6+`7'>R,38SJ,H@(]QA"^4'OQ<>E&:\8^?0DW>7$[_AK..1`]H]C"IN@+O MBT)CKU8;F_8(3HF M:3W8J)H'Q&*V!R4X+"7#76UWHH;13:8P0TG:T=Y#+UHUM:BPS,V?;.CR.(P? M6'=D]@*96@&T?BT8>K([0) M/3.Q-[;[Q;<`+UB!SX_&%4:H>Y)GHINY_)^/.O>X4RJ@BJ^\%JMOOK\,[WV7 MMYM61JDOO@K*](9W9MRKE_>V"\([\`2\&/"?":B,4E^&%92S]WYGWOY'.%EK\%-C'=^Y#9@;RY7RBGG_;:=S"RGN"T7J*_,7>USJM)%YQ0H ME^7W-,K*9H];EZD16=/*=C7TMIF!>Y-&X\Q"VT5 M+1BDR"9TH15KYWO8.&2*;=DP2@BMOKZ,C;RPK&7J"%,18V'9+6>L$K(1J5HA M6,2F06E[:E!YJU[)K5#!^#<(I>@/)Y>G5V=DLL8M0HDRQFDA3@;>TD:FFRPY M[86%$LP M)`X&SZ0E8-25M20!U(2-JW+FT)[N:LTD7@#24N0%"JC,U2]1D-F++FT8)!J] M2FKW\4,.AZ#*);"C.$!_+(5=6.^1CO1-=35H)`;0O883X5(I/BG#C&+9ZH-? M)#?=9\^0!:[!DCO)%7YT!)"#U!V(;"2=):TU:JNEP^-E@"8/SR2J[1]G/>6X M,NM2>M'V@P67C_.X=6[NX0#7 M3@]8L%HJ`HN0K&3K6)V&R;Q+$B]"M(3028\0\_4Z(,Y,>DQ=Y=:[A/B%QU\W MF9N]>'8`SN>H.9+)QLVE9E97UWHE,].Q MKUT*A=6LT>]P?Z#)Y2`3[_ZZ9_2:8S&\6WH#?I&_\/.9I&`UD7L](501/KWO MX=T.Q780H4O64A$JP-IJ0H623!4^'9O72^`EM=(]^?KUP]%7=@Q38Q'*^#-$ MJ1_M$"?K;G%_(2*T.Y`E&5[87??G\Z4BA MHVUOJB"39=IT+N.4H1Q!_S36QC9Z`QK<<"DCZ=N->K:F7NM4)AB;>I13XJ1M?'9E\5KC%OY[N/MU@[V:.T7L:*Z`'XH M+X#I1*33UF$JZS"7E4TVQ>&E0E)-?RT1P"3!E#9K35/@*3V8>@D5@BI-#7?X MK-W13?';DB`N=M3J8W]#8C2;OEDNZ[:VQ=64-TAY]1T"@O- M8>%)+#2+E4RCP`-@(DOD#E7AY3*1#0K&3F9S-7RGUB=`W5QKP[=Z,$D10#:7 M/.:^!AX[?/NULK4=H(G!%>$GZL3,(4?:IVPXQU0-IVM1K/-`FTXR:=^_-G(M MM[!N0JS);NQ\'0!RK?431IL?'B1U"JS[ZI.RO6>0UB\$:IT%Y&4:W[-RL_12 M%L[&4/0J>RU(/_7J[*_P3$T29K+GBB3Y?*CXKB7%9+M)TC8?[&?&WCA[7[:5 M9+25#)]@C\BPK=WX7/+`HV#T-"]J5A"JV]#$(%.YGQ)RR&]48B)$CJC>KWF= M@0"7,)'X+(Z0;.`.[]1IO/;6#M`R(XJ[S"K)5>F,5F%*XJ:FDUIDULGC,CP2 M!=9:#S*%R?*PDHO>-(*>RIAE947/E(V(,O>4>;'=N?X>@*29481OIC=^@B9#,F4^0U. MENVGF\JN6\BWD*+0FF!S;#[-4#B\R7EFAYM+U_]5L?39QU9/<>+Y+#*A]=L/ MSXZ7$(V9^@G.C$CYES<9(!,5UV%,;@,?5Y,O3_<_$/^OO`5]%WZ.=JHG&-4G M/;:92(FJ!X'T2@5[C>D[5.BJ4@3S(BLRV^MX?<6F0GU@!BC5Q*5^G@-=4"#^ MP>]GR1CF4_IKVC!\$;Y9J['"_D1?!XO5:K$Z3ZG`62FT8@VG>''43P9PTJSV M`2VQ\+"\!!],59Y#\A\KEY;UQ@1C\$M0$A[M(T;ZNSZ"QDR;OGC&/X(T0O/@ M$SHOGIV-[:V9]=ZMIC%90]ISY>`>*Z,[?>6`(O0=2.,(\ZT?1&G-(2MS733: M9,VI)3[KNVG:`0HQ,`#(6LY!\O\,=Q:>@IM:6Y6=1H"9O$'GP6-3LB5CF0%KB&M_8>/ZJ9=+\. M8H0RM!^A2RQ/6F/D)C-)@>0H[N_52\66'/G5NW-0V(1MJ@FU_9V;(A^IM>(: M<^4]X4NB[M<)PHD,N$X0TF=J$":KN_1)L_4`?+<1IST0,-L3E&^9)8$57%XD MK*)PO2Q):0\>L)KN#>*?`\`RO$3,O;==1'\48X1(*K?K@B2I9K%*^$IXQ3AN MMYI%7^UI33)5(X5N+SF1O=0P[H`#X!-88BJOO!#B^CE$^0HR,\4E@/05NBR% M5,;&!5CDV=?9_]!93]I0^[(\U[0+7'?/53B1`9ZKD#X%@W*36H`IZ]^-"`R MU0SS'K!@TUYYBS#Y!7[4E*4M9=^]R43ZJD\7JK.-YN3(N,R\/$]PZ7(`'W%? MBS2P+;'0L(#T51-9"JE*?/UB\AJ#6\30:PH)52@.-TL)BK29FH.=M=X/%RL) MX?.'ZR]\/FVI\#N$-_J.A/)"6/D(W:'_T[5O5YY>E1BOKT@EB*,R_:K2:8(C M5O;[&%RI"H=K+E0A;:E,OWX\/FKOM6EP:8$)7Q"ZPHMG$#@P/%35"79K#IR^ M&M&`2`5#1V,''#L'&DU0E2;4&AJBQO3C*SOT/WS=^V2[V.=)'F4KYRYQ=*;9 M%#J%I9M1]J(T9(XL)PCVR$A$CR5*PNJO$Q62:'C:R!>5!U<)91[![%,I,4WH?[W8N89KM4J9=N+4OM\F!Z:`,\M0,4-PE0/Z\9"QX2T9KK%`Z0VC"Z-)V<)G;GB7\9O#&*$$SLNEME3+*T,]6\,V&WL+#M02BMLR3-.U0P2+_"3$;8=6@-4$!1C\]D"3L4))GUJJ`MTB\WRX\ MY'_M_*1L8+%B[A/89&K&F^Q52)"?55M\^MPA0VJDQ#>JW_L#XUAG#>8PD^7, MIYJ*]_C3*#GNXW<,K[Y_>4O$L0$1=`YQB*R/^/&L31_QW%?^/;22[UB_G8,5 M=&#T-^NWPC>G[B]>98E\HW$1[#1ONZ:H/0C2E.J6$A`I6S.!EH2Y.VNWUB;+QGUQ-KWB$ M$F6,TT*<#+REC4PW6CZTB+LY@G3IS+8>NT(%E#51")#S-*FRH#.25=EOO`8XU MSQMXKT*(29^+YVI8P7Y$Z"OHR/)2>`@9&15GOD>>Y?8]_NY7"Z*N\.3P[Z^P M0]7-[1IZX`K]6+NKY08JL7;6;V.U!V>MU1&+WJ/X-W:P2(@K%R2HC]J)?4Q/3ZD MNEK1B(Q,_*8EKN9S](EE),90+_+B:*W$7$0]$^V),J+EY8:4>T8F='AH2WNR MR9.5`(>VF/DBLJ#J"K(9'32F8%R?L_PFE=/FY-=HX9HQ\L,D8-25NR0!A[:& MJC?!RA.3CTO3LBF6_=;#J"M`20*R*.`8S6]'RN**MUL[V".=A6L/KJ!C>U'Z MA!9:I&Y]%SHX8)/^OYS(]?']!^NM=:C`P5E=R80D7^LPI768TZ*36;_1GR;) MU:I26??VN0!@HF4VS91#FD!0VC\@^9^Z_/).,]+`\2!^9EC$7%>)J+$5.TRLY\Y6#U4?FD@2)RG,U5H4L M5UQ.^OSA^@B<3T.6U6"6C&\#?X?\__VMBQVKW*-O,XP^<^7."8`0UQAZ(>RNW\ME#ZRKR6% M2MXT[^\."08Q%3L]N?2^B^<=+GY*N,"U?0E(?31`BARJ!:8Y?B0T>&J'.`%F MBRDF)*H5I3NI$S;<^.HK]U>`6 MJ=5,^JA**_(.S[*KHC6`CL)4"TDV9W*0O#.^``^(0K`83G#4E8]96B(4'TIFKP54"E[)!S$-G0#;%) MQ-5F/Y^[Y8BDDUOI["\M5817.B8EF)1G'&2[3*2^X7:ASM!F\-GE:[5C)WO( M%%+NKM[,^^9\1\[.*+MYPOMWB%BW!+TB>0WICRK@Q95XZ6.C7,2ITES^7PYTI"A4I/QZ?UQ^;Q-@2W;6UH9N/5;,L$D1VIN M$F#-R5H"3JDTS]8)GHJ$3J7E))7A.461QG3VF8:NJ@$Q:0--9WBUT![\*`>= M"6.7]-/@::>HN[4TN';6*D]:MJFJUP.-B_KI_@%]6]!%4`IRTM+5AIHKM1+G MB9-V()0"E))6ZUJK-S>FJ-+88E^MQ%/T"&ML%,*FQ4*(9248%4Y M\Q(4TJ-<[2KG`NHR#CP8(>_E$C[C_X6(F&O\_A%N,7:UW07^4_)P![^78>,I M-))U.P*5>WNV)]?+7T6_$(?%+4E+@S02-H\$0X/0=[:W%CE4N;_KZC;E2)"\ M/YI,$$*C*HR84A@5G:EPN^$&.(WK\@RW\9;)<=P"J/3WR?E=1)0V*BIA*3K3 M:;SG?(>>6%;%OZLJJR*6AN:E<-?GZYI6R3*`NFY!,K1).AA*R?0&T`-NRS`B M8P(E?<6*\DI)ET'=2[/Z'R%8Q>XU7/%BL5*02NH$5_FE="-/GG)Q@N&7C18+ MA9%JD$]E[-PZ-/(CVU5E2<-@'@T%4DQ6S^RPZ6 M%]N=Z^\!2-KLQX&S02.PVN,V$XG!AF&\)=H=$F'6Y?8,^L4IEI0^1"_*/QB` M38;ZR2R>Y:5!>)7TR0GG3@2?$*&M=;;IQ&:K9E-NC%:`,N7^R$UU:[!!3IGL M]KI#I9R%]:`@S<$S+*'[WU2"&X&K6R?CHPZLI M\)EW!\,_+P,`KKP((/6+1G:GA)]_-8P!F9NUSQO^7373S&,\5TKX^5?S&)"Y M64OS(^6?CNR5*>GZ0/?4!Q"4%7VD;[X@[1Z)HUG7S*/C%Z;3B5&/J].L;[[J M=-\CT9_7?^!W"Q"_]8`5(R1OC$#O:5U\5NW^>'E3[Z\>7N6"/K=OLK[[J M=O\\/>CVR8^B86%>WW_YWIVA&VMK]>8D)\CM!$#+0]?49+1N?] M:0>0>BXOO*4IVGKQ#`('ACCO;E!M97SGA6LK@R.T(,"TUQ=[9-5/`-<;M,'- M$57V&J1_`;%EN-3EM5KHIH_UC/PL9Z!5UX40"^$#CF&S42: M/=`'35#F@5A#]=>T=Q&Z+@#_1.=H9//>,HOL^OA78[D8\I\W0;='8135=&:I M]*NF"S@X7Z\#4H];7#TF4WTN/J^VT)9SF7%P,@M>L'WD3N(3..R27__CPXO7 M_@:^,B,993=,R+7_< M_/+E1*'#YD!ZSO?$>)Q:>(/4N694E\RD0.!]+MQH>/D56^7_Q> MLB7TR\GLT'E\-!N^VZ@"S2SP8QLQ)BW]Q*&EQ8?F+2W2R5X;6ZCT3E/3!(7" MJ[H-7[AI,+_^C3,&8`J-(]2=LZ;0K;OR,_0EWQ) M1),T*..+IOAW%453Q+"OBJOI1=/:Q[\NOP/?UP5';F)C-ZL^F"/Y`%\_9W[V MZ[')F4+8MTT.4,OVCQ4+.!R9H&?W,=YK=EL&;%I8F2CE6GVVEXB`L&D MN]UYBBR'3S]AM+GREOB)&\3R"L_0.O^`@S"+U6&0X-0UU,>,W16'8ACMW:;@ M>;"",2:2Q#NP86[@[L&_\"*$X;F/0Z,<36L\RY0J-*P-YO6I,5L&"1QP7*HS MA$+L1GCE99Z+>(.F%%U+;NT&H+C/-$`#@'Z3B]O[4HT.>?/E M$B;8MC[N":;0_ZJA'=UTV6-?)VB\\"'ZM^DU\YF]@U&ZA8=W2+S!$UA>^L%E MC(NL<)&Y[7&7KQ;S*+8(U1I.?CEJ0:YR.R=G64D62$0`VOTI1\CBN5B1]92U MCM3#Z"AL2=*&"2[W+]@T)IZD6J<'0EQ%^7,#G0WY%R$H/+.]4T!(K'3:Z#"/ MM@K0CMQ4*3YKHA0D:V>5HZ9>_GP0W47-IRR5*K.IO$I2[3O"B/YUCORL[#&C M(?+XZK^IK5X-SYKL`1EE-%/%NXG2J:]6KR?#0D=-GXQ95/?5\:S[T?VY2R8' M2S9'<9*N%_)45A989TV3I9$JB/(>NAQ!=P#A$2+6A!>K%7#00>1L@VWKRKL( M([C%\+G>**RM>ICOZ*A*`[*#:ITZ1P`UMF1.E<%8A=CRG]=1G\?G$E5S=CHZ/]&V=%7PD%F5!VU?MEF-?%BY-?X7'\=[<&AN)5WV7YU5VX668 MXK_09M,]>!3M.TU_Z'SPRM^=3ZY"4J;X8#^?`@^L8'2)Q"!_;N]K M4/4;_@0V3O7Q.7B,ZFJ-/Y5+C3&0(F7%&/T,-4Y:2MW@*0P>20ZGG2!M05]@K&3YO(*>)_W@`%!"ADK&S&M&NV<8?0O\>,=/:ZZ.48W7+`7*XKM5]'7)Q?H> MW._PM953IYS3,YR67'D10"*,[NP(Y*.5#;2$/X4)6L*G M3CGO2VH?O\(7%TGSP?K-O#!8%VG6T:'/*90`.AG]>!@#D'9X&JL$&-T$UV)29 MFLTG,@Z&TR@/9H(J%"DR->5MOO6#"/Y%!+1874+/]AS2NCR,>.%7,8ANHA=3 M8VK"%XM9B!.QET]F;G)%7(7531$DR>HM>VOH4,!/.R`U8VF9[H-_&P?.Q@[! M?+T.R#/6N78-K/!`PPETD7<;VJ@#H$XLF7=O33>RQ8J2R+RZ9@W32H!,"JB8 MF#WR#%NMLU=&N@3]19/HH@YMZ:,+.=.IU_CM3WIT86?4XK91E1&ZB)J)_'CY MK-,;_97G!`#O4EGB<*;839(EQ-/HH@WM*:0J4]=+M;OICY,"G3;;>D#;8(B8 MA$^O=1G1G\L9T>D<5GX2-3*D+_X5,][WRJUGY0']-8NA7N%MX*\#>\M*;ZX; M/%5O0#;7BLU7V!C3GMD=EU-WT#8^)=2O.2EC,@#3/FXG4C&AM'(4]'4[W5UD M/;TOE/2OO+4#M`'DUJ/3??XOHJ>B&DR@MOC;4*1PI_`\LL+$=M;`2=^2:JR2 M/.D-FL[>CY1.?=SS8'4.`^"@3X1G&W3:WMH>,R]4%D@5Z5730F4ID)38>`=& MS@99IH.?SLL;J:ZLA&C3#M7*G`2Y/:H1A3AYYRB''<2190$[$W(:FO,$Q/ M?5U$#Z14J2&/O*`?$ZK8CI`4H":";4*2H54$'.K)M3K/Q!O":J(,#:GJJ\I@ M6$._12S'^;2!873P#)X[@$UBL5DC!`[[3+`VJ>*!`F@[U.L5+QG9H MC&KA`?DP#P-(<4%*4$`=L<&?HAKG3O?4#J&#U/8B]; MO=?]4K[7)?-8Z+QHI3-9:"H+SV6AR2PR6W;/.\W]KAW@%)V,-M%-+W?H)/MG M]HSLW(O@$K,7K2SW:(5!&@-!>/'LN#&2.6W%%D=IEG&9#%';K+X_,ME]=(V4 M"]MPSS0K?-72D<#3/7L"P=WHH%]4XU7G/LVQ4"LP).NT4](;>PN$=[CU8%.J MRPB65Z\[>68HK`#Y3K;"2V#60/6$7-7*M#1&-VF6 MT)=LJJ6;(#LN9I4;BGY]ANMID^VT<1"NY5+Z>H\I"(^:$C=R#2=0^0C2AA[E MF@/UM#D4'YE+[KY2EB21\5QAY'SYWW$8X8MLWC;2=K;)0LBMS**P];0E6;D[ M1=[+;,SE[M(/RI9V9KM.[":2$ZPCW>93SS-IO_\>7F'KQ)+18J):>3M)53D>[5`^4CFFO]U"XLJ%^-[91WSRUL!S$'?JRC*_5LHR#W.1]:(P MFQKUF2)R91^V:3C'M"O+8H?\>8S@-2XQ7L[#$$2AW!V>"'1*_[65#-G+@HC$ M03+]^Q$OSCY`U#[XF'A,)3[<'5Z&%5RH24&J$?>JU]R\3*4(4_C6H@9_8=1; M$G9*L3;0V`92;7CCT5?7:API\;T[?V^[T7Z^#@!?1'(@"DNF2%6^C;68).7" M0OV8*7-1JKN1J`/2<;VMHVG4!V'X#H%,B4X#Z"DE):=Z!PMM0-:+,-;P#O$B M[<1T`WC.?0W,=#GBC76<;ZT5JOHJVQHX1YSDMR]6Z9;#S`4O#]%,7FPB#"WI M2.D3OZ9<'J290'ED*/?V`]_F',SE-(:H+\)^4@?S:AA6>TLBFMPYQ=0_V\#(X\*8>O"9,TZD#Z22UA?T7B["D+ M.=TMO1S/#RD@D@0I=^)LXO^T]'N4\7>:Z:O8U^'Y.*H+]COT\".;27,,S(L? M^!G>6,"J?"_'"DO?AMY2E%:KBTO M<0DH[80L05/V:MC1%]4%>P?@]C$.0H)Y84]"TD"XAS,L\\ MK:?2305:$TKUXN3H6`/%$-`BO0*TF44_=6A.XT$3/G\=7A7&.1Q?>>A'\&`_ MUR:[S=Z7S\$)K$6`U%`P=UF_BLDK&>S&\5/D!RU]-/6.0;"CXTQ&.!8,>O M!U'EZ3!1?KI@_%1N@JPLZAX"JW_32,%GW@3)YOSA4^;1U2I<[4.[JN>2LY"^ MQ@LO^^4`K,+U(*J)K)PR+D<%W]/JYU8AN-_A\GD/[U*7@1]&WP(_WO%3PVL` MIEK19#7H<'D@IL/0`Q"3337)X#4PJIE9HY7Q>J+\[V9>HDQ.>,<959-B12D/ M:>(=*7U!EOW=?L9W9%W>L.9/,5U252_&4[HQ64R-%B[6%TSHMA-`$T1M22Y5.S*W!J_UI0-O[;+U9D= MJY\]]!W:6R@XMN?_K,\A/8^UOO MD3Z4[Y'H)%8ZBT6F4>.F"#>V0M)+M!5K300#DM,CE2;2"+H7@V<)1")D(P4V MU5+=0@:9N4H19F@8YAQ1[`%2ZA7`QQC3A.E/HPF)]UGX(P@HNU(WE7?:[F'B MR?:#!A92.'CW0+/@;M(\-4NI#[[;:,?`0:LBDG(RH$[VXO"_X>8`U<0+!/SH7TCZ\($4E/HH@CMJ*,=$!0J..AU,F>6H9X[9"!UT5#6I!&R[`Y=0<:YK+A/LHA+IC,BH>_")24_C_MB=0D]VW.@[=ZCWX"D MT)]_-.EIWFG[LY[&(3*),)P[2&8A3.T@]R^Y7JVRTTQU`.I5!]B]7&590(]* M3)]C\K?+4IHO$-;1'A\;?8^P@)]E5P.C1G/!9FI>?.%,2)[":7@EA(7/#W+& M3BH\&5W,2XI#@\(2NJ6N`WE&3]QCESET2OD(U:O01)>)>E_Q_Y[NV?LT.5H5 M<16&,5@N`OQ_O+R<[A\0`H*E5!Y<]U55GM)!$OG&D#8F06+-E0&?WLSE55I> MRGD*%5ZD<=`7ZGE^@YW&1>LQ[F_Z[[@YD@1 MM7-502!"*RN,F%(H%=VI<'O0UP'ZX7=Z]R+D>&G,Y#ROO@C`P=30.\FT59)8 M9L4Q*LNLB*ER64']R(RQ;@NV'>YHW3X;NS:@>"]F]((U?C,5)]<1501>T.W,09CKFM*%\4@!BZ..>J$ M=2E#/'(ON"J4?.6^R0R*F6A%$PO/W3WLIV8Q:,6"+,'I_?%,G9?->3N[O8,1OGCUG3^3MW7C:(.^\5=% M4^J':RC[>J(R:7Y52)B]1UD3#>;*7@I"0_%+T563EJ1M)#9']*T=+`)R^;O\ MI^W&@+Z!7:\&?$@SU(%/7^8='IT8IAC%R^.&NB$+K+%ZR))(-61V]&4V0O_< M*95$PL,4`1BC#$Q/P8#P]1S9SZR! MME0@#5.2"GVT2GLDW1BG?N(V\'<@B/:X'AWQBSQ94%F?X'UE^: MS%26=2]I[WJ7C"S9&:;O4JX,4U"BJ&6L=L9R:4P]SJGCT)UQ1]9K*B*NQNCB M'/\;O1G]TYAXVYU@ZXTROIM\GZDU&(1M7!()/*&>;NS5^2@HD>:&NL2`[G+Y M\6RCU/;]WFNXL('S_N!(.RY#CFZC"ZR'C M4A%NTHC>8?SW"G(L7D'_8O9[]&%O1N_>O1OJTC-#$;&FZC-QJ=P2D\;DDMA4 M*J;,S;GIN=#`Z-7%N]<7$6\)I?6TU*&(Q;4GW"FUB>^HCV=_^,1A-J/6F4&4 M$FSE*YHA\'F*)&B-`PZ^6RRZI<10[;9T"$0#H**"F7&]^DK9"DA@J;A.>GS? M#H/",\#;,#X0SCU%%$PA_1O?;+>,VU[X$U[@`+\7GD/OH"4#'[XL9V6#AL7# MA?"V5*C=F%M7?_ALBX,WI8HP1][11P7##TR!L:42=/QI"\H_(AX&H1;1LS5^"[D:X2,O_\PS+/+M^3#$IGS'_7S5E`) M;/1`W<"+L'9(4E73)([I.P=43'I67B]\&X'S%,Q`(S`YMQ`U-P-SS;2_#6J<0L]JG6H7KE;Q]M1>DDY-*P6#N&R",H&=-7X MC5[E\8M8&B%/0S/M(:N#;`+:BS"^I$%?Y89M)2PK_9M:"P*Z[4[`2!)3%Q>A M^306-4#O+=2P-2/3G%ZH88.&;M%(-]E/@[II,`,#T:5WY)$60EQ>7`/?11Z^ M@).A6?6PU,$R7@NJC<&O3&TF@J*9[?$OG&E#O'B?;%FG9J-\EPZS*%HXB:_+W(:#4U;B%;`_@: MR-@`SH9F;7P7,.^Q:X5=./.;@!>1UJR]`]$+N??PY54HV3)%G%KCM):L!K8? M]E1FP+$W,%O!-:6K0J=,P?L:0-[F`4$6/0!U`-PJS_Q=.V)AS]]2F+K8=!$D MC2AK0'JS=T#77$-/<)IOC]R3D!LUP&Q4B];>*;L>K5&/4QN<&L!4BU)KD'J( M&D&4MM,K*6KL\Q8`]39YVU!.;0RG-GC3,G;3@],`G/32J2BO63B-H>F73;%: M\UV7B-W-T^#-WKJ<=VS3(C2;G4),*'9L/$&;BT,@1.Z&9F]\]X43WV)`TT.5 MR#UZ/RO,;RC,:JC%[U32'H<>C%(^6F0<'I2O4H?@L"0H]QJ48IU(/ M]G(1ZK"IS#[HQ[QTS#,I!$E,FL>4ZJ`X**O>(E2^K_7!Q:1RY#IM&D>,>BU(L,*Z;!(GK M1KLP+-R/;NGH%@NUR'2T*_>XU&^2AJY3MNX M6>LP>X)[M<>QTA*K^'BHT1=&=<@=\DU1#UD%9`Y^QGF[H53)`@=X17FULW34 MT-\=-F`$+?0>[1:F155HHDGXHBYB<9"[NSIBT>/9",\YV`\D=2XJ*:O&[]5! M^"7L^W!%>PU:H#3K]&1#E+)ZLL>C"(]I>,$"6N]@M*G=C-N><%-GKDJ*2J"T MESNZP"'UJ&U\S^`W$/7]TG8@$^5=<':$767Z$PH8C%D28>USV+I0`)OIJE#GB%+?(/\CB0L3M*VXN3E])*$G M22M'$AV66%O1LZOR2))/XT8*!?\P3-\6`K^RMXE\`+D]H0R^=RU+U24QP24T M-YZI&554P5^#J-X`7PU&KT"WGS]**^ICFRXD8]"N"U&]UEW0O"0US]?>/>#) M])4S@XL1,"CM0V$=?!@DE0\8@.+K9YJ,0[KFYZ`B#L0['(C1#\VZ8A.YTLQ\ M.5@3LFT\$(45A]11,GKS7,-RV)`<.!X9D.FCN6D],^)*^JGU(&1X:;>6V+7N M0[I>]..PGN3O+FJZ0*,*",#;3'OAE4[:T$-5_%N5M3=>226(">UB_ZHMPX26 MA$\?SY3P0:D$>X&^+.L]E#"^GH$AC]82R..OT$SUDE:)N`M4%,)5HM-A<`X`@_O#OM$W145D6RU9($8 MP556[RW/)8R_J!P8.1V'-VXAKSL/@^$>3_LLT$D8Q&S#,@RRYE%\!D8=@WB* MZ1O6E-TS.!5:\6S-O4UW$D2BBHC=4;H9E*V"PR@4T!53Y9V?2>DCX=Q.#;4< MRR7=DAV29MQ2GSU%?R$.=B&0\N#JIQH.$U;7\XY'0''X@$3U,[-8OWO169QT M/-9"NJ,E,3O$53YXA@GMW8_,-GD@4\`@G;U.BH$EX$ MJF%)3"6Z5,IFAJX9J*WN)GSAS:ET1P4&/RS8@'+\O'04JF6CY8\J86VDK/QP: M.>,J[6&)!OGI?+JJ))\J6?90^%S<3GVZ1],13@IFJ+G&:S!0UB3R/L3>"NQR ML%/,>;GH\8GYF;EV=4HM!#-I]"G*C!?;#A*=.8G9U+Q&:`F"&;B-*KRL%9CJ M:AG2-40G%N&SC\X+&-NG3.8G,CGY`K^'WY[8);MGLDH+BCJZO16[3V<.V#58^GLFOVB/_H M`",EDN(^/'.WPKL/TFNSOO/6U4[M/"^\>:P8V$:D'8-1+ZP]1[!><_.M3H@> MFPI4Y;Z;\9":WX3P8W3NK#7IY2XA">,$XP^_[UK/LU[4&:9N$N>."C^GMB).$FO9>GURW M581A"Q!I2MTQ-%(7@94(5D71,6%:WDI7MK:>R*5C@Y)80"!$F8%70]0UFTD? MI`.-<>W![F4SD]YB#GJ<*%Q.<'*]4G3-9#@_LGQIGK MNYA49V)^6>KLRV"ZO,18%K=TXK$L=.8EB4&M?(`5U3JVD\?V$]Y9$?99.VGGML8O M>W2KHCNY9@FG539,#SW^NF'F)HBY84_EA/!+JON>A.<.JWOB6&O8:53L89># M3A;+5DYV/@ M]\/4*AZ!^+,.=+Z`8I57M@WVS=R>Z`\[9OP*NNUB_61_23)'C\*[HP.9C2GD M%E9A6==.,(O`#B!K3!V$3A!GB68!-P4>_>>V]@"D=J@FQ*>U,CXQXK*<6R;] MJFL(+*GE:Q?8C-_"<1>LDY\IIP+6!K?&E@M&,?97L7LZ\:3V4X=K*/4=Q>$< M3K6P:M,]4U,-?87,9%O4MO^"2<=L1JU@_N7SUEM7.^UN(,+B^?+!A?-3=QB)1)7&_\R%*25-$\ M3UC68M"`#(W%XXHVU1.G3KB(JFMS\.[!N]MXOB3*3GZ"C))7YRF%K37M)=QZW/M-'%:B13QY7F\04:4S_+=A@\:QJ,0&[ M-?%"]W*@Y['H"[>HR"N%Y,C0C/K(V,5I/NW.I;$KL9W0K:N=?E&"E8)W<>B< M@FK9&E!VU,NPI,Q=^4+JUYF55AC>W3\>'EC]M.NULG>54!]2LZ/08RKDW,ZZ MDDK")(U(.V;"11CAK/U>XY<#&CVRCU'_[]T2Q86X)DTGL M14.QY_S90EP'-OZMC_DO8/:BK]B*,WL\?'52*)ZW3Z=&*._;GFQ@,W0)A\Y5 M.\$+"$^I93\,@PN9X?&_4$L!`AX#%`````@`F6AN05GA\IZ[=P``L2@%`!$` M&````````0```*2!`````'-F97,M,C`Q,C`Y,S`N>&UL550%``-!W:-0=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`F6AN01B+'V"[#0``J:D``!4`&``` M`````0```*2!!G@``'-F97,M,C`Q,C`Y,S!?8V%L+GAM;%54!0`#0=VC4'5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`)EH;D%]GA"#$!H``"O^`0`5`!@` M``````$```"D@1"&``!S9F5S+3(P,3(P.3,P7V1E9BYX;6Q55`4``T'=HU!U M>`L``00E#@``!#D!``!02P$"'@,4````"`"9:&Y![$9N5&UL550%``-!W:-0 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`F6AN03I<]-X$-0``18H#`!4` M&````````0```*2!C/D``'-F97,M,C`Q,C`Y,S!?<')E+GAM;%54!0`#0=VC M4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`)EH;D%++VBR:0\``.VD```1 M`!@```````$```"D@=\N`0!S9F5S+3(P,3(P.3,P+GAS9%54!0`#0=VC4'5X C"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``"3/@$````` ` end XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Summary of Significant Accounting Policies
    9 Months Ended
    Sep. 30, 2012
    Summary of Significant Accounting Policies [Abstract]  
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Isis Tele-Communications, Inc., which has no current operations, and SafeStitch LLC. All inter-company accounts and transactions have been eliminated in consolidation.

    Use of estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions, such as useful lives of property and equipment, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

    Cash and cash equivalents. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company holds cash and cash equivalent balances in banks and other financial institutions, and includes overnight repurchase agreements collateralizing its depository bank accounts (sweep accounts) in its cash balances. Balances in excess of Federal Deposit Insurance Corporation (“FDIC”) limitations may not be insured.

    Allowances for Doubtful Accounts. The Company provides an allowance for receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance for doubtful accounts at the end of each period are determined using a combination of customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure.

    Inventories. Inventories are stated at lower of cost or market using the weighted average cost method and are evaluated for impairment when conditions exist that suggests impairment may be necessary. The $1.7 million inventory balance at September 30, 2012 consists of $1.0 million in components, $664,000 in finished units of the AMID HFD and $19,000 in standard mesh. Scrap materials and quality testing costs are included in Cost of Goods Sold (“COGS”), as incurred. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, obsolescence and future sales forecasts.

    Property and equipment. Property and equipment are carried at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs that do not extend the lives of assets are expensed. Gain or loss, if any, on the disposition of fixed assets is recognized currently in operations. Depreciation is calculated primarily on a straight-line basis over estimated useful lives of the assets.

    Revenue Recognition. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured.

    Advertising Costs. The Company expenses all costs of advertising as incurred. Advertising and promotional costs are included in selling, general and administrative costs and expenses for all periods presented, and totaled $22,000 and $106,000, respectively, for the three and nine months ended September 30, 2012. Advertising and promotional costs and expenses totaled $2,000 and $11,000, respectively, for the three and nine months ended September 30, 2011.

    Research and development. Research and development costs principally represent salaries of the Company’s medical and biomechanical engineering professionals, material and shop costs associated with manufacturing product prototypes and payments to third parties for clinical trials and additional product development and testing. All research and development costs are charged to expense as incurred.

    Patent costs. Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred.

    Stock-based compensation. The Company accounts for all share-based payments to employees and directors, based on their grant date fair values. Compensation for share-based payments to non-employees is based on the fair value at the measurement date, which is generally the performance completion date. The fair value is initially measured at the grant date and subsequently measured at each reporting period until the final measurement date. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Stock-based compensation is included in general and administrative costs and expenses for all periods presented.

    Therapeutic discovery project tax credit. The Company records the therapeutic discovery project tax credit on an accrual basis when the credit is considered realized, which is generally when approved by the government agency. Such credit is reported as other income in the accompanying financial statements.

    Fair value of financial instruments. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. Related party receivables and stockholder loans are carried at cost.

    Long-lived assets. The Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less costs to sell.

    Income taxes. The Company follows the liability method of accounting for income taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of the assets and liabilities. The Company’s policy is to record a valuation allowance against deferred tax assets, when the deferred tax asset is not recoverable. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance.

    Comprehensive income (loss). Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive net loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive income (loss) has been included in the condensed consolidated financial statements.

    EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]F83(Y-3AA8E\Q9#1C7S1A,F1?.3%E,E]D93'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D)A#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-U;6UA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E!R;W!E#I7 M;W)K#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D)A#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]# M;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I%>&-E;%=O&5S/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K5]A;F1?17%U:7!M96YT7U1A8FQE#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)A#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O M=6YT,CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R M;W!E#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E!R;W!E#I7;W)K#I7;W)K#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E8G1?1&5T86EL#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D%G#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE'1U86P\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP M/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!#96YT3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#@W-C,W.#QS<&%N M/CPO'0^,3`M M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!D97!O'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$F5D+"`T M."PW.37!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&-E<'0@4&5R(%-H M87)E(&1A=&$L('5N;&5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F83(Y-3AA M8E\Q9#1C7S1A,F1?.3%E,E]D93'0O:'1M;#L@8VAA2`S,2P@,C`P M.#QB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&]F(&1E M9F5R'!E M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S<\&-H86YG93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C<\2!!9&IU'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA3QB M3IT:6UEF4] M,T0R/CQB/CQU/CPO=3X\+V(^/"]F;VYT/@T*("`@/&9O;G0@3IT:6UEF4],T0R/CQB/DY/5$4@,2`F(S@R,3$[($)!4TE3($]&(%!215-%3E1!5$E/ M3B!!3D0@3$E154E$2519(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@'0M:6YD M96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!F;VQL;W=I;F<@*&$I)B,Q-C`[8V]N9&5N M28C.#(R,3LI(&AA=F4@8F5E;B!P2!'04%0(&9O28C.#(Q-SMS($%N;G5A;"!2 M97!O&-H86YG92!#;VUM:7-S:6]N("@F(S@R,C`[4T5#)B,X,C(Q.RD@ M;VX@36%R8V@F(S$V,#LS,"P@,C`Q,BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T M>6QE/3-$)VUA#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X M="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@2P@9V%S=')O97-O<&AA9V5A M;"!R969L=7@@9&ES96%S92`H)B,X,C(P.T=%4D0F(S@R,C$[*2P-"B`@($)A M6QE/3-$)VUA#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2P@ M26YC+B`H)B,X,C(P.T-E;&QU;&%R)B,X,C(Q.RDL(&$@;F]N+6]P97)A=&EN M9R!P=6)L:6,@8V]M<&%N>2P@=V%S(&EN8V]R<&]R871E9"!I;B`Q.3@X(&%S M($Y#4R!696YT=7)E2!C;VUP86YY+B!/;B!397!T96UB97(F M(S$V,#LT+"`R,#`W+"!#96QL=6QA0T*("`@:6YT97)E2!O9B!#96QL=6QA2!F;VQL;W=I;F<@=&AE(%-H87)E($5X8VAA M;F=E+B!%9F9E8W1I=F4@2F%N=6%R>28C,38P.S@L(#(P,#@L($-E;&QU;&%R M#0H@("!C:&%N9V5D(&ETF%T:6]N(&]F(%-A9F53=&ET8V@@3$Q#+"!W:71H(%-A M9F53=&ET8V@@3$Q#(&%S('1H92!A8W%U:7)E6EN9R!F:6YA M;F-I86P@2!W:6QL(&-O;G1I M;G5E(&%S(&$@9V]I;F<@8V]N8V5R;BX@1F]R('1H92!P97)I;V0@9G)O;2!3 M97!T96UB97(F(S$V,#LQ-2PF(S$V,#LR,#`U("AI;F-E<'1I;VXI)B,Q-C`[ M=&AR;W5G:"!397!T96UB97(F(S$V,#LS,"P@,C`Q,BP@=&AE($-O;7!A;GD@ M:&%S(&%C8W5M=6QA=&5D(&$@9&5F:6-I="!O9B`D,C@N,R!M:6QL:6]N(&%N M9"!H87,@;F]T(&=E;F5R871E9"!P;W-I=&EV92!C87-H(&9L;W=S(&9R;VT- M"B`@(&]P97)A=&EO;G,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT M.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!#;VUP86YY(&AA2!F:6YA;F-I;F<@86YD(&QO86YS(&9R;VT@28C.#(Q-SMS(&5F9F]R=',@:&%V92!B M965N('!R:6YC:7!A;&QY(&1E=F]T960@=&\@9&5V96QO<&EN9R!I=',@=&5C M:&YO;&]G:65S(&%N9"!C;VUM97)C:6%L:7II;F<@:71S('!R;V1U8W1S+B!" M87-E9"!U<&]N(&ET2!U;F1E2!!9W)E96UE;G0@*'1H92`F(S@R M,C`[0W)E9&ET($9A8VEL:71Y)B,X,C(Q.RD@=VET:"!B;W1H(%1H92!&2!'+B!3<')A9V5N2!B92!A8FQE('1O(&9U;F0@:71S(&5X M:7-T:6YG(&]P97)A=&EO;G,@=&AR;W5G:"!*=6YE)B,Q-C`[,S`L(#(P,3,@ M=VAE;B!T:&4@0W)E9&ET($9A8VEL:71Y(&UA='5R97,N($AO=V5V97(L(&=I M=F5N('1H92!S:&]R="!T:6UE('!E28C.#(Q-SMS('!L86YN960@;W!E'!A;G-I;VX@:6X@,C`Q,R!O9B!C;&EN:6-A;"!T2!$979I8V4N($EF(&%D97%U871E(&9U;F1S(&%R92!N;W0@879A M:6QA8FQE+"!T:&4@0V]M<&%N>2!M87D@8F4@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@28C.#(Q-SMS(&QI M;6ET960@28C.#(Q-SMS(&%B:6QI='D@ M=&\@8V]N=&EN=64@87,@82!G;VEN9R!C;VYC97)N+@T*("`@/"]F;VYT/CPO M<#X-"B`@(#QP('-T>6QE/3-$)VUA#MM87)G:6XM8F]T M=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6EN9R!F:6YA;F-I86P@2!T;R!C;VYT:6YU92!A2!D97!E;F1E;G0@=7!O;B!G96YE'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$ M;6%R9VEN+71O<#HQ.'!X.VUA6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQI/CPO M:3X\8CX\:3Y#;VYS;VQI9&%T:6]N+CPO:3X\+V(^/&D^(#PO:3Y4:&4@8V]N M9&5N2!W:71H(&%C8V]U M;G1I;F<@<')I;F-I<&QE2!L:7%U:60@:6YV97-T;65N=',-"B`@('=I=&@@82!M M871U2!O9B!T:')E92!M;VYT:',@;W(@;&5S2!H;VQDFEN M9R!I=',@9&5P;W-I=&]R>0T*("`@8F%N:R!A8V-O=6YT#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/CQB/CQI/D%L;&]W86YC M97,@9F]R($1O=6)T9G5L($%C8V]U;G1S+B`\+VD^/"]B/E1H92!#;VUP86YY M('!R;W9I9&5S(&%N(&%L;&]W86YC92!F;W(-"B`@(')E8V5I=F%B;&5S(&ET M(&)E;&EE=F5S(&ET(&UA>2!N;W0@8V]L;&5C="!I;B!F=6QL+B!296-E:79A M8FQE2UC=7-T;VUE7-I28C.#(Q-SMS(&%C8V]U;G1S(')E8V5I=F%B;&4@96%C:"!P M97)I;V0@86YD('-U8FIE8W1I=F4@87-S97-S;65N=',@;V8@=&AE($-O;7!A M;GDF(S@R,3<[2!B M92!N96-E2!A2!L979E;',L(&]B6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2P@;VX@=&AE(&1I&5D(&%SF5D(&-U2!I;@T*("`@;W!E M6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@&5D(&]R(&1E=&5R;6EN86)L92P@86YD('1H M92!C;VQL96-T:6]N(&]F('1H92!S86QE6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2P@9F]R M('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q M-C`[,S`L(#(P,3(N($%D=F5R=&ES:6YG(&%N9`T*("`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`@=F%L=65S(&]F(&ET6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@'!E8W1E M9"!F=71U"!B87-E2!C;VYS:61E3IT:6UEF4],T0R/CQI/CPO:3X\8CX\:3Y#;VUP2!O9B!A M(&)U7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!A;F0@17%U:7!M96YT M/&)R/CPO&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!" M96=I;B!";&]C:R!486=G960@3F]T92`S("T@=7,M9V%A<#I05!L M86YT06YD17%U:7!M96YT1&ES8VQO'1";&]C:RTM/@T*("`@/'`@ M#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/CQB/DY/5$4@,R`F(S@R,3$[(%!23U!%4E19($%.1"!%455)4$U%3E0@ M/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/D1E M8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/C4F(S$V,#MY96%R3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D9UF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT M97(^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C@W+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1C96YT97(^/&9O;G0@65AF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C4W+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/B@S,C@L,#`P M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@ M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@/'`@'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/CQB/B0\ M+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4] M,T0R/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/CQB/C0W,"PP,#`\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@"!S M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@3IT:6UEF4],T0R/D1E<')E8VEA=&EO;B!O9B!F:7AE9"!A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]F83(Y-3AA8E\Q9#1C7S1A,F1?.3%E,E]D93'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@ M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#0@+2!U'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM M8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('-T;V-K:&]L9&5R M2!T:&4@0V]M<&5N65E&5R8VES92!P2`Q,B!M;VYT:`T* M("`@<&5R:6]D+"!N;R!P97)S;VX@;6%Y(')E8V5I=F4@65A'0M:6YD96YT.C@E)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!#;VUP86YY(&=R86YT960@.#$S+#4P,"!A;F0@-38R+#4P M,"!S=&]C:R!O<'1I;VYS('5N9&5R('1H92`R,#`W(%!L86X@9'5R:6YG('1H M92!N:6YE(&UO;G1H2P@:6YC;'5D:6YG(#(Q."PP,#`@ M86YD(#8X+#`P,"!S=&]C:R!O<'1I;VYS('1H870@=V5R92!I'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/E1O=&%L('-T;V-K+6)A'!E;G-E9"!O=F5R('1H92!V97-T:6YG(&QI9F4@;V8@=&AE('5N M9&5R;'EI;F<@2!O9B!T:&4@0V]M M;6]N(%-T;V-K+B!4:&4@2!E<75A;"!T;R!T:&4@97AP96-T960@=&5R;2!O9B!T:&4@65E65E(&1I'!E8W1E9"!L:69E(&]F(&%L;"!O=&AE6QE/3-$)V)OF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0Q/CQB/DYI;F4F(S$V M,#MM;VYT:',F(S$V,#ME;F1E9#QB6QE/3-$)V)O M6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)VUA6QE/3-$)VUA3IT:6UEF4],T0R/D5X<&5C=&5D M(&QI9F4\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/D9O3IT:6UE MF4],T0R/C`E("T@-24\+V9O;G0^/"]T9#X-"B`@ M(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L M93X@#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O M='1O;3HP<'@[('1E>'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/E1H92!F;VQL;W=I M;F<@28C.#(Q-SMS('-T;V-K#0H@("!O M<'1I;VX@86-T:79I='D@9F]R('1H92!N:6YE(&UO;G1H6QE M/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS M1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G M(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM M/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#8R)3XF(S$V,#L\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3XF(S$V,#L\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M6QE M/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q M/CQB/D%G9W)E9V%T93QB2`M M+3X-"B`@(#QT3IT:6UEF4],T0R/D]U='-T86YD:6YG(&%T($1E M8V5M8F5R)B,Q-C`[,S$L(#(P,3$\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@ M/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C`N-C8\+V9O M;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CDN,SD\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/D5X97)C:7-E9#PO9F]N M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q M,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B@R,S6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/C$N.3D\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@;F]W3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\ M+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/C(L,C`T+#`P,#PO M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C$N,#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/CF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[ M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M/'`@"!D M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@"!D;W5B M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@/'`@3IT:6UEF4],T0R/D5X97)C:7-A8FQE(&%T M(%-E<'1E;6)E6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C$N,C0\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C4N-#$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$ M9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P,#`P,"<^ M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@/'`@3IT:6UEF4],T0R/E9E3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C(L,34U+#(S.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C$N,#,\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@2`M+3X-"B`@(#PO=&%B;&4^(`T*("`@/'`@65A2`D,S,S+#`P,"!O9B!T;W1A;"!U;G)E M8V]G;FEZ960@8V]M<&5N65E(&%N9"!D:7)E8W1O65A'0M:6YD M96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/DYO(&]P=&EO;G,@=V5R92!E>&5R8VES960@9'5R M:6YG('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD960-"B`@(%-E<'1E M;6)E3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F83(Y-3AA8E\Q9#1C7S1A,F1?.3%E M,E]D93'0O:'1M;#L@8VAA M'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO M+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#4@ M+2!U3IT:6UEF4] M,T0R/CQB/DY/5$4@-2`F(S@R,3$[($1%0E0@/"]B/CPO9F]N=#X\+W`^#0H@ M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P M>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@'1E;F0@=&AE($UA M='5R:71Y($1A=&4L('=H:6-H(&ES(&YO=R!*=6YE)B,Q-C`[,S`L(#(P,3,N M(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[ M;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C@E)SX\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/DEN M(&-O;FYE8W1I;VX@=VET:"!T:&4@0W)E9&ET#0H@("!&86-I;&ET>2P@=&AE M($-O;7!A;GD@9W)A;G1E9"!W87)R86YT2!O9B`X,B4L M(&1I=FED96YD('EI96QD(&]F(#`E+"!R:7-K+69R964@:6YT97)E2!R96-O'0M:6YD96YT.C@E)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/E1H92!#;VUP86YY(&)O2!D:60@;F]T(')E8V]G;FEZ960@:6YT97)E2!H87,@82`D M,S`P+#`P,"!O=71S=&%N9&EN9R!B86QA;F-E(&%N9"`D,RPW,#`L,#`P(&%V M86EL86)L92!U;F1E3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F83(Y-3AA8E\Q9#1C7S1A M,F1?.3%E,E]D93'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!0 M54),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!.;W1E(#8@+2!U4YO=&5$:7-C M;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/CQB/DY/5$4@-B`F(S@R M,3$[($-!4$E404P@5%)!3E-!0U1)3TY3(#PO8CX\+V9O;G0^/"]P/@T*("`@ M/'`@'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/CQI/C(P,3(@4')I=F%T92!0;&%C M96UE;G0@;V8@0V]M;6]N(%-T;V-K+B`\+VD^3VX@1F5B28C.#(Q-SMS($)O87)D(&]F($1I2!I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z M."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@2!D:79I9&EN9R!N970@;&]S2!T:&4@=V5I9VAT960-"B`@(&%V M97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;W5T&5R8VES92!O M9B!O=71S=&%N9&EN9R!O<'1I;VYS(&%N9"!W87)R86YT6QE/3-$)VUA#MM87)G M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE.C$R<'@[ M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T* M("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0W-B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T* M("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT M9"!W:61T:#TS1#8T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\ M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3XF(S$V,#L\ M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]TF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/C@P-2PU,C$\+V9O M;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C@P-2PU,C$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]TF4Z M,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V)O6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/DY/5$4@ M."`F(S@R,3$[($-/34U)5$U%3E13($%.1"!#3TY424Y'14Y#2453(#PO8CX\ M+V9O;G0^/"]P/@T*("`@/'`@'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!# M;VUP86YY(&ES(&]B;&EG871E9"!U;F1E2P@ M=&AE(&QE87-E(&%G6UE;G0@ M;V8@8F%S92!R96YT('!L=7,@97-C86QA=&EO;G,@9F]R(&EN8W)E87-E&5S+B!296YT86P@97AP96YS92!U;F1E2X@/"]F;VYT/CPO<#X-"B`@ M(#QP('-T>6QE/3-$)VUA#MM87)G:6XM8F]T=&]M.C!P M>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@2!T;R!$B!!;6ED(&EN('1H92!A;6]U M;G0@;V8@)#0P,"!A;F0@)#@P,"!H879E(&)E96X@:6YC=7)R960@9'5R:6YG M('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q M-C`[,S`L(#(P,3(L(')E2X@3F\@6QE/3-$)VUA'!E8W1E9"!C M;VUP;&5T:6]N('=I=&AI;B!T:&4@;F5X="!T=V5L=F4@;6]N=&AS+B!4:&4@ M0V]M<&%N>2!C=7)R96YT;'D@:&%S(&YO(&UA=&5R:6%L(&-O;6UI=&UE;G1S M('=I=&@@=&5R;7,@8F5Y;VYD('1W96QV92!M;VYT:',N(#PO9F]N=#X\+W`^ M#0H\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\6QE/3-$;6%R9VEN+71O M<#HQ.'!X.VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@#MM M87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@&-L=7-I=F4@;&EC96YS92!A;F0@9&5V96QO<&UE;G0@86=R965M M96YT("AT:&4@)B,X,C(P.T-R96EG:'1O;@T*("`@06=R965M96YT)B,X,C(Q M.RD@=VET:"!#2D@ M;&EC96YS92P@=VET:"!R:6=H=',@=&\@&-L=7-I=F4@2!B87-I2!P2!I;G9E2!H860@2!F;W(@=&AE('1H3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M83(Y-3AA8E\Q9#1C7S1A,F1?.3%E,E]D93'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO M+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$P M("T@=7,M9V%A<#I);F-O;65487A$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@ M("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T=&]M.C!P M>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/DY/5$4@,3`@)B,X,C$Q.R!)3D-/344@5$%815,@/"]B M/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM M87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!D:69F97)E;F-E M"!R871E'!E8W1E9"!T;R!B92!I M;B!E9F9E8W0@=VAE;B!S=6-H(&%M;W5N=',@87)E(')E86QI>F5D(&]R('-E M='1L960N#0H@("!!('9A;'5A=&EO;B!A;&QO=V%N8V4@F5D M+B!!;&P@;V8@=&AE($-O;7!A;GDF(S@R,3<[2!R97-E2!A#0H@("!V86QU871I M;VX@86QL;W=A;F-E(&1U92!T;R!M86YA9V5M96YT)B,X,C$W.W,@=6YC97)T M86EN='D@2!O9B!T M:&4@0V]M<&%N>2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF5D(&YO(&%D M:G5S=&UE;G0@9F]R('5N8V5R=&%I;B!T87@@<')O=FES:6]NF5S(&EN=&5R97-T(&%N9"!P96YA;'1I97,@"!P M;W-I=&EO;G,@:&%V92!B965N(')E8V]R9&5D(&%S(&]F(%-E<'1E;6)E'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/E1H90T*("`@ M=&%X('EE87)S(#(P,#DM,C`Q,2!R96UA:6X@;W!E;B!T;R!E>&%M:6YA=&EO M;B!B>2!T:&4@;6%J;W(@=&%X(&IU'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!4'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$51R86YS86-T M:6]N6QE/3-$;6%R M9VEN+71O<#HQ.'!X.VUA6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@2!D97-C2!E;G1E6QE/3-$)VUA&EM871E;'D@)#$Y+#`P,"!P M97(@;6]N=&@N(%1H92!#;VUP86YY(')E8V]R9&5D(')E;G0@97AP96YS92!R M96QA=&5D('1O('1H92!-:6%M:2!L96%S92!T;W1A;&EN9R!A<'!R;WAI;6%T M96QY("0W,RPP,#`@86YD("0Q.3@L,#`P+"!R97-P96-T:79E;'DL(&9O2!T:&%T(&1I2UT2!O<&5R871I;F<@<')I;6%R M:6QY(&EN($-H:6YA+"!A;F0@4V]R2UT28C.#(Q-SMS($-H:65F($9I M;F%N8VEA;"!/9F9I8V5R(&%L'!E;G-E2P@9F]R('1H92!T:')E92!A;F0@;FEN M92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$N($%G9W)E M9V%T92!A8V-O=6YT&EM871E;'D@)#0U+#`P,"!A;F0@)#8V+#`P,"!A3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F83(Y-3AA8E\Q9#1C7S1A,F1?.3%E,E]D M93'0O:'1M;#L@8VAA65E($)E;F5F:70@4&QA;G,\8G(^/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/"$M+41/0U194$4@:'1M;"!054), M24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I M=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!. M;W1E(#$R("T@=7,M9V%A<#I096YS:6]N06YD3W1H97)0;W-T'1";&]C:RTM/@T*("`@/'`@6QE/3-$)VUA2!B M92!M861E(&]N(&$@<')E+71A>"!B87-I2!C;VYT M2!R96-O'!E;G-E(&]F#0H@("!A<'!R;WAI M;6%T96QY("0R,RPP,#`@86YD("0S-RPP,#`L(')E2P@9F]R M('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q M-C`[,S`L(#(P,3(@86YD("0Y+#`P,"!A;F0@)#(X+#`P,"P@7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!O9B!3:6=N:69I M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T'0^/"$M+41/0U194$4@ M:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K M(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@5]T86)L93$@+2!U6QE/3-$;6%R9VEN M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@'0^/"$M+41/0U194$4@:'1M;"!0 M54),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!!8V-O=6YT:6YG(%!O;&EC>3H@5]T86)L93(@+2!U3IT:6UEF4],T0R/CQB/CQI/CPO:3X\+V(^/&D^/"]I/CQB/CQI/E5S M92!O9B!E2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T* M("`@/"$M+2!"96=I;B!";&]C:R!486=G960@06-C;W5N=&EN9R!0;VQI8WDZ M('-F97,M,C`Q,C`Y,S!?;F]T93)?86-C;W5N=&EN9U]P;VQI8WE?=&%B;&4S M("T@=7,M9V%A<#I#87-H06YD0V%S:$5Q=6EV86QE;G1S4&]L:6-Y5&5X=$)L M;V-K+2T^#0H@("`\<"!S='EL93TS1&UA#MM87)G:6XM M8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQI/CPO:3X\8CX\:3Y#87-H(&%N9"!C87-H M(&5Q=6EV86QE;G1S/"]I/CPO8CX\:3XN(#PO:3Y792!C;VYS:61E2!N;W0@8F4@:6YS=7)E9"X@ M/"]F;VYT/CPO<#X-"CQS<&%N/CPO#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/CQB/CQI/D%L;&]W86YC97,@9F]R($1O=6)T9G5L($%C8V]U;G1S+B`\+VD^ M/"]B/E1H92!#;VUP86YY('!R;W9I9&5S(&%N(&%L;&]W86YC92!F;W(-"B`@ M(')E8V5I=F%B;&5S(&ET(&)E;&EE=F5S(&ET(&UA>2!N;W0@8V]L;&5C="!I M;B!F=6QL+B!296-E:79A8FQE2UC=7-T;VUE M7-I28C.#(Q-SMS(&%C8V]U;G1S(')E M8V5I=F%B;&4@96%C:"!P97)I;V0@86YD('-U8FIE8W1I=F4@87-S97-S;65N M=',@;V8@=&AE($-O;7!A;GDF(S@R,3<['0^/"$M+41/0U194$4@:'1M;"!054), M24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I M=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!! M8V-O=6YT:6YG(%!O;&EC>3H@5]T86)L934@+2!U5!O;&EC>51E M>'1";&]C:RTM/@T*("`@/'`@2!B92!N96-E2!A2!L979E;',L(&]B'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^ M#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC M>3H@5]T86)L M938@+2!U6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@2P@;VX@=&AE M(&1I&5D(&%SF5D(&-U M2!I;@T*("`@;W!E'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO M+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT M:6YG(%!O;&EC>3H@5]T86)L93<@+2!U51E>'1";&]C:RTM/@T*("`@/'`@&ES=',L('1H92!G;V]D&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM M/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@06-C;W5N=&EN9R!0;VQI M8WDZ('-F97,M,C`Q,C`Y,S!?;F]T93)?86-C;W5N=&EN9U]P;VQI8WE?=&%B M;&4X("T@=7,M9V%A<#I!9'9E6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@2P@9F]R('1H92!T:')E92!A;F0@;FEN92!M M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(N($%D=F5R=&ES M:6YG(&%N9`T*("`@<')O;6]T:6]N86P@8V]S=',@86YD(&5X<&5N&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!" M;&]C:R!486=G960@06-C;W5N=&EN9R!0;VQI8WDZ('-F97,M,C`Q,C`Y,S!? M;F]T93)?86-C;W5N=&EN9U]P;VQI8WE?=&%B;&4Y("T@=7,M9V%A<#I297-E M87)C:$%N9$1E=F5L;W!M96YT17AP96YS95!O;&EC>2TM/@T*("`@/'`@7!E'0^/"$M+41/ M0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T14 M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN M($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@5]T86)L93$P("T@=7,M9V%A<#I$ M97!R96-I871I;VY$97!L971I;VY!;F1!;6]R=&EZ871I;VY0;VQI8WE497AT M0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^ M#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC M>3H@5]T86)L M93$Q("T@=7,M9V%A<#I3:&%R94)A6QE/3-$;6%R9VEN M+71O<#HQ,G!X.VUA6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!M96%S M=7)E9"!A="!E86-H(')E<&]R=&EN9R!P97)I;V0@=6YT:6P@=&AE(&9I;F%L M(&UE87-U'!E;G-E9"!O M=F5R('1H92!V97-T:6YG(&QI9F4-"B`@(&]F('1H92!U;F1E2!P"!C51E>'1";&]C:RTM/@T*("`@ M/'`@2!P"!C6EN9R!F:6YA;F-I86P-"B`@('-T871E;65N=',N(#PO9F]N=#X\ M+W`^#0H\6QE/3-$ M;6%R9VEN+71O<#HQ,G!X.VUA6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!R979I97=S('1H92!C87)R>6EN9PT*("`@ M=F%L=65S(&]F(&ET&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@ M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G%!O;&EC>51E>'1";&]C:RTM/@T*("`@/'`@2!D:69F97)E;F-E6EN9R!A;6]U;G1S(&%N9"!T:&4@=&%X(&)A2!I"!A"!A&%B;&4@:6YC;VUE(&]R(&QO`T*("`@=F%L=6%T:6]N(&%L M;&]W86YC92X@/"]F;VYT/CPO<#X-"CQS<&%N/CPO'0^/"$M+41/ M0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T14 M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN M($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@5]T86)L93$V("T@=7,M9V%A<#I# M;VUP3IT:6UEF4],T0R/CQI/CPO:3X\8CX\:3Y#;VUP2!O M9B!A(&)U7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!A;F0@17%U:7!M M96YT("A486)L97,I/&)R/CPO'0^/"$M+41/0U194$4@:'1M;"!054),24,@ M(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO M;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E M(%1A8FQE.B!S9F5S+3(P,3(P.3,P7VYO=&4S7W1A8FQE,2`M('5S+6=A87`Z M4')O<&5R='E0;&%N=$%N9$5Q=6EP;65N=%1E>'1";&]C:RTM/@T*("`@/'`@ M'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/E!R;W!EF4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM M8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T M>6QE/3-$)V)OF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0Q/CQB/D5S=&EM871E9"8C M,38P.U5S969U;"8C,38P.TQI=F5S/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/E-E<'1E;6)EF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^ M/&9O;G0@65AF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C8V,"PP,#`\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@;F]W3IT:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@65A MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C@Q+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/E-O9G1W87)E/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@/'`@6QE/3-$ M)V)O6QE M/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D%C8W5M=6QA=&5D M(&1E<')E8VEA=&EO;B!A;F0@86UOF%T:6]N/"]F;VYT/CPO<#X-"B`@ M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@6QE/3-$)V)O6QE/3-$)V)O M3IT:6UEF4],T0R/CQB M/E!R;W!EF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/CQB/C,T M.2PP,#`\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O2`M M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F83(Y-3AA8E\Q9#1C7S1A,F1?.3%E,E]D93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)VUA#MM87)G M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/@T*("`@/&9O;G0@'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I M;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#8P M)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0S)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]TF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1C96YT97(@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0Q/CQB/DYI;F4F(S$V,#MM;VYT:',F M(S$V,#ME;F1E9#QB2`M+3X-"B`@(#QT M3IT:6UEF4],T0R/D5X<&5C=&5D('9O;&%T:6QI='D\+V9O;G0^ M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6EE;&0\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)VUAF4],T0R M/C4N-28C,38P.R8C.#(Q,3LF(S$V,#LQ,"XP)B,Q-C`[>65AF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0Q/CQB/E=E:6=H=&5D/&)R("\^079EF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/@T*("`@/"]T6QE/3-$ M)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C@Q M,RPU,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ MF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T6QE M/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/D-A;F-E;&5D(&]R(&5X<&ER960\+V9O;G0^/"]P/@T* M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)VUA3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/CDY,"PX-S4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VUAF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0M M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E!O=&5N=&EA;"!C;VUM;VX@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/E-E<'1E;6)E'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C(L,C`T+#`P,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\ M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@/'`@'0M:6YD96YT.BTQ+C`P96TG/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/CQB/C,L,#`Y+#4R,3PO8CX\+V9O M;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V)O6QE/3-$)V)O'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2`H1&5T86EL2`H5&5X M='5A;"D@6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\2!A=F%I;&%B;&4@0F]R7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]F83(Y-3AA8E\Q9#1C7S1A,F1?.3%E,E]D93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!O M9B!02!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-34L M,#`P*3QS<&%N/CPO'0^-2!Y96%R'1U2!O9B!02!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\2!O9B!02!A M;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\65A65A2!O9B!02!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\&EM=6T@6TUE;6)E'0^-2!Y96%R2!O9B!02!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\65A'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA2!A;F0@17%U:7!M96YT("A$971A:6QS(%1E M>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@@8V]L'1U86PI(%M!8G-T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2P@36EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E8W1E9"!6;VQA=&EL:71Y+"!-87AI;75M M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3$N,S8E/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6EE;&0\+W1D/@T*("`@("`@("`\=&0@ M8VQA'!E8W1E9"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XU('EE87)S(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^-2!Y96%R'!E8W1E9"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XQ,"!Y96%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-B!Y96%R7,\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^.2!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES960L(%-H87)E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES M960L(%=E:6=H=&5D($%V97)A9V4@17AE&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^-R!Y96%R7,\7,\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!T;R!V97-T+"!796EG:'1E9"!! M=F5R86=E(%)E;6%I;FEN9R!#;VYT7,\7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]F83(Y-3AA8E\Q9#1C7S1A,F1?.3%E,E]D93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI("A54T0@)"D\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3(@;6]N=&AS/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3`@>65A'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3,L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$"!B96YE9FET'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F83(Y-3AA8E\Q9#1C7S1A M,F1?.3%E,E]D93'0O:'1M M;#L@8VAA2!A=F%I;&%B;&4@0F]R'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA M=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!,:69E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\F%T M:6]N(&5X<&5N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E(')E M;&%T960@=&\@;W5T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'1U M86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'1U86PI(%M! M8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^2G5N(#,P+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(&EN=&5R97-T(&5X M<&5N'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA&5C=71I=F4@3V9F:6-E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F83(Y-3AA M8E\Q9#1C7S1A,F1?.3%E,E]D93'0O:'1M;#L@8VAA2!O9B!0;W1E;G1I86P@0V]M;6]N(%-H87)E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!O9B!0;W1E;G1I86P@0V]M;6]N(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T7V9A,CDU.&%B7S%D-&-?-&$R9%\Y,64R7V1E-SAB,C0S,&0Q80T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F83(Y-3AA8E\Q9#1C7S1A M,F1?.3%E,E]D93'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%L='D@06=R965M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'1U86PI(%M!8G-T2!O9B!S<&5C M:69I8R!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^,3`@>65A6%L='D@26YC=7)R960\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^,3(@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6]N M9"!N97AT('1W96QV92!M;VYT:',\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L2!O9B!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S6%L='D@86=R965M96YT/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'1U86PI(%M!8G-T"!P7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!43PO=&0^#0H@("`@("`@(#QT M9"!C;&%S65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!4'1U86PI(%M!8G-T'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F83(Y-3AA8E\Q M9#1C7S1A,F1?.3%E,E]D93'0O:'1M;#L@8VAA65E(&-O;G1R:6)U=&EO;B!T;R!A;FYU86P@8V]M<&5N'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E&UL/@T*+2TM+2TM/5].97AT4&%R=%]F G83(Y-3AA8E\Q9#1C7S1A,F1?.3%E,E]D93 XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Stock-Based Compensation (Details 1) (USD $)
    3 Months Ended 9 Months Ended 11 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Sep. 30, 2011
    Dec. 30, 2011
    Summary of Company's Stock Option activity          
    Outstanding, Shares, Beginning Balance     1,628,167    
    Outstanding, Weighted Average Exercise Price, Beginning Balance     $ 1.35    
    Outstanding, Weighted Average Remaining Contractual Term, Beginning Balance     6 years 3 months 4 days    
    Granted, Shares     813,500 562,500  
    Granted, Weighted Average Exercise Price     $ 0.66   $ 1.12
    Granted, Weighted Average Remaining Contractual Term     9 years 4 months 21 days    
    Exercised, Shares 0 0    0  
    Exercised, Weighted Average Exercise Price           
    Canceled or expired, Shares     (237,667)    
    Canceled or expired, Weighted Average Exercise Price     $ 1.99    
    Outstanding, Shares, Ending Balance 2,204,000   2,204,000    
    Outstanding, Weighted Average Exercise Price, Ending Balance $ 1.02   $ 1.02    
    Outstanding, Weighted Average Remaining Contractual Term, Ending Balance 7 years 1 month 2 days   7 years 1 month 2 days    
    Outstanding, Intrinsic Value, Ending Balance $ 0   $ 0    
    Exercisable, Shares 990,875   990,875    
    Exercisable, Weighted Average Exercise Price $ 1.24   $ 1.24    
    Exercisable, Weighted Average Remaining Contractual Term 5 years 4 months 28 days   5 years 4 months 28 days    
    Exercisable, Intrinsic Value 0   0    
    Vested and expected to vest, Shares 2,155,239   2,155,239    
    Vested and expected to vest, Weighted Average Exercise Price $ 1.03   $ 1.03    
    Vested and expected to vest, Weighted Average Remaining Contractual Term 7 years 18 days   7 years 18 days    
    Vested and expected to vest, Aggregate Intrinsic Value $ 0   $ 0    
    XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Stock-Based Compensation (Details)
    9 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Summary of Share-Based Compensation of Fair Value Assumptions    
    Expected Volatility, Minimum 85.41% 76.91%
    Expected Volatility, Maximum 111.36% 102.63%
    Expected Dividend yield 0.00% 0.00%
    Risk Free Interest Rate, Minimum 1.02% 2.25%
    Risk Free Interest Rate, Maximum 1.98% 3.25%
    Minimum Expected Term 5 years 6 months 5 years 6 months
    Maximum Expected Term 10 years 10 years
    Minimum Forfeiture Rate 0.00% 0.00%
    Maximum Forfeiture Rate 2.00% 5.00%
    XML 21 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Stock-Based Compensation (Details Textual) (USD $)
    3 Months Ended 9 Months Ended 11 Months Ended 9 Months Ended 12 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Sep. 30, 2011
    Dec. 30, 2011
    Jun. 19, 2012
    Sep. 30, 2012
    Consultants [Member]
    Sep. 30, 2011
    Consultants [Member]
    Dec. 31, 2012
    Minimum [Member]
    Dec. 31, 2012
    Maximum [Member]
    Stock-Based Compensation (Textual) [Abstract]                    
    Stock option granted     813,500 562,500     218,000 68,000    
    Stock option exercise price     $ 0.66   $ 1.12       $ 0.65 $ 0.85
    Stock-Based Compensation (Additional Textual) [Abstract]                    
    Common stock shares available for issuance           5,000,000        
    Period for conditional grant of award     12 months              
    Maximum number of Shares for which share awards can be granted     1,000,000              
    Stock option exceeding period     10 years              
    Estimated aggregate fair value of stock option     $ 441,000   $ 502,000          
    Weight average fair value of the options granted     $ 0.54 $ 0.89            
    Share-based Compensation Expense 113,000 98,000 336,000 240,000            
    Stock based compensation forfeiture experience recorded       113,000            
    Number of options vested 0   0              
    Unrecognized compensation cost related to non vested employee and director share based compensation arrangement 333,000   333,000              
    Weighted average period for which cost is expected to be recognized     1 year 6 months 11 days              
    Stock option exercised 0 0    0            
    Tax benefits attributed to the stock-based compensation expense     $ 0              
    XML 22 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Debt (Details Textual) (USD $)
    3 Months Ended 9 Months Ended 84 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Line of Credit Facility (Textual) [Abstract]          
    Credit facility available Borrowing $ 4,000,000   $ 4,000,000   $ 4,000,000
    Credit facility accrue interest rate     10.00%    
    Credit facility initial term     28 months    
    Warrants granted to purchase aggregate common stock     805,521    
    Fair value of warrants     1,985,000    
    Expected volatility     82.00%    
    Dividend yield     0.00%    
    Risk free interest rate     4.88%    
    Expected Life     10 years    
    Amortization expenses related to deferred financing cost 2,000 5,000 7,000 36,000  
    Borrowing credit facility     300,000    
    Outstanding loans 300,000   300,000   300,000
    Recognized interest expense related to outstanding borrowings   7,000 43,000 7,000 155,000
    Remaining credit facility 3,700,000   3,700,000   3,700,000
    The Frost Group [Member]
             
    Line of Credit Facility (Textual) [Abstract]          
    Credit facility available Borrowing 3,900,000   3,900,000   3,900,000
    Mr. Spragens [Member]
             
    Line of Credit Facility (Textual) [Abstract]          
    Credit facility available Borrowing 100,000   100,000   100,000
    Credit Facility [Member]
             
    Line of Credit Facility (Textual) [Abstract]          
    Maturity date     Jun. 30, 2013    
    Recognized interest expense related to outstanding borrowings $ 0        
    XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Basis of Presentation and Liquidity
    9 Months Ended
    Sep. 30, 2012
    Basis of Presentation and Liquidity [Abstract]  
    BASIS OF PRESENTATION AND LIQUIDITY

    NOTE 1 – BASIS OF PRESENTATION AND LIQUIDITY

    The following (a) condensed consolidated balance sheet as of December 31, 2011, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of SafeStitch Medical, Inc. (“SafeStitch” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of results that may be expected for the year ending December 31, 2012. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2011 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2012.

    SafeStitch Medical, Inc. (together with its consolidated subsidiaries, “SafeStitch” or the “Company”) is a developmental stage medical device company focused on the development of medical devices that manipulate tissues for endoscopic and minimally invasive surgery for the treatment of obesity, gastroesophageal reflux disease (“GERD”), Barrett’s Esophagus, esophageal obstructions, upper gastrointestinal bleeding, hernia formation and other intraperitoneal abnormalities.

    Cellular Technical Services Company, Inc. (“Cellular”), a non-operating public company, was incorporated in 1988 as NCS Ventures Corp. under the laws of the State of Delaware. On July 25, 2007 Cellular entered into a Share Transfer, Exchange and Contribution Agreement (the “Share Exchange”) with SafeStitch LLC, a Virginia limited liability company. On September 4, 2007, Cellular acquired all of the members’ equity interests in SafeStitch LLC in exchange for 11,256,369 shares of Cellular’s common stock, which represented a majority of Cellular’s outstanding shares immediately following the Share Exchange. Effective January 8, 2008, Cellular changed its name to SafeStitch Medical, Inc. and increased the aggregate number of shares of capital stock that may be issued from 35,000,000 to 250,000,000, comprising 225,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”), and 25,000,000 shares of preferred stock, par value $0.01 per share. For accounting purposes, the acquisition has been treated as a recapitalization of SafeStitch LLC, with SafeStitch LLC as the acquirer (reverse acquisition). The historical financial statements prior to September 4, 2007 are those of SafeStitch LLC, which began operations on September 15, 2005. The accompanying financial statements give retroactive effect to the recapitalization as if it had occurred on September 15, 2005 (inception).

    The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the period from September 15, 2005 (inception) through September 30, 2012, the Company has accumulated a deficit of $28.3 million and has not generated positive cash flows from operations.

    The Company has been dependent upon equity financing and loans from stockholders to meet its obligations and sustain operations. The Company’s efforts have been principally devoted to developing its technologies and commercializing its products. Based upon its current cash position, availability under the extended term of its $4.0 million Note and Security Agreement (the “Credit Facility”) with both The Frost Group LLC (“The Frost Group”) and the Company’s President and CEO, Jeffrey G. Spragens, and by monitoring its discretionary expenditures, management believes that the Company may be able to fund its existing operations through June 30, 2013 when the Credit Facility matures. However, given the short time period until the Credit Facility matures and the probable inability to pay back the amounts due at maturity on June 30, 2013, the Company is exploring more permanent or longer term financing alternatives.

    The Company does not currently generate sufficient revenue from sales of the AMID™ Hernia Fixation Device (the “AMID HFD”) and external financing will therefore be necessary in order to fund the Company’s planned operations, including the continued development of our Intraluminal Gastroplasty Device for Obesity and GERD (“Gastroplasty Device”), and the anticipated expansion in 2013 of clinical trials for certain of the Company’s product candidates. The Company has taken several steps to preserve cash, including eliminating staff and focusing efforts solely on sales of the AMID HFD and development of our Gastroplasty Device. If adequate funds are not available, the Company may be required to delay, further reduce the scope of or eliminate its research and development programs, reduce its planned commercialization efforts or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain product candidates that it might otherwise seek to develop or commercialize independently.

    Although the Company is seeking to secure additional funds through the issuance of equity and/or debt, no assurance can be given that additional financing will be available to the Company on acceptable terms, or at all. Unless the Credit Facility Maturity Date is extended or replaced with similar terms, additional funding will be required to repay both the Credit Facility and to continue operations. This uncertainty, along with the Company’s limited remaining cash balances, raises substantial doubt about the Company’s ability to continue as a going concern.

    The accompanying financial statements do not include any adjustments that might be necessary as a result of the outcome of such uncertainty. In addition to securing additional funds, the Company’s ability to continue as a going concern is ultimately dependent upon generating revenues from those products that do not require further marketing clearance by the U.S. Food and Drug Administration (“FDA”), obtaining FDA clearance to market its other product candidates, and achieving profitable operations and generating sufficient cash flows from operations to meet future obligations.

    XML 24 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Capital Transactions (Details Textual) (USD $)
    In Thousands, except Share data, unless otherwise specified
    12 Months Ended 1 Months Ended 1 Months Ended
    Dec. 31, 2010
    Dec. 31, 2008
    Feb. 29, 2012
    2012 PIPE investors [Member]
    Feb. 17, 2012
    2012 PIPE investors [Member]
    Investor
    Feb. 29, 2012
    2012 PIPE investors [Member]
    Chairman of Board [Member]
    Feb. 29, 2012
    2012 PIPE investors [Member]
    Chairman of Board 1 [Member]
    Feb. 29, 2012
    2012 PIPE investors [Member]
    Board of Directors [Member]
    Feb. 29, 2012
    2012 PIPE investors [Member]
    President and Chief Executive Officer [Member]
    Capital Transactions (Textual) [Abstract]                
    Number of Investors       35        
    Purchase of Common stock     20,794,000   4,500,000 4,500,000 125,000 250,000
    Stock issued during period price per shares     $ 0.40          
    Aggregate Consideration $ 4,974 $ 3,988 $ 8,300          
    XML 25 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Condensed Consolidated Balance Sheets (USD $)
    In Thousands, unless otherwise specified
    Sep. 30, 2012
    Dec. 31, 2011
    CURRENT ASSETS    
    Cash and cash equivalents $ 118 $ 298
    Accounts Receivable - trade 9  
    Other receivable - related-party 45 66
    Prepaid expenses 83 143
    Inventories 1,687  
    Total Current Assets 1,942 507
    FIXED ASSETS    
    Property and equipment, net 349 470
    OTHER ASSETS    
    Security deposits 2 2
    Deferred financing costs, net 7 14
    Total Other Assets 9 16
    TOTAL ASSETS 2,300 993
    CURRENT LIABILITIES    
    Accounts payable and accrued liabilities 860 469
    Total Current Liabilities 860 469
    Stockholder loans, including accrued interest (Note 5) 300 2,523
    Commitments and contingencies (Note 8)      
    STOCKHOLDERS' EQUITY (DEFICIT)    
    Common stock, $0.001 par value per share, 225,000,000 shares authorized, 48,797,755 and 28,003,755 shares issued and outstanding 49 28
    Additional paid-in capital 29,396 20,762
    Deficit accumulated during the development stage (28,305) (22,789)
    Total Stockholders' Equity (Deficit) 1,140 (1,999)
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 2,300 $ 993
    XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Condensed Consolidated Statements of Stockholder's Equity (Deficit) (Parenthetical) (USD $)
    1 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended 12 Months Ended
    Jun. 30, 2010
    Dec. 30, 2008
    May 31, 2008
    Jan. 31, 2010
    Series A Preferred Stock
    Jul. 31, 2009
    Series A Preferred Stock
    Dec. 31, 2010
    Series A Preferred Conversion
    Sep. 30, 2010
    Preferred Stock
    Jan. 31, 2010
    Preferred Stock
    Series A Preferred Stock
    Jul. 31, 2009
    Preferred Stock
    Series A Preferred Stock
    Sep. 30, 2010
    Common Stock
    Jun. 30, 2010
    Common Stock
    Dec. 30, 2008
    Common Stock
    May 31, 2008
    Common Stock
    Sep. 30, 2012
    Common Stock
    Jan. 08, 2008
    Common Stock
    Sep. 30, 2010
    Additional Paid-in Capital
    Jun. 30, 2010
    Additional Paid-in Capital
    Dec. 30, 2008
    Additional Paid-in Capital
    May 31, 2008
    Additional Paid-in Capital
    Sep. 30, 2012
    Additional Paid-in Capital
    Jan. 31, 2010
    Additional Paid-in Capital
    Series A Preferred Stock
    Jul. 31, 2009
    Additional Paid-in Capital
    Series A Preferred Stock
    Dec. 31, 2010
    Additional Paid-in Capital
    Series A Preferred Conversion
    Conversion of shares of series A Preferred Stock             4,000,000     4,000,000           4,000,000              
    Conversion of accumulated dividends             4,366,000     4,366,000           4,366,000              
    Issuance of common shares in private offering $ 1.00   $ 2.15               $ 1.00   $ 2.15       $ 1.00   $ 2.15        
    Repayment of stockholder related to Issuance of common shares   $ 1.22                   $ 1.22           $ 1.22          
    Issuance of Series A Preferred Stock       $ 1.00 $ 1.00     $ 1.00 $ 1.00                       $ 1.00 $ 1.00  
    Intrinsic value of aggregate shares of Common Stock issued on conversion of Series A Preferred Stock           5,063,000                                 5,063,000
    Common stock, par value                           $ 0.40 $ 0.001         $ 0.40      
    Common stock, shares issued                           20,794,000           20,794,000      
    XML 27 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Agreement With Creighton University (Details Textual) (USD $)
    3 Months Ended 9 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Sep. 30, 2011
    Agreement with Creighton University (Textual) [Abstract]        
    Percentage of royalty of product revenue     1.50%  
    Minimum investment under royalty agreement $ 2,500,000   $ 2,500,000  
    Period for minimum investment under royalty agreement     36 months  
    Patent related under royalty agreement     150,000  
    Reimbursement percentage of research and development expenses     20.00%  
    Research and development expense under royalty agreement $ 10,000 $ 12,000 $ 34,000 $ 33,000
    XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Stock-Based Compensation (Tables)
    9 Months Ended
    Sep. 30, 2012
    Stock-Based Compensation [Abstract]  
    Summary of Share Based Compensation of Fair Value Assumptions

    The fair value of each option granted during the nine months ended September 30, 2012 and 2011 was estimated using the following assumptions.

             
        Nine months ended
    September 30, 2012
      Nine months ended
    September 30, 2011

    Expected volatility

      85.41% - 111.36%   76.91% - 102.63%

    Expected dividend yield

      0.00%   0.00%

    Risk-free interest rate

      1.02% – 1.98%   2.25% – 3.25%

    Expected life

      5.5 – 10.0 years   5.5 – 10.0 years

    Forfeiture rate

      0% - 2%   0% - 5%
    Summary of Company's Stock Option activity

    The following summarizes the Company’s stock option activity for the nine months ended September 30, 2012:

     

                                     
        Shares     Weighted
    Average
    Exercise
    Price
        Weighted
    Average
    Remaining
    Contractual
    Term (Years)
        Aggregate
    Intrinsic
    Value
     

    Outstanding at December 31, 2011

        1,628,167     $ 1.35       6.26          

    Granted

        813,500     $ 0.66       9.39          

    Exercised

        —         —                    

    Canceled or expired

        (237,667   $ 1.99                  
       

     

     

                             

    Outstanding at September 30, 2012

        2,204,000     $ 1.02       7.09     $ 0  
       

     

     

       

     

     

       

     

     

       

     

     

     

    Exercisable at September 30, 2012

        990,875     $ 1.24       5.41     $ 0  
       

     

     

       

     

     

       

     

     

       

     

     

     

    Vested and expected to vest at September 30, 2012

        2,155,239     $ 1.03       7.05     $ 0  
       

     

     

       

     

     

       

     

     

       

     

     

     
    XML 29 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Income Taxes (Details Textual) (USD $)
    9 Months Ended
    Sep. 30, 2012
    Dec. 31, 2011
    Income Taxes (Textual) [Abstract]    
    Uncertain tax provisions adjustment $ 0  
    Provisions for accrued interest and penalties related to uncertain tax positions $ 0 $ 0
    XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Basis of Presentation and Liquidity (Details Textual) (USD $)
    9 Months Ended 1 Months Ended
    Sep. 30, 2012
    Dec. 31, 2011
    Sep. 15, 2005
    Jan. 08, 2008
    Maximum [Member]
    Jan. 08, 2008
    Minimum [Member]
    Jan. 08, 2008
    Common Stock [Member]
    Sep. 30, 2007
    Common Stock [Member]
    Cellular [Member]
    Jan. 08, 2008
    Preferred Stock [Member]
    Basis of Presentation and Liquidity (Textual) [Abstract]                
    Common stock, shares issued             11,256,369  
    Capital stock , share authorized       250,000,000 35,000,000      
    Common stock, shares authorized 225,000,000 225,000,000       225,000,000    
    Common Stock at Par value $ 0.001 $ 0.001            
    Preferred Stock, Par value               $ 0.01
    Preferred Stock, Share issued               25,000,000
    Accumulated deficit     $ 28,300,000          
    Credit facility available Borrowing $ 4,000,000              
    Maturity Date for line of Credit Jun. 30, 2013              
    XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

    "+ text.join( "

    \n" ) +"

    "; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

    " + text[p] + "

    \n"; } } }else{ formatted = '

    ' + raw + '

    '; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
    '+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
    '+ "\n"+' '+ "\n"+'
    '+ "\n"+' '+ "\n"+'
    '+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
    XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
    In Thousands, unless otherwise specified
    9 Months Ended 84 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    OPERATING ACTIVITIES      
    Net loss $ (5,516) $ (4,150) $ (28,305)
    Adjustments to reconcile net loss to net cash used in operating activities:      
    Amortization of deferred finance cost 7 36 1,977
    Stock-based compensation expense 337 240 1,642
    Stock-based compensation expense related to Share Exchange     77
    Depreciation and amortization 127 100 469
    Loss from disposal of assets   20 20
    Inventory Adjustments     139
    Gain on sale of True Position investment     (903)
    Changes in operating assets and liabilities      
    Inventories (1,687) 5 (1,826)
    Other current assets 72 (8) (117)
    Other assets     (2)
    Accounts payable and accrued liabilities 391 194 576
    Accrued Interest (48) 7  
    NET CASH USED IN OPERATING ACTIVITIES (6,317) (3,556) (26,253)
    INVESTING ACTIVITIES      
    Purchase of equipment (6) (199) (838)
    Proceeds from sale of True Position investment     903
    Payment received under Rule 16b     4
    NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES (6) (199) 69
    FINANCING ACTIVITIES      
    Net cash provided in connection with the acquisition of SafeStitch LLC     3,192
    Issuance of Common Stock, net of offering costs 8,318   17,280
    Issuance of Preferred Stock, net of offering costs     3,980
    Capital contributions     1,431
    Proceeds from notes payable     141
    Repayment of notes payable   (49) (141)
    Proceeds from stockholder loans 800 1,100 6,135
    Repayment of stockholder loans (2,975)   (5,751)
    Exercise of options     35
    NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 6,143 1,051 26,302
    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 180 (2,704) 118
    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 298 3,032  
    CASH AND CASH EQUIVALENTS AT END OF PERIOD 118 328 118
    Supplemental disclosures:      
    Cash paid for interest 91   155
    Non cash activities:      
    Non-cash dividend upon issuance & conversion of Preferred Stock     5,001
    Stock dividends     366
    Stockholder loans contributed to capital     84
    Warrants issued in connection with credit facility     $ 1,985
    XML 33 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Condensed Consolidated Balance Sheets (Parenthetical) (USD $)
    Sep. 30, 2012
    Dec. 31, 2011
    Condensed Consolidated Balance Sheets [Abstract]    
    Common stock, par value $ 0.001 $ 0.001
    Common stock, shares authorized 225,000,000 225,000,000
    Common stock, shares issued 48,797,755 28,003,755
    Common stock, shares outstanding 48,797,755 28,003,755
    XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Income Taxes
    9 Months Ended
    Sep. 30, 2012
    Income Taxes [Abstract]  
    INCOME TAXES

    NOTE 10 – INCOME TAXES

    The Company accounts for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. All of the Company’s deferred tax assets have been fully reserved by a valuation allowance due to management’s uncertainty regarding the future profitability of the Company.

    The Company has recognized no adjustment for uncertain tax provisions. SafeStitch recognizes interest and penalties related to uncertain tax positions in selling, general and administrative costs and expenses; however no such provisions for accrued interest and penalties related to uncertain tax positions have been recorded as of September 30, 2012 or December 31, 2011.

    The tax years 2009-2011 remain open to examination by the major tax jurisdictions in which the Company operates.

    XML 35 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Document and Entity Information
    9 Months Ended
    Sep. 30, 2012
    Nov. 10, 2012
    Document and Entity Information [Abstract]    
    Entity Registrant Name SafeStitch Medical, Inc.  
    Entity Central Index Key 0000876378  
    Document Type 10-Q  
    Document Period End Date Sep. 30, 2012  
    Amendment Flag false  
    Document Fiscal Year Focus 2012  
    Document Fiscal Period Focus Q3  
    Current Fiscal Year End Date --12-31  
    Entity Filer Category Smaller Reporting Company  
    Entity Common Stock, Shares Outstanding   48,797,755
    XML 36 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Certain Relationships and Related Party Transactions
    9 Months Ended
    Sep. 30, 2012
    Certain Relationships and Related Party Transactions [Abstract]  
    CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

    NOTE 11 – CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

    As more fully described in Note 5, the Company entered into a $4.0 million Credit Facility with both Jeffrey G. Spragens, the Company’s President, Chief Executive Officer and director, and The Frost Group.

    The Company entered into a five-year lease for office space in Miami, Florida with a company controlled by Dr. Frost. The non-cancelable lease, which commenced January 1, 2008, provides for a 4.5% annual rent increase over the life of the lease. The Miami office lease was amended in August 2011 to include additional office space in the same building, and current rental payments under the lease are approximately $19,000 per month. The Company recorded rent expense related to the Miami lease totaling approximately $73,000 and $198,000, respectively, for the three and nine months ended September 30, 2012, and $51,000 and $145,000, respectively, for the three and nine months ended September 30, 2011.

    Dr. Hsiao, Dr. Frost and director Steven Rubin are each significant stockholders and/or directors of Non-Invasive Monitoring Systems, Inc. (“NIMS”), a publicly-traded medical device company, Aero Pharmaceuticals, Inc. (“Aero”), a privately-held pharmaceutical distribution company that dissolved in December 2011, Tiger X Medical, Inc. (“Tiger X”) (formerly known as Cardo Medical, Inc.), a publicly-traded former medical device company, and SearchMedia Holdings Limited (“SearchMedia”), a publicly-traded media company operating primarily in China, and Sorrento Therapeutics, Inc. (“Sorrento”), a publicly-traded development stage biopharmaceutical company. Director Richard Pfenniger is also a shareholder of NIMS. The Company’s Chief Financial Officer also serves as the Chief Financial Officer and supervises the accounting staffs of NIMS and, until its dissolution, Aero, under a Board-approved cost sharing arrangement whereby the total salaries of the accounting staffs of the three companies are shared. Aero has not participated in the cost sharing arrangement since June 30, 2011 and was dissolved in December 2011. Since December 2009, the Company’s Chief Legal Officer has served under a similar Board-approved cost sharing arrangement as Corporate Counsel of SearchMedia and as the Chief Legal Officer of each of NIMS and Tiger X, and from June 2011 through September 19, 2012, as Corporate Counsel for Sorrento. The Company has recorded reductions to selling, general and administrative costs and expenses to account for the sharing of costs under these arrangements of $51,000 and $154,000, respectively, for the three and nine months ended September 30, 2012, and $51,000 and $205,000, respectively, for the three and nine months ended September 30, 2011. Aggregate accounts receivable from NIMS, Aero, Tiger X, Sorrento and SearchMedia were approximately $45,000 and $66,000 as of September 30, 2012 and December 31, 2011, respectively.

    XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Condensed Consolidated Statements of Operations (Unaudited) (USD $)
    In Thousands, except Per Share data, unless otherwise specified
    3 Months Ended 9 Months Ended 84 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Revenues $ 11   $ 20   $ 20
    Cost of sales 8   179   179
    Gross margin 3   (159)   (159)
    Operating costs and expenses          
    Research and development 557 975 2,504 2,480 15,441
    Selling, general and administrative 822 506 2,803 1,627 11,799
    Total operating costs and expenses 1,379 1,481 5,307 4,107 27,240
    Operating loss (1,376) (1,481) (5,466) (4,107) (27,399)
    Other income and expense          
    Other income         1,147
    Interest income, net         79
    Amortization of deferred financing cost (2) (5) (7) (36) (1,977)
    Interest expense   (7) (43) (7) (155)
    Total other income and expense (2) (12) (50) (43) (906)
    Loss before income tax (1,378) (1,493) (5,516) (4,150) (28,305)
    Provision for income tax               
    Net loss (1,378) (1,493) (5,516) (4,150) (28,305)
    Loss attributable to common stockholders and loss per common share:          
    Net loss (1,378) (1,493) (5,516) (4,150) (28,305)
    Net loss attributable to common stockholders (1,378) (1,493) (5,516) (4,150) (33,672)
    Weighted average shares outstanding, basic and diluted 48,798 28,004 45,155 28,004  
    Net loss per basic and diluted share $ (0.03) $ (0.05) $ (0.12) $ (0.15)  
    Series A Preferred Conversion
             
    Loss attributable to common stockholders and loss per common share:          
    Deemed dividend         (4,301)
    Series A Preferred Stock
             
    Loss attributable to common stockholders and loss per common share:          
    Deemed dividend         (700)
    Dividends - Series A Preferred Stock         $ (366)
    XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Debt
    9 Months Ended
    Sep. 30, 2012
    Debt [Abstract]  
    DEBT

    NOTE 5 – DEBT

    Credit Facility. In connection with the acquisition of SafeStitch LLC, the Company entered into a Note and Security Agreement (the “Credit Facility”) with both The Frost Group and Jeffrey G. Spragens, the Company’s Chief Executive Officer and President and a director. The Frost Group is a Florida limited liability company whose members include Frost Gamma Investments Trust (“Frost Gamma”), a trust controlled by Dr. Phillip Frost, the largest beneficial holder of the issued and outstanding shares of Common Stock, Dr. Jane H. Hsiao, the Company’s Chairman of the Board, and Steven D. Rubin, a director. The Credit Facility provides $4.0 million in total available borrowings, consisting of $3.9 million from The Frost Group and $100,000 from Mr. Spragens. The Company has granted a security interest in all present and subsequently acquired collateral in order to secure prompt, full and complete payment of the amounts outstanding under the Credit Facility. The collateral includes all assets of the Company, inclusive of intellectual property (patents, patent rights, trademarks, service marks, etc.). Outstanding borrowings under the Credit Facility accrue interest at a 10% annual rate. The Credit Facility had an initial term of 28 months, expiring in December 2009, and was amended on four occasions to extend the Maturity Date, which is now June 30, 2013.

    In connection with the Credit Facility, the Company granted warrants to purchase an aggregate of 805,521 shares of Common Stock to The Frost Group and Mr. Spragens. The fair value of the warrants was determined to be $1,985,000 on the grant date based on the Black-Scholes valuation model using the following assumptions: expected volatility of 82%, dividend yield of 0%, risk-free interest rate of 4.88% and expected life of 10 years. The fair value of the warrants was recorded as deferred financing costs and is being amortized over the life of the Credit Facility. The Company recorded amortization expense related to these deferred financing costs of $2,000 and $7,000, respectively, for the three and nine months ended September 30, 2012 and $5,000 and $36,000, respectively, for the three and nine months ended September 30, 2011. In October 2012, The Frost Group and Mr. Spragens exercised the warrants for the purchase of 805,521 shares of Common Stock.

    The Company borrowed $300,000 under the Credit Facility during September 2012. The Company did not recognized interest expense related to the outstanding borrowings under the Credit Facility for the three months ended September 30, 2012. The Company has a $300,000 outstanding balance and $3,700,000 available under the Credit Facility as of September 30, 2012.

    XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Stock-Based Compensation
    9 Months Ended
    Sep. 30, 2012
    Stock-Based Compensation [Abstract]  
    STOCK-BASED COMPENSATION

    NOTE 4 – STOCK-BASED COMPENSATION

    On November 13, 2007, the Board of Directors and a majority of the Company’s stockholders approved the SafeStitch Medical, Inc. 2007 Incentive Compensation Plan (the “2007 Plan”), which was amended on June 19, 2012 to increase the number of shares of Common Stock available for issuance to 5,000,000. Under the 2007 Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock and/or deferred stock to employees, officers, directors, consultants and vendors up to an aggregate of 5,000,000 shares of Common Stock, which are fully reserved for future issuance. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company’s shares at the date of grant and, within any 12 month period, no person may receive stock options or stock appreciation rights for more than one million shares. Additionally, no stock options or stock appreciation rights granted under the 2007 Plan may have a term exceeding ten years.

    The Company granted 813,500 and 562,500 stock options under the 2007 Plan during the nine months ended September 30, 2012 and 2011, respectively, including 218,000 and 68,000 stock options that were issued to consultants. The options granted during 2012 were issued at an exercise price ranging from $0.65 to $0.85 per share and had an estimated aggregate grant date fair value of $441,000. The options granted during 2011 were issued at an exercise price of $1.12 per share and had an estimated aggregate grant date fair value of $502,000. The weighted average grant date fair value of the options granted during the nine months ended September 30, 2012 and 2011 was $0.54 per share and $0.89 per share, respectively.

    Total stock-based compensation recorded for the three and nine months ended September 30, 2012 was $113,000 and $336,000, respectively. Total stock-based compensation recorded for the three and nine months ended September 30, 2011 was $98,000 and $240,000, respectively. The stock-based compensation recorded for the nine months ended September 30, 2011 included a credit of $113,000 for a change in forfeiture experience. All stock-based compensation is included in selling, general and administrative costs and expenses. The fair values of options granted are estimated on the date of their grant using the Black-Scholes option pricing model based on the assumptions included in the table below. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Expected volatility is based on the historical volatility of the Common Stock. The risk-free interest rate for periods within the contractual life of the stock option award is based on the yield of U.S. Treasury bonds on the grant date with a maturity equal to the expected term of the stock option. The expected life of stock option awards granted to employees and non-employee directors is based upon the “simplified” method for “plain vanilla” options described in SEC Staff Accounting Bulletin No. 107, as amended by SEC Staff Accounting Bulletin No. 110. The expected life of all other stock option awards is the contractual term of the option. Forfeiture rates are based on management’s estimates. The fair value of each option granted during the nine months ended September 30, 2012 and 2011 was estimated using the following assumptions.

             
        Nine months ended
    September 30, 2012
      Nine months ended
    September 30, 2011

    Expected volatility

      85.41% - 111.36%   76.91% - 102.63%

    Expected dividend yield

      0.00%   0.00%

    Risk-free interest rate

      1.02% – 1.98%   2.25% – 3.25%

    Expected life

      5.5 – 10.0 years   5.5 – 10.0 years

    Forfeiture rate

      0% - 2%   0% - 5%

    The following summarizes the Company’s stock option activity for the nine months ended September 30, 2012:

     

                                     
        Shares     Weighted
    Average
    Exercise
    Price
        Weighted
    Average
    Remaining
    Contractual
    Term (Years)
        Aggregate
    Intrinsic
    Value
     

    Outstanding at December 31, 2011

        1,628,167     $ 1.35       6.26          

    Granted

        813,500     $ 0.66       9.39          

    Exercised

        —         —                    

    Canceled or expired

        (237,667   $ 1.99                  
       

     

     

                             

    Outstanding at September 30, 2012

        2,204,000     $ 1.02       7.09     $ 0  
       

     

     

       

     

     

       

     

     

       

     

     

     

    Exercisable at September 30, 2012

        990,875     $ 1.24       5.41     $ 0  
       

     

     

       

     

     

       

     

     

       

     

     

     

    Vested and expected to vest at September 30, 2012

        2,155,239     $ 1.03       7.05     $ 0  
       

     

     

       

     

     

       

     

     

       

     

     

     

    None of the 813,500 options granted during the first nine months of the Company’s 2012 fiscal year were vested as of September 30, 2012. At September 30, 2012, there was approximately $333,000 of total unrecognized compensation cost related to non-vested employee and director share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.53 years.

    No options were exercised during the three and nine months ended September 30, 2012 and 2011.

    No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.

    XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Basic and Diluted Net Loss Per Share (Tables)
    9 Months Ended
    Sep. 30, 2012
    Basic and Diluted Net Loss Per Share [Abstract]  
    Summary of Potential Common Shares

    Potential common shares not included in calculating diluted net loss per share are as follows:

     

                     
        September 30, 2012     September 30, 2011  

    Stock options

        2,204,000       1,629,667  

    Stock warrants

        805,521       805,521  
       

     

     

       

     

     

     

    Total

        3,009,521       2,435,188  
       

     

     

       

     

     

     
    XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Employee Benefit Plans
    9 Months Ended
    Sep. 30, 2012
    Employee Benefit Plans [Abstract]  
    EMPLOYEE BENEFIT PLANS

    NOTE 12 – EMPLOYEE BENEFIT PLANS

    Effective May 1, 2008, the SafeStitch 401(k) Plan (the “401k Plan”) permits employees to contribute up to 100% of qualified annual compensation up to annual statutory limitations. Employee contributions may be made on a pre-tax basis to a regular 401(k) account or on an after-tax basis to a “Roth” 401(k) account. The Company contributes to the 401k Plan a “safe harbor” match of 100% of each participant’s contributions to the 401k Plan up to a maximum of 4% of the participant’s qualified annual earnings. The Company recorded 401(k) Plan matching expense of approximately $23,000 and $37,000, respectively, for the three and nine months ended September 30, 2012 and $9,000 and $28,000, respectively, for the three and nine months ended September 30, 2011.

    XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Commitments and Contingencies
    9 Months Ended
    Sep. 30, 2012
    Commitments and Contingencies [Abstract]  
    COMMITMENTS AND CONTINGENCIES

    NOTE 8 – COMMITMENTS AND CONTINGENCIES

    The Company is obligated under various operating lease agreements for office space. Generally, the lease agreements require the payment of base rent plus escalations for increases in building operating costs and real estate taxes. Rental expense under operating leases amounted to $76,000 and $209,000 for the three and nine months ended September 30, 2012, respectively, and $58,000 and $163,000 for the three and nine months ended September 30, 2011, respectively.

    The Company is obligated to pay royalties to Creighton University (“Creighton”) on the sales of products licensed from Creighton pursuant to an exclusive license and development agreement (see Note 9). The Company is also obligated under an agreement with Dr. Parviz Amid to pay a 4% royalty to Dr. Amid on the sales of any product developed with Dr. Amid’s assistance, including the AMID HFD, for a period of ten years from the first commercial sale of such product. Royalties to Dr. Parviz Amid in the amount of $400 and $800 have been incurred during the three and nine months ended September 30, 2012, respectively. No royalties have been incurred or paid for the three and nine months ended September 30, 2011.

    The Company has placed orders with various suppliers for the purchase of certain tooling, contract engineering and research services. Each of these orders has a duration or expected completion within the next twelve months. The Company currently has no material commitments with terms beyond twelve months.

    XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Capital Transactions
    9 Months Ended
    Sep. 30, 2012
    Capital Transactions [Abstract]  
    CAPITAL TRANSACTIONS

    NOTE 6 – CAPITAL TRANSACTIONS

    2012 Private Placement of Common Stock. On February 17, 2012, the Company entered into a stock purchase agreement (the “2012 Stock Purchase Agreement”) with 35 investors (the “2012 PIPE Investors”) pursuant to which the 2012 PIPE Investors agreed to purchase an aggregate of 20,794,000 shares of Common Stock (the “2012 PIPE Shares”) at a price of $0.40 per share for aggregate consideration of $8.3 million. Among the Investors purchasing Shares were Frost Gamma, Dr. Jane Hsiao, the Company’s Chairman of the Board, Jeffrey Spragens, the Company’s President and Chief Executive Officer and Richard Pfenniger, a member of the Company’s Board of Directors. Frost Gamma and Dr. Hsiao each purchased 4,500,000 shares, Mr. Spragens purchased 250,000 shares, and Mr. Pfenniger purchased 125,000 shares. The Company issued the 2012 PIPE Shares in reliance upon the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated thereunder.

    XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Basic and Diluted Net Loss Per Share
    9 Months Ended
    Sep. 30, 2012
    Basic and Diluted Net Loss Per Share [Abstract]  
    BASIC AND DILUTED NET LOSS PER SHARE

    NOTE 7 – BASIC AND DILUTED NET LOSS PER SHARE

    Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period reported. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding for the period reported. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three and nine months ended September 30, 2012 and 2011, no adjustment has been made to the weighted average outstanding common shares as the assumed exercise of outstanding options and warrants and conversion of preferred stock is anti-dilutive.

    Potential common shares not included in calculating diluted net loss per share are as follows:

     

                     
        September 30, 2012     September 30, 2011  

    Stock options

        2,204,000       1,629,667  

    Stock warrants

        805,521       805,521  
       

     

     

       

     

     

     

    Total

        3,009,521       2,435,188  
       

     

     

       

     

     

     
    XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Agreement with Creighton University
    9 Months Ended
    Sep. 30, 2012
    Agreement With Creighton University [Abstract]  
    AGREEMENT WITH CREIGHTON UNIVERSITY

    NOTE 9 – AGREEMENT WITH CREIGHTON UNIVERSITY

    On May 26, 2006, SafeStitch LLC entered into an exclusive license and development agreement (the “Creighton Agreement”) with Creighton, granting the Company a worldwide exclusive (even as to the university) license, with rights to sublicense, to all the Company’s product candidates and associated know-how based on Creighton technology, including the exclusive right to manufacture, use and sell the product candidates.

    Pursuant to the Creighton Agreement, the Company is obligated to pay Creighton, on a quarterly basis, a royalty of 1.5% of the revenue collected worldwide from the sale of any product licensed under the Creighton Agreement, less certain amounts including, without limitation, chargebacks, credits, taxes, duties and discounts or rebates. The Creighton Agreement does not provide for minimum royalties. Also pursuant to the Creighton Agreement, the Company agreed to invest, in the aggregate, at least $2.5 million over 36 months, beginning May 26, 2006, towards development of any licensed product. This $2.5 million investment obligation excluded the first $150,000 of costs related to the prosecution of patents, which the Company invested outside of the Creighton Agreement. The Company is further obligated to pay to Creighton an amount equal to 20% of certain of the Company’s research and development expenditures as reimbursement for the use of Creighton’s facilities. Failure to comply with the payment obligations above will result in all rights in the licensed patents and know-how reverting back to Creighton. As of December 31, 2007, the Company had satisfied the $2.5 million investment obligation described above. The Company recorded research and development costs and expenses related to the 20% facility reimbursement obligation totaling approximately $10,000 and $34,000, respectively for the three and nine months ended September 30, 2012, and $12,000 and $33,000, respectively, for the three and nine months ended September 30, 2011.

    XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Commitments and Contingencies (Details Textual) (USD $)
    3 Months Ended 9 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Sep. 30, 2011
    Commitments and Contingencies (Textual) [Abstract]        
    Operating Leases     $ 19,000  
    Creighton Royalty Agreement [Member]
           
    Commitments and Contingencies (Textual) [Abstract]        
    Operating Leases 76,000 58,000 209,000 163,000
    Percentage of royalty of specific product revenue     4.00%  
    Period of Royalty     10 years  
    Royalty Incurred 400 0 800 0
    Period of supply agreement     12 months  
    Purchase obligation beyond next twelve months     $ 0  
    XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Property and Equipment (Tables)
    9 Months Ended
    Sep. 30, 2012
    Property and Equipment [Abstract]  
    Summary of Property and equipment

    Property and equipment consist of the following:

     

                         
        Estimated Useful Lives   September 30, 2012     December 31, 2011  

    Machinery and equipment

      5 years   $ 660,000     $ 660,000  

    Furniture, fixtures and leasehold improvements

      3-5 years     87,000       81,000  

    Software

      3-5 years     57,000       57,000  
           

     

     

       

     

     

     
              804,000       798,000  

    Accumulated depreciation and amortization

            (455,000     (328,000
           

     

     

       

     

     

     

    Property and equipment, net

          $ 349,000     $ 470,000  
           

     

     

       

     

     

     
    XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Property and Equipment (Details) (USD $)
    9 Months Ended
    Sep. 30, 2012
    Dec. 31, 2011
    Summary of Property and equipment    
    Property and equipment, Gross $ 804,000 $ 798,000
    Accumulated depreciation and amortization (455,000) (328,000)
    Property and equipment, net 349,000 470,000
    Machinery and Equipment [Member]
       
    Summary of Property and equipment    
    Estimated Useful Lives 5 years  
    Property and equipment, Gross 660,000 660,000
    Furniture, Fixtures and Leasehold Improvements [Member]
       
    Summary of Property and equipment    
    Property and equipment, Gross 87,000 81,000
    Furniture, Fixtures and Leasehold Improvements [Member] | Maximum [Member]
       
    Summary of Property and equipment    
    Estimated Useful Lives 5 years  
    Furniture, Fixtures and Leasehold Improvements [Member] | Minimum [Member]
       
    Summary of Property and equipment    
    Estimated Useful Lives 3 years  
    Software [Member]
       
    Summary of Property and equipment    
    Property and equipment, Gross $ 57,000 $ 57,000
    Software [Member] | Maximum [Member]
       
    Summary of Property and equipment    
    Estimated Useful Lives 5 years  
    Software [Member] | Minimum [Member]
       
    Summary of Property and equipment    
    Estimated Useful Lives 3 years  
    XML 49 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Condensed Consolidated Statements of Stockholder's Equity (Deficit) (USD $)
    In Thousands, except Share data
    Total
    Preferred Stock
    Preferred Stock
    Series A Preferred Stock
    Preferred Stock
    Series A Preferred Conversion
    Common Stock
    Additional Paid-in Capital
    Deficit Accumulated During the Development Stage
    Beginning Balance at Sep. 15, 2005                   
    Beginning Balance, Shares at Sep. 15, 2005                
    Capital contributed 1         1  
    Net loss (76)           (76)
    Ending Balance at Dec. 31, 2005 (75)           1 (76)
    Ending Balance, Shares at Dec. 31, 2005                
    Capital contributed 1,504       11 1,493  
    Capital contributed, Shares         11,256,000    
    Net loss (1,060)           (1,060)
    Ending Balance at Dec. 31, 2006 369        11 1,494 (1,136)
    Ending Balance, Shares at Dec. 31, 2006          11,256,000    
    Capital contributed 5,093       5 5,088  
    Capital contributed, Shares         4,837,000    
    Net loss (3,041)           (3,041)
    Ending Balance at Dec. 31, 2007 2,421        16 6,582 (4,177)
    Ending Balance, Shares at Dec. 31, 2007          16,093,000    
    Issuance of common shares in private offering 3,988       2 3,986  
    Issuance of common shares in private offering, Shares         1,862,000    
    Issuance of common shares as repayment of stockholder note per share 10         10  
    Issuance of common shares as repayment of stockholder note per share, Shares         8,000    
    Stock-based compensation 239         239  
    Net loss (5,185)           (5,185)
    Ending Balance at Dec. 31, 2008 1,473        18 10,817 (9,362)
    Ending Balance, Shares at Dec. 31, 2008          17,963,000    
    Issuance of Series A Preferred Stock, net of offering costs 1,982   20     1,962  
    Issuance of Series A Preferred Stock, net of offering costs , shares     2,000,000        
    Fair value of beneficial conversion feature of Series A Preferred Stock 200         200  
    Deemed dividend to Series A Preferred Stockholders, charged to additional paid-in capital in the absence of retained earnings (200)         (200)  
    Stock-based compensation 195         195  
    Net loss (2,366)           (2,366)
    Ending Balance at Dec. 31, 2009 1,284 20     18 12,974 (11,728)
    Ending Balance, Shares at Dec. 31, 2009   2,000,000     17,963,000    
    Issuance of Series A Preferred Stock, net of offering costs 1,998   20     1,978  
    Issuance of Series A Preferred Stock, net of offering costs , shares     2,000,000        
    Fair value of beneficial conversion feature of Series A Preferred Stock 500         500  
    Deemed dividend to Series A Preferred Stockholders, charged to additional paid-in capital in the absence of retained earnings (500)         (500)  
    Issuance of common shares in private offering 4,974       5 4,969  
    Issuance of common shares in private offering, Shares         4,978,000    
    Conversion of shares of Series A Preferred Stock and accumulated dividends into shares of Common Stock       (40) 4 36  
    Conversion of shares of Series A Preferred Stock and accumulated dividends into shares of Common Stock , shares       (4,000,000) 4,366,000    
    Issuance of shares of Common Stock as Consideration Shares         1 (1)  
    Issuance of shares of Common Stock as Consideration Shares , shares         697,000    
    Intrinsic value of aggregate shares of Common Stock issued on conversion of Series A Preferred Stock 4,301         4,301  
    Dividend paid to Series A Preferred Stockholders on conversion, charged to additional paid-in capital in the absence of retained earnings (4,301)         (4,301)  
    Stock-based compensation 471         471  
    Net loss (5,303)           (5,303)
    Ending Balance at Dec. 31, 2010 3,424        28 20,427 (17,031)
    Ending Balance, Shares at Dec. 31, 2010          28,004,000    
    Stock-based compensation 335         335  
    Net loss (5,758)           (5,758)
    Ending Balance at Dec. 31, 2011 (1,999)        28 20,762 (22,789)
    Ending Balance, Shares at Dec. 31, 2011          28,004,000    
    Issuance of shares of Common Stock as Consideration Shares 8,318       21 8,297  
    Issuance of shares of Common Stock as Consideration Shares , shares         20,794,000    
    Stock-based compensation 337         337  
    Net loss (5,516)           (5,516)
    Ending Balance at Sep. 30, 2012 $ 1,140        $ 49 $ 29,396 $ (28,305)
    Ending Balance, Shares at Sep. 30, 2012          48,798,000    
    XML 50 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Property and Equipment
    9 Months Ended
    Sep. 30, 2012
    Property and Equipment [Abstract]  
    PROPERTY AND EQUIPMENT

    NOTE 3 – PROPERTY AND EQUIPMENT

    Property and equipment consist of the following:

     

                         
        Estimated Useful Lives   September 30, 2012     December 31, 2011  

    Machinery and equipment

      5 years   $ 660,000     $ 660,000  

    Furniture, fixtures and leasehold improvements

      3-5 years     87,000       81,000  

    Software

      3-5 years     57,000       57,000  
           

     

     

       

     

     

     
              804,000       798,000  

    Accumulated depreciation and amortization

            (455,000     (328,000
           

     

     

       

     

     

     

    Property and equipment, net

          $ 349,000     $ 470,000  
           

     

     

       

     

     

     

    Depreciation of fixed assets utilized in research and development activities is included in research and development costs and expenses. All other depreciation is included in selling, general and administrative costs and expenses. Depreciation and amortization expense was $43,000 and $127,000, respectively for the three and nine months ended September 30, 2012, and was $43,000 and $100,000, respectively for the three and nine months ended September 30, 2011.

    XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Property and Equipment (Details Textual) (USD $)
    3 Months Ended 9 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Sep. 30, 2011
    Property and Equipment (Textual) [Abstract]        
    Depreciation and amortization expense $ 43,000 $ 43,000 $ 127,000 $ 100,000
    XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 151 236 1 false 27 0 false 5 false false R1.htm 00 - Document - Document and Entity Information Sheet http://safestitch.com/2011-03-31/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Condensed Consolidated Balance Sheets Sheet http://safestitch.com/2011-03-31/role/BalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://safestitch.com/2011-03-31/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://safestitch.com/2011-03-31/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) false false R5.htm 0130 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) Sheet http://safestitch.com/2011-03-31/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholder's Equity (Deficit) false false R6.htm 0131 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) (Parenthetical) Sheet http://safestitch.com/role/StatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholder's Equity (Deficit) (Parenthetical) false false R7.htm 0140 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://safestitch.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) false false R8.htm 0201 - Disclosure - Basis of Presentation and Liquidity Sheet http://safestitch.com/2011-03-31/role/BasisOfPresentationAndLiquidity Basis of Presentation and Liquidity false false R9.htm 0202 - Disclosure - Summary of Significant Accounting Policies Sheet http://safestitch.com/2011-03-31/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R10.htm 0203 - Disclosure - Property and Equipment Sheet http://safestitch.com/2011-03-31/role/PropertyAndEquipment Property and Equipment false false R11.htm 0204 - Disclosure - Stock-Based Compensation Sheet http://safestitch.com/2011-03-31/role/StockBasedCompensation Stock-Based Compensation false false R12.htm 0205 - Disclosure - Debt Sheet http://safestitch.com/2011-03-31/role/Debt Debt false false R13.htm 0206 - Disclosure - Capital Transactions Sheet http://safestitch.com/2011-03-31/role/CapitalTransactions Capital Transactions false false R14.htm 0207 - Disclosure - Basic and Diluted Net Loss Per Share Sheet http://safestitch.com/2011-03-31/role/BasicAndDilutedNetLossPerShare Basic and Diluted Net Loss Per Share false false R15.htm 0208 - Disclosure - Commitments and Contingencies Sheet http://safestitch.com/2011-03-31/role/CommitmentsAndContingencies Commitments and Contingencies false false R16.htm 0209 - Disclosure - Agreement with Creighton University Sheet http://safestitch.com/2011-03-31/role/AgreementWithUniversity Agreement with Creighton University false false R17.htm 0210 - Disclosure - Income Taxes Sheet http://safestitch.com/2011-03-31/role/IncomeTaxes Income Taxes false false R18.htm 0211 - Disclosure - Certain Relationships and Related Party Transactions Sheet http://safestitch.com/2011-03-31/role/CertainRelationshipsAndRelatedPartyTransactions Certain Relationships and Related Party Transactions false false R19.htm 0212 - Disclosure - Employee Benefit Plans Sheet http://safestitch.com/2011-03-31/role/EmployeeBenefitPlans Employee Benefit Plans false false R20.htm 0402 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://safestitch.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R21.htm 0503 - Disclosure - Property and Equipment (Tables) Sheet http://safestitch.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) false false R22.htm 0504 - Disclosure - Stock-Based Compensation (Tables) Sheet http://safestitch.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) false false R23.htm 0507 - Disclosure - Basic and Diluted Net Loss Per Share (Tables) Sheet http://safestitch.com/role/BasicAndDilutedNetLossPerShareTables Basic and Diluted Net Loss Per Share (Tables) false false R24.htm 0601 - Disclosure - Basis of Presentation and Liquidity (Details Textual) Sheet http://safestitch.com/role/BasisOfPresentationAndLiquidityDetailsTextual Basis of Presentation and Liquidity (Details Textual) false false R25.htm 0602 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://safestitch.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) false false R26.htm 0603 - Disclosure - Property and Equipment (Details) Sheet http://safestitch.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) false false R27.htm 06031 - Disclosure - Property and Equipment (Details Textual) Sheet http://safestitch.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) false false R28.htm 0604 - Disclosure - Stock-Based Compensation (Details) Sheet http://safestitch.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) false false R29.htm 06041 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://safestitch.com/role/StockBasedCompensationDetails1 Stock-Based Compensation (Details 1) false false R30.htm 06042 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://safestitch.com/role/StockBasedCompensationDetailsTextual Stock-Based Compensation (Details Textual) false false R31.htm 0605 - Disclosure - Debt (Details Textual) Sheet http://safestitch.com/role/DebtDetailsTextual Debt (Details Textual) false false R32.htm 0606 - Disclosure - Capital Transactions (Details Textual) Sheet http://safestitch.com/role/CapitalTransactionsDetailsTextual Capital Transactions (Details Textual) false false R33.htm 0607 - Disclosure - Basic and Diluted Net Loss Per Share (Details) Sheet http://safestitch.com/role/BasicAndDilutedNetLossPerShareDetails Basic and Diluted Net Loss Per Share (Details) false false R34.htm 0608 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://safestitch.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R35.htm 0609 - Disclosure - Agreement With Creighton University (Details Textual) Sheet http://safestitch.com/role/AgreementWithCreightonUniversityDetailsTextual Agreement With Creighton University (Details Textual) false false R36.htm 0610 - Disclosure - Income Taxes (Details Textual) Sheet http://safestitch.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) false false R37.htm 0611 - Disclosure - Certain Relationships and Related Party Transactions (Details Textual) Sheet http://safestitch.com/role/CertainRelationshipsAndRelatedPartyTransactionsDetailsTextual Certain Relationships and Related Party Transactions (Details Textual) false false R38.htm 0612 - Disclosure - Employee Benefit Plans (Details Textual) Sheet http://safestitch.com/role/EmployeeBenefitPlansDetailsTextual Employee Benefit Plans (Details Textual) false false All Reports Book All Reports Element us-gaap_CommonStockSharesIssued had a mix of decimals attribute values: -3 0. Element us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity had a mix of decimals attribute values: -5 0. Element us-gaap_StockIssuedDuringPeriodSharesNewIssues had a mix of decimals attribute values: -3 0. 'Shares' elements on report '0130 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit)' had a mix of different decimal attribute values. 'Shares' elements on report '0131 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) (Parenthetical)' had a mix of different decimal attribute values. 'Monetary' elements on report '0601 - Disclosure - Basis of Presentation and Liquidity (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '0602 - Disclosure - Summary of Significant Accounting Policies (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '0609 - Disclosure - Agreement With Creighton University (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Dec. 31, 2008' Process Flow-Through: Removing column 'Dec. 31, 2007' Process Flow-Through: Removing column 'Dec. 31, 2006' Process Flow-Through: Removing column 'Dec. 31, 2005' Process Flow-Through: Removing column 'Sep. 15, 2005' Process Flow-Through: 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2005' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2010' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2009' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2008' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2007' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2006' Process Flow-Through: 0131 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) (Parenthetical) Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0140 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) sfes-20120930.xml sfes-20120930.xsd sfes-20120930_cal.xml sfes-20120930_def.xml sfes-20120930_lab.xml sfes-20120930_pre.xml true true XML 53 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Employee Benefit Plans (Details Textual) (USD $)
    3 Months Ended 9 Months Ended
    Sep. 30, 2012
    Sep. 30, 2011
    Sep. 30, 2012
    Sep. 30, 2011
    Employee Benefit Plans (Textual) [Abstract]        
    Employee contribution to annual compensation     100.00%  
    Employer contribution matching plan     100.00%  
    Percentage of participant's qualified annual earnings     4.00%  
    Expenses recorded related to plan $ 23,000 $ 9,000 $ 37,000 $ 28,000
    XML 54 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
    Summary of Significant Accounting Policies (Policies)
    9 Months Ended
    Sep. 30, 2012
    Summary of Significant Accounting Policies [Abstract]  
    Consolidation

    Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Isis Tele-Communications, Inc., which has no current operations, and SafeStitch LLC. All inter-company accounts and transactions have been eliminated in consolidation.

    Use of estimates

    Use of estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions, such as useful lives of property and equipment, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

    Cash and cash equivalents

    Cash and cash equivalents. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company holds cash and cash equivalent balances in banks and other financial institutions, and includes overnight repurchase agreements collateralizing its depository bank accounts (sweep accounts) in its cash balances. Balances in excess of Federal Deposit Insurance Corporation (“FDIC”) limitations may not be insured.

    Allowances for Doubtful Accounts

    Allowances for Doubtful Accounts. The Company provides an allowance for receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance for doubtful accounts at the end of each period are determined using a combination of customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure.

    Inventories

    Inventories. Inventories are stated at lower of cost or market using the weighted average cost method and are evaluated for impairment when conditions exist that suggests impairment may be necessary. The $1.7 million inventory balance at September 30, 2012 consists of $1.0 million in components, $664,000 in finished units of the AMID HFD and $19,000 in standard mesh. Scrap materials and quality testing costs are included in Cost of Goods Sold (“COGS”), as incurred. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, obsolescence and future sales forecasts.

    Property and equipment

    Property and equipment. Property and equipment are carried at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs that do not extend the lives of assets are expensed. Gain or loss, if any, on the disposition of fixed assets is recognized currently in operations. Depreciation is calculated primarily on a straight-line basis over estimated useful lives of the assets.

    Revenue Recognition

    Revenue Recognition. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured.

    Advertising Costs

    Advertising Costs. The Company expenses all costs of advertising as incurred. Advertising and promotional costs are included in selling, general and administrative costs and expenses for all periods presented, and totaled $22,000 and $106,000, respectively, for the three and nine months ended September 30, 2012. Advertising and promotional costs and expenses totaled $2,000 and $11,000, respectively, for the three and nine months ended September 30, 2011.

    Research and development

    Research and development. Research and development costs principally represent salaries of the Company’s medical and biomechanical engineering professionals, material and shop costs associated with manufacturing product prototypes and payments to third parties for clinical trials and additional product development and testing. All research and development costs are charged to expense as incurred.

    Patent costs

    Patent costs. Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are charged to expense as incurred.

    Stock-based compensation

    Stock-based compensation. The Company accounts for all share-based payments to employees and directors, based on their grant date fair values. Compensation for share-based payments to non-employees is based on the fair value at the measurement date, which is generally the performance completion date. The fair value is initially measured at the grant date and subsequently measured at each reporting period until the final measurement date. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. Stock-based compensation is included in general and administrative costs and expenses for all periods presented.

    Therapeutic discovery project tax credit

    Therapeutic discovery project tax credit. The Company records the therapeutic discovery project tax credit on an accrual basis when the credit is considered realized, which is generally when approved by the government agency. Such credit is reported as other income in the accompanying financial statements.

    Fair value of financial instruments

    Fair value of financial instruments. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and notes payable approximate fair value based on their short-term maturity. Related party receivables and stockholder loans are carried at cost.

    Long-lived assets

    Long-lived assets. The Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less costs to sell.

    Income taxes

    Income taxes. The Company follows the liability method of accounting for income taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of the assets and liabilities. The Company’s policy is to record a valuation allowance against deferred tax assets, when the deferred tax asset is not recoverable. The Company considers estimated future taxable income or loss and other available evidence when assessing the need for its deferred tax valuation allowance.

    Comprehensive income (loss).

    Comprehensive income (loss). Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive net loss is equal to its net loss for all periods presented, and, as a result, no statement of comprehensive income (loss) has been included in the condensed consolidated financial statements.